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1 Summary 
 
The blood-brain barrier (BBB) controls the passage of endogenous and xenobiotic substances 
between the blood and the interstitial fluid environment of the brain. The transfer of compounds is 
strictly regulated by brain capillary endothelial cells (BCEC), which are interconnected by well 
developed tight junctions. Porcine brain capillary endothelial cells (PBCEC) cultured in serum-free and 
hydrocortisone supplemented medium closely mimic the BBB phenotype in vitro. After differential 
screening of a subtracted cDNA library of PBCEC we focussed on one gene which by northern blot 
analysis was shown to be fivefold overexpressed upon hydrocortisone treatment. The gene product 
was named brain multidrug resistance protein (BMDP). 
 
The full-length cDNA sequence was obtained by RACE-PCR technology and revealed a transcript 
length of 2112 bp encoding a protein of 656 amino acids. Amino acid sequence analysis showed that 
BMDP consists of one hydrophilic N-terminal ATP-binding cassette (ABC) domain and one hydro-
phobic C-terminal transmembrane domain of six α-helices. Multiple sequence alignment revealed that 
BMDP is highly homologous to the human breast cancer resistance protein (BCRP) with an amino 
acid identity of 80%. Phylogenetic analysis showed only a distant relationship of BMDP to the ABC 
transporters P-glycoprotein (Pgp) and multidrug resistance associated protein 1 (MRP1) both of which 
are known to be expressed at the BBB and to mediate drug transport from the brain into the blood.  
 
BMDP expression at the BBB was studied in more detail by northern blot and immunocyto-
chemical analysis. Comparison of BMDP mRNA expression in cultured PBCEC with brain and 
capillary tissue as well as freshly isolated PBCEC revealed that BMDP is also significantly expressed 
at the BBB in vivo and thus, BMDP synthesis in PBCEC is not an artefact due to in vitro conditions. 
BMDP is significantly less expressed in plexus epithelial cells, that separate the blood from the 
cerebrospinal fluid, and in pericytes that are localised around the brain capillaries. No BMDP 
expression was found in astrocytes which are the connection between BCEC and surrounding brain 
parenchyma with its nerve cells. Thus, in the brain BMDP is predominantly expressed at the BBB. 
Apart from brain tissue BMDP is expressed at high levels in kidney and lung, at moderate levels in 
liver, colon and small intestine, and at low levels in heart, skeletal muscle, spleen, stomach and 
pancreas. Northern blot analysis of the ABC transporters BMDP, Pgp and MRP1 demonstrated that 
BMDP is much higher expressed in brain capillaries than Pgp and MRP1 indicating that BMDP might 
play a more important physiological role at the BBB than these well-known drug transporters.  
 
BMDP mediated drug transport across the BBB in vitro was demonstrated for the 
chemotherapeutic drug daunorubicin using monolayers of PBCEC grown on porous filters. 
Experiments revealed that daunorubicin is actively transported from the basolateral (brain) to the 
apical (blood) compartment indicating that BMDP is localised in the apical membrane of polarised 
PBCEC. These indications were confirmed by immunocytochemical staining of BMDP predominantly 
at the apical plasma membrane of PBCEC. 
 
All the data provide evidence that active exclusion of chemotherapeutics at least from the porcine 
CNS is predominantly mediated by this new transporter BMDP rather than by Pgp or MRP1. 
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2 Introduction 
 
Disorders of the central nervous system like Alzheimer, Multiple Sclerosis, Kreutzfeld-Jakob-
Syndrome and Parkinson remain difficult to treat pharmacologically due to poor drug passage across 
the blood-brain and blood-cerebrospinal fluid barriers (Section 2.1). The blood-brain barrier is built up 
by the endothelial cells of brain capillaries separating the blood from the interstitial fluid that surrounds 
neurons and glial cells. The blood-cerebrospinal fluid barrier is mainly located in the choroid plexus 
separating the blood in the choroid plexus capillaries from the cerebrospinal fluid that fills the 
ventricles and cushions external surfaces of the brain. Both barriers provide the brain with a highly 
regulated and stable environment established and maintained by a canon of transport phenomena like 
restricted passive diffusion, facilitated diffusion and active transport mechanisms, receptor-mediated 
endocytosis and metabolism (Section 2.1.2). These features on the one hand protect the central 
nervous system from uncontrolled changes on the other hand prevent the treatment of brain diseases 
with drugs. Thus, drug transport mechanisms at the brain barriers need to be well characterised. So 
far, the organic cation, organic anion, nucleoside and ABC transport systems have been identified to 
influence many pharmacokinetic characteristics of drugs in processes of absorption, distribution and 
elimination (Section 2.2). 
 
2.1 Permeability barriers of the central nervous system 
 
The neuronal signal transmission in the central nervous system can be divided into two main parts: the 
rapid propagation of electrical activity along the membranes of nerve cells by modulation of the 
membrane potential (nerve impulse) mediated by voltage-gated Na+ channels and the conversion of 
the electrical signal into a chemical signal by secretion of neurotransmitters at the synapses mediated 
by voltage-gated Ca2+ channels (Alberts et al., 1998). Both processes require a constant chemical 
milieu of the interstitial fluid, the homeostasis of the brain. Changes in ion concentrations would disturb 
the resting membrane potential of the neurons und thus, the electrical signal transmission 
(Bradbury, 1993). An unhindered entry of neurotransmitters into the interstitial fluid will influence the 
chemical signal transmission within the synaptic cleft (Abbott, 1992). Furthermore, neurotoxic 
substances must be hindered from entering the brain, as neurons are terminally differentiated and are 
unable to divide and thus, have to last a lifetime without replacement (Alberts et al., 1998). Whereas 
elsewhere in the body the extracellular concentrations of hormones, amino acids and ions undergo 
small but frequent fluctuations, particularly after meals or bouts of exercise, the brain must be kept 
rigorously isolated from such transient changes in the composition of the blood. If the brain was 
exposed to such fluctuations, the result might be uncontrolled nervous activity, since some hormones 
and amino acids serve as neurotransmitters and especially potassium ions influence the threshold for 
the firing of nerve cells.  
The concept of a barrier system in the brain arose in the late 19th century when the bacteriologist 
Ehrlich observed that certain dyes, administered intravenously to small animals, stained all the organs 
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except the brain (Ehrlich, 1885). Ehrlich’s interpretation of his result was that the brain had a lower 
affinity for the dye than the other tissues, but in 1913 Goldmann proved his teacher wrong. He injected 
the dye trypan blue directly into the cerebrospinal fluid of rabbits and dogs and found that the dye 
readily stained the entire brain but did not enter the bloodstream to stain the other internal organs. 
Thus, Goldmann showed that the central nervous system is separated from the blood by a barrier of 
some kind (Goldmann, 1913). His findings correlated with results of other researchers (Biedl and 
Kraus, 1898; Lewandowsky, 1900) and these three investigators attributed their results to special 
permeability properties of the small blood vessels in the brain. But the hypothesis that brain capillaries 
provide the anatomical basis of the barrier could not be confirmed immediately, as in the early 1900’s 
no method was available for examining the fine ultrastructure of the blood vessels. With the 
development of the electron microscope in the 1950’s insights into the anatomical structures of the 
brain were provided. Today, detailed knowledge about the cellular organisation of the different 
permeability barriers of the central nervous system is available.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1  
The mammalian brain (Spector and 
Johanson, 1989). 
 
Three structures in the brain (Figure 2-1) ensure the maintenance of a constant internal milieu: (i) The 
large network of cerebral capillaries that separates the blood from the cerebral interstitial fluid and 
which is defined as the blood-brain barrier (BBB). (ii) The arachnoid membrane that covers the brain’s 
outer surface. (iii) The highly vascularised choroid plexus. The latter structures act as barriers between 
the blood and the cerebrospinal fluid (CSF) and are, thus, named the blood-cerebrospinal fluid barrier. 
While these two systems protect the central nervous system at its macroscopic border areas, the BBB 
controls the entry and exit of compounds within the brain and is mainly responsible for the provision 
with nutrients. The choroid plexus produces the cerebrospinal fluid, which is a clear fluid that contains 
nutrients, ions and other essential molecules and which flows through the ventricular system, around 
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the spinal cord and into the subarachnoid space surrounding the brain. Finally, it drains back into the 
blood. Moreover, the cerebrospinal fluid forms a protecting fluid layer all around the brain that 
cushions the bumps to the skull during abrupt movements and it provides the brain with nutrients and 
ions. As the cerebrospinal fluid freely exchanges substances with the interstitial fluid that surrounds 
the brain’s neurons, the blood-CSF barrier must also keep toxic compounds out of the brain. While the 
arachnoid membrane is generally impermeable to water-soluble substances and its role in forming the 
blood-CSF barrier is largely passive, the choroid plexus, however, actively regulates concentrations of 
molecules in the CSF and renders the blood-CSF barrier a selective one. Different from the BBB, the 
capillary endothelial cells in the choroid plexus are fenestrated. Here, the surrounding epithelial cells 
are sealed together by intercellular junctions that impede the passage of even small water-soluble 
molecules between blood and CSF. Active transport systems provide an ion gradient across the 
epithelial cell layer and thereby induce an osmotically driven waterflow into the ventricles that forms 
the CSF. The CSF is enriched with substances derived from the blood that are essential to the brain 
but are only needed in relatively small amounts like vitamin C, folates, vitamin B6 and deoxyribo-
nucleosides (Spector and Johanson, 1989). 
 
 
 
2.1.1 Organisation of the blood-brain barrier 
 
Reese and Karnovsky (1967) were the first who showed by electron microscopy that the capillary 
endothelial cells are the anatomic site of the blood-brain barrier. After injection of horseradish 
peroxidase into the bloodstream, in most organs the enzyme penetrated the capillary wall through 
channels and gaps between endothelial cells or was engulfed in pinocytotic vesicles. However, in the 
brain the infiltration of peroxidase was stopped by the tight connection between endothelial cells. Not 
long after, Brightman and Reese (1969) injected horseradish peroxidase into one of the cerebral 
ventricles and observed that the enzyme flowed into the extracellular spaces of the brain, but it was 
prevented from leaving the brain, however, by the tightly joined endothelial cells. 
 
Figure 2-2 shows a cross-section of a brain capillary and the adjacent tissue. The capillary lumen (2) is 
completely surrounded by endothelial cells, which are joined intra- and intercellularly by continuous 
tight junctions that seal off the intercellular cleft even against the smallest molecules. These junctions 
actually convert the endothelial cell layer into a closed interface between the blood and the brain 
extracellular fluid (for more details see section 2.1.3). At the abluminal, the brain parenchyma facing 
site, the endothelial cells are surrounded by a basement membrane (4) of 100 to 150 nm thicknesses. 
It consists of proteins of the extracellular matrix like laminin A and B, fibronectins, collagen IV and 
proteoglycans (Dermietzel and Krause, 1991; Webersinke et al., 1992). The pericytes (3) are 
embedded in the abluminal basement membrane and their cell bodies are orientated parallel to the 
capillary while its long processes extend around the capillary (Shepro and Morel, 1993). Their exact 
function is unclear, but experimental evidence indicates that they influence endothelial cell proliferation 
(Balabanov and Dore-Duffy, 1998; Orlidge and D'Amore, 1987), that they play a role in phagocytic 
2  Introduction  5 
procedures of neuronal immune defense (Balabanov and Dore-Duffy, 1998) or other transport 
processes (Dermietzel and Krause, 1991; Sims, 1986) and finally, that they participate in endothelial 
cell differentiation (Balabanov and Dore-Duffy, 1998). The brain capillary is separated from the 
surrounding brain parenchyma with its nerve and glial cells (neuropil, 5) by the so called Membrana 
limitans gliae perivascularis which consists of the astrocytic end feet (1). The end feet of astrocytes 
cover the surface of the capillaries and form cell-cell contacts to the surrounding neurons. They ensure 
a rapid recovery of the resting membrane potential by up-take of potassium ions directly after an 
action potential was triggered (Hertz, 1989). Furthermore, it is debated that astrocytes play an 
important role in the induction of the blood-brain barrier phenotype (Holash et al., 1993; 
Minakawa et al., 1991; Stewart and Wiley, 1981; Svendgaard et al., 1975).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2 Cross-section of a brain capillary (Krstic, 1988). 
(1) astrocytic end feet; (2) lumen with erythrocyte; (3) pericytes; (4) basal lamina; 
(5) neuropil. 
 
 
 
2.1.2 Brain capillary endothelial cells (BCEC) 
 
In contrast to other tissues, the brain capillary endothelial cells convert the cell layer into a single 
continuous interface between the blood and the brain interstitial fluid. Thus, the properties of this 
interface are a reflection of the properties of the individual endothelial cells. Three major functions are 
implicated in the term blood-brain barrier and are therefore properties of the differentiated cerebral 
capillary endothelial cells. Firstly, the protection of the brain from the blood milieu as achieved by 
complex tight junctions between endothelial cells, which prevent the unspecific passage of molecules 
and maintain the homeostasis of the brain (see section 2.1.2.1). Secondly, the selective transport by 
specialised transport systems to either provide the brain with necessary nutrients or remove 
metabolites (see section 2.1.2.2) and finally, the metabolism or modification of blood- or brain-borne 
substances (see section 2.1.2.3). 
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2.1.2.1 BCEC: a permeability barrier 
 
The molecular basis of the blood-brain barrier are the tight junctions (Brightman and Reese, 1969; 
Reese and Karnovsky, 1967) sealing the paracellular cleft between adjacent endothelial cells and thus 
forming a close permeability barrier for hydrophilic molecules. In electron micrographs of freeze-
fracture replicas the tight junctions appear as networks of small ridges on the one side and 
complementary grooves on the other side (Dermietzel, 1975; Nico et al., 1992). The molecular 
structure of the tight junctions is still not clarified completely, but there is unequivocal evidence for both 
a lipidic and a proteinaceous nature of tight junctions. The lipidic model describes the cell-cell contact 
as inverse-micellar lipid domains that arise from the fusion of the outer membrane domains of adjacent 
cells (Grebenkemper and Galla, 1994; Hein et al., 1992; Kachar and Reese, 1982).The protein model 
bases on transmembrane proteins that span the intercellular cleft and that are connected extracellular 
by non covalent interactions (van Meer et al., 1996; van Meer and Simons, 1986). Generally accepted 
is the participation of the transmembrane proteins occludin (Furuse et al., 1993), claudin-1 and 
claudin-5 (Furuse et al., 1998) as well as the cytosolic peripheral membrane proteins ZO-1 (Stevenson 
et al., 1986), ZO-2 (Jesaitis and Goodenough, 1994) and ZO-3/p130 (Balda and Anderson, 1993; 
Haskins et al., 1998). The proteins cingulin (Citi et al., 1989) and 7H6 antigen (Zhong et al., 1994) 
seem to be associated to the tight junctions. In novel discussions the participation of lipid-protein-
structures (Wegener and Galla, 1996) are assumed to be responsible for forming tight junctions. In this 
integrative model, the tight junction associated proteins mainly have the function to induce the 
formation of the inverse-micellar lipid phase and to stabilise it. Independently of the above mentioned 
models Wolburg has suggested that the P-face association of tight junction particles is an indicator of 
a functional blood-brain barrier (Kniesel and Wolburg, 2000; Wolburg et al., 1994). Besides these 
morphological investigations a lot of data suggest that the phosporylation state of the junctional 
proteins is involved in the restricted permeability characteristics in brain capillary endothelial cells 
rather than their quantity (Kniesel and Wolburg, 2000; Rubin and Staddon, 1999). 
 
Apart from the tight junctions, which prevent an unselective paracellular diffusion of blood derived 
substances into the brain, the continuity of the capillary endothelium without any fenestrations and 
pores contribute to the characteristic features of a controlled compound exchange between blood and 
brain. Another specific feature of brain capillary endothelial cells in contrast to capillary endothelial 
cells of other tissues is the presence of minor amounts of pinocytotic vesicles in the cytosol 
(Brightman, 1989) that probably serve for their own nutritional supply rather than for any transcytotic 
transport (Reese and Karnovsky, 1967). 
 
2.1.2.2 BCEC: selective transport functions as barrier 
 
As the tight junctions completely seal the paracellular cleft of adjacent brain capillary endothelial cells, 
each transfer across the brain endothelium has to be transcellular. There are numerous transfer 
mechanisms that are essential for the stabilisation of the internal environment of the normal adult 
brain, as well as mechanisms important for the supply of adequate nutrients.  
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The most decisive factor for passive diffusion across the brain endothelium is the compound’s lipid 
solubility, enabling the molecules to dissolve in the lipid core of cell membranes and, thus to traverse 
them. What happens inside the predominantly aqueous interior of the cell is less clear but presumably 
such lipid-soluble molecules are able to leave the cytoplasm at the other side of the cell along the 
concentration gradient to reach the interior of the brain. Several studies have shown a clear correlation 
between the octanol/water partition coefficient and penetration into the brain as long as the regarded 
compounds are no substrates of specific transport systems (Levin, 1980; Pardridge, 1993; Lohmann et 
al., 2002). Apart from lipid solubility the molecular size is a further key factor that determines the 
penetration of a molecule into the CNS (Abraham et al., 1994; Habgood et al., 2000; Habgood et al., 
1997). 
 
D-glucose as the main source of energy for the brain is a water-soluble substance that enters the brain 
via facilitated diffusion. In the brain the glucose transport via the GLUT-1 protein (Crone, 1965) is 
highly stereospecific for D-glucose (Johansson, 1990) and directed from a region of high concentration 
(blood) to a region where its concentration is lower (brain). In such movement the energy of transport 
is provided by the concentration gradient itself and the carriers merely facilitate the diffusion that would 
take place, albeit more slowly, without them. In the same way the stereospecific transport of large 
amino acids is mediated which are required for the synthesis of neurotransmitters and proteins 
(Oldendorf and Szabo, 1976).  
 
In contrast to the facilitated diffusion active transport systems transfer substrates from regions of 
lower to regions of higher concentration powered by external energy. For example, the small neutral 
amino acid transporter is distributed in the abluminal membrane and ensures that small neutral amino 
acids can be transported out of the brain into the endothelial cell (Goldstein and Betz, 1986) protecting 
the CNS from for example glycine which is a potent inhibitory neurotransmitter. In this special case the 
inward movement is coupled to the sodium gradient which provides the needed energy. 
 
The fourth way to transfer substances across the endothelium is given by receptor-mediated 
endocytosis. For example Brightman (1989) found receptors for insulin expressed in the luminal 
membrane of brain capillaries, but it is still unclear whether insulin is degraded after up-take in 
endothelial cells or transported into the brain.  
 
2.1.2.3 BCEC: metabolism as barrier 
 
The combination of a permeability barrier and selective transport mechanisms is not the only means of 
the blood-brain barrier to prevent the brain from uncontrolled chemical fluctuations within the interstitial 
fluid. Compounds, that enter the endothelial cells either because of their lipophilic character or by their 
affinity to one of the transport proteins, can be converted by metabolic processes into a chemical 
compound incapable of traversing the abluminal membrane. For example, L-dopa, an amino acid 
precursor of the neurotransmitters dopamine and norepinephrine, readily enters the cytosol of brain 
endothelial cells by means of the carrier for large neutral amino acids. Once in the endothelium, it is 
converted into dopamine and DOPAC and both cannot cross the abluminal membrane into the brain 
(Goldstein and Betz, 1986; Johansson, 1990). This phenomenon is called the metabolic BBB. 
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2.1.3 In vitro models of the blood-brain barrier 
 
There has been considerable interest in establishing blood-brain barrier cell culture models. The first 
and original reason was to set up an assay system for pharmacological studies that predict drug 
penetration across the blood-brain barrier, as such predictions are not easy to make in vivo. The 
second major reason has been to understand more about how phenotypic characteristics of capillary 
endothelial cells are modulated. In culture, numerous structural and functional properties of endothelial 
cells, including junctional tightness, rate of endocytosis and the presence of specific transporters, can 
be assayed reproducibly. A third motivation was that a cell culture model would provide an excellent 
tool to investigate pathological disorders affiliated to the blood-brain barrier, such as brain tumors, 
Alzheimer’s disease, Multiple sclerosis and AIDS-associated syndromes. The information from the 
pharmacological, physiological and pathological investigations could finally accelerate the 
development of new pharmaceuticals and novel drug delivery strategies. Therefore, the major goal 
has been to derive cultures of endothelial cells that express the BBB phenotype. The features that 
distinguish cerebral microvascular endothelial cells from those elsewhere in the body include 
impermeable intercellular tight junctions, low pinocytotic activity and expression of specific transporters 
including glucose transporter-1, neutral amino acid transporter, P-glycoprotein, transferrin receptor 
and the blood-brain barrier specific enzymes γ-glutamyl transpeptidase and alkaline phosphatase. 
These features need to be demonstrated in a functional in vitro blood-brain barrier model system. 
However among the variety of specialised properties, the most important one is an efficient endothelial 
barrier function with a low paracellular permeability which can easily be probed by monitoring the 
passage of small solutes (e.g. sucrose, inulin) across the cellular monolayer. Often used tracer 
methods however have a rather limited time resolution and tight junction complexity and barrier 
function is thus most sensitively and readily quantified by the measurement of the transendothelial 
electrical resistance (Schneeberger and Lynch, 1992). 
 
For these purposes most groups use primary isolated capillary endothelial cells (reviewed in 
Audus et al., 1996) derived from rat (Abbott et al., 1992; Barrand et al., 1995), cow (Audus and 
Borchardt, 1987; Cecchelli et al., 1999; Dehouck et al., 1990; Meresse et al., 1989; Rubin et al., 1991), 
pig (Mischeck et al., 1989) or human (Stanimirovic et al., 1996) brain. However, the isolation of pure 
cerebral endothelial cells, as a BBB model, is fraught with a number of problems. While there have 
been improvements in the techniques for isolation and growth of these cells, the process is still time 
consuming, labour intense and expensive. Isolating primary endothelial cells is prone to preparation 
variations, the cells are fastidious in their growth requirements and they have a limited life and utility 
span. Furthermore, very often cells dedifferentiate in vitro. These facts make it difficult to compare 
results from experiments with different cell preparations or passages. 
 
An alternative approach is to use immortalised brain capillary endothelial cells which would 
represent a significant progress in this area as long as they can be shown to maintain barrier 
characteristics. Higher reproducibility, more homogeneity, the ease of propagation, a short population 
doubling time and the lack of exogeneous growth requirements motivate researchers to develop cell 
lines derived from rat (RBE4; Greenwood et al., 1996; Roux et al., 1994; Trautmann et al., 1993; 
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Trautmann et al., 1991), mouse (b.End5; Tan et al., 2001), bovine (t-BBEC-117; Sobue et al., 1999; 
Stins et al., 1997), porcine (PBMEC/C1-2; Teifel and Friedl, 1996) and human brain microvessels (SV-
HCEC; Muruganandam et al., 1997). However, to date, none of these immortalised cell lines 
expresses all of the features necessary for an entirely useful blood-brain barrier model in a consistent 
fashion. This is particularly evident for the measure of barrier function/integrity by transendothelial 
resistance. Some cerebral endothelial cell lines have been demonstrated to restrict the passage of 
macromolecules and hence have been utilised in studies of paracellular permeability, but none have 
been shown to consistently express a transendothelial resistance that is comparable with the blood-
brain barrier in vivo situation but similar to what would be seen with macrovascular endothelial cells.  
 
To overcome this problem attempts have been made to reinduce blood-brain barrier properties in 
endothelial cells by co-culturing them with astrocytes or glioma cells (Gaillard et al., 2000; Gaillard et 
al., 2001; Hurst and Fritz, 1996; Rubin et al., 1991), as there is considerable evidence that the 
establishment and maintenance of the unique cerebral endothelial cell phenotype is the consequence 
of the neuronal milieu, especially specific interactions provided by astrocytic foot processes which 
surround brain microvessels (Dermietzel and Krause, 1991; Janzer and Raff, 1987; Stewart and Wiley, 
1981). Furthermore, numerous studies have utilised conditioned medium generated from cultures of 
rat brain astrocytes or of C6 glioma cells and found that induction does not require direct cell-cell 
interactions (Cancilla et al., 1993; Dehouck et al., 1994; Hurst and Fritz, 1996; Igarashi et al., 1999; 
Ramsohoye and Fritz, 1998; Raub, 1996; Rist et al., 1997; Rubin et al., 1991). However, neither co-
cultures with astrocytes nor addition of astrocytic conditioned medium provided endothelial cell 
monolayers with such low permeability properties as found in vivo.  
Therefore, other approaches to achieve high resistance junctions have been made. For instance, 
Rubin et al. (1991) found that elevating cyclic AMP levels in brain endothelial cells produced a striking 
increase in tight junction resistance and structural changes consistent with induction of high-resistance 
junctional complexes. By supplemention of the medium with hydrocortisone in physiological 
concentrations (550 nM) and removal of serum Galla et al. have established a cell culture model of 
porcine brain capillary endothelial cells (Franke et al., 1999; Franke et al., 2000; Hoheisel et al., 1998) 
that closely mimics the blood-brain barrier phenotype. For the first time, a cell culture model shows 
transendothelial electrical resistances across its cell monolayer of more than 1000 Ωcm2 and up to the 
value of 1900 Ωcm2 measured in brain capillaries in vivo (Crone and Olesen, 1982). Consistently the 
paracellular permeability of 14C-sucrose of 5 x 10-7 cm/s has also been shown to be as low as 
measured in vivo (Levin, 1980). The expression of tight junction proteins was confirmed both by 
northern blot analysis (Nitz et al., 2001) and immunocytochemistry (Eisenblätter et al., 2001). Even P-
glycoprotein (Ferfer, 2000), the transferrin, the scavenger and the LDL (Hoheisel, 1997) receptor and 
the blood-brain barrier specific enzymes γ-glutamyl transpeptidase (Mischeck et al., 1989) and alkaline 
phosphatase (Meyer et al., 1990) have been proven to be expressed. Thus, a cell culture model has 
been developed with fully differentiated brain capillary endothelial cells well suited to study the 
physiology, pharmacology and pathology of the blood-brain barrier. 
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2.2 Drug transporters in the central nervous system 
 
Disorders of the central nervous system are still difficult to treat pharmacologically due to poor drug 
permeability across the blood-brain and blood-cerebrospinal fluid barrier. It was originally believed that 
membrane carriers, localised at the brain barriers as described in section 2.1.2.2, were solely 
responsible for the transport of endogenous substances into and out of the brain and that drug 
transport across the brain barriers was largely dependent on the physicochemical characteristics of 
the drug such as lipophilicity, molecular weight and ionic state (Tamai and Tsuji, 2000). Generally, 
small, non-ionic and/or lipid-soluble molecules penetrate easily the blood-brain barrier whereas larger, 
water-soluble and/or ionic molecules will less likely be capable to cross the plasma membrane by 
passive diffusion (Spector, 1990). But for many drugs the rate of entry and distribution in the central 
nervous system cannot be explained by passive processes that depend on the physicochemical 
characteristics listed above. Meanwhile, many drug transporters, that have been well characterised in 
peripheral tissues, have now been identified in the brain and are known to be involved in the cerebral 
influx and efflux of drugs. Many pharmacokinetic characteristics of drugs in the processes of cerebral 
absorption, distribution and elimination are influenced by the organic cation, organic anion, nucleoside 
and ABC transport systems. An overview will be provided in the following sections with special 
emphasis on the ABC transport systems.  
 
 
 
2.2.1 Organic cation transport systems (OCT) 
 
The organic cation transport systems primarily characterised in liver and kidney actively transport the 
organic cations including endogenous bioactive amines like acetylcholine, choline, dopamine, 
epinephrine, norepinephrine, guanidine, N-methylnicotinamide or thiamine and therapeutic drugs like 
cimetidine, amiloride, mepiperphenidol, morphine, quinidine, quinine, tetraethylammonium, verapamil 
and trimethoprim (Zhang et al., 1998). In the brain, the physiological role of the organic cation 
transport systems further includes the transport of cationic neurotoxins and neurotransmitters like 
amphetamine, desipramine, metamphetamine, dopamine and serotonin (Murakami et al., 2000). 
 
In general, all known organic cation transporters contain 12 transmembrane domains with a large 
extracellular hydrophobic loop between the first and second domain and a large intracellular 
hydrophobic loop between the sixth and seventh domain (Koepsell, 1998). The extracellular loop 
contains several glycosylation sites and the intracellular loop has a number of potential 
phosphorylation sites.  
 
So far two distinct classes of organic cation transport systems have been defined: a potential-sensitive 
transporter usually involved in the influx into cells and an pH gradient-dependent transporter, 
mediating the efflux (Ullrich, 1994). At present the organic cation transporter family includes three 
voltage dependent (OCT1, OCT2, OCT3) and two H+-driven systems (OCTN1, OCTN2) (Table 2-1). 
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Table 2-1 Organic cation transport systems and their tissue specificity.  
 
OCT processes tissue specificity and expression level 
hOCT1 high in liver; low in kidney, intestine and brain 
hOCT2 liver, kidney, brain, placenta; low in small intestine and spleen 
rOCT3 high in placenta; moderate in intestine, heart and brain; low in lung and kidney; undetectable in liver 
hOCTN1 liver, kidney, trachea, bone marrow, skeletal muscle, prostate, lung pancreas, placenta, heart, uterus, spleen, spinal cord 
hOCTN2 high in heart, placenta, kidney and pancreas; low in brain, liver and lung 
 
H, human; r, rat. Adapted from Lee et al. (2001). 
 
Although not detectable by northern blot analysis, RT-PCR studies indicate that the voltage dependent 
transporters OCT1 and OCT2 may be expressed in the brain, but at very low levels (Gorboulev et al., 
1997; Grundemann et al., 1997), whereas OCT3 appears to be expressed more abundantly than 
either OCT1 and OCT2 demonstrated by in situ hybridisation studies (Wu et al., 1998a). The H+-
driven organic cation transporter OCTN2 has been found to be weakly expressed in brain (Wu et al., 
1998b). 
Although organic cation transport mechanisms in the kidney and liver are well characterised, there is 
still only evidence for the transport of endogenous bioactive amines such as choline across the blood-
brain barrier (Koepsell, 1998). However, the membrane localisation of these transporters remains to 
be elucidated. 
 
 
 
2.2.2 Organic anion transport systems (OAT) 
 
Liver and kidney are organs of central importance for the elimination of endogenous and exogenous 
organic anions, many of which are harmful to the body (Muller and Jansen, 1997). In analogy to the 
OCT systems, the organic anion transporters possess 12 putative transmembrane domains, with large 
hydrophobic loops between the first and second as well as the sixth and seventh domain. N-
glycosylation sites are predicted on the extracellular loop between the first and second 
transmembrane domain. Several phosphorylation sites are present at the intracellular loop between 
the sixth and seventh domain (Sekine et al., 2000). 
 
Several families of multispecific organic anion transporters have been identified, of which the two main 
families, the organic anion transporter polypeptide (oatp) and the organic anion transporter (OAT) will 
be discussed here. To date, seven isoforms have been identified in the oatp family and four isoforms 
in the OAT family (Table 2-2) (Sekine et al., 2000). 
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Table 2-2 Organic anion transport systems and their tissue expression and substrate specificity.  
 
OAT processes tissue expression substrate specificity 
Oatp family   
roatp1 liver, CP, kidney bile salts, steroid hormones, bulky organic cations, leukotriene C4 
roatp2 liver, kidney, BBB, CP taurocholate, cholate, estrogen conjugates, ouabain, digoxin 
roatp3 kidney, retina thyroxine, triiodothyronine, taurocholate 
rOAT-K1 kidney methotrexate, folate 
rOAT-K2 kidney taurocholate, methotrexate, folate, prostaglandin 
OATP liver, BBB, lung, kidney, testes bromosulfophathalein, cholate, taurocholate, glycocholate, opiod peptides 
PGT unknown unknown 
LST-1 liver taurocholate 
OAT family   
hOAT1 kidney, brain PAH, dicarboxylates, cyclic nucleotides, prosta-glandin, urate, diuretics 
rOAT2 liver, kidney PAH, salicylate, acetylsalicylate, prostaglandin, dicarboxylates 
hOAT3 liver, kidney, brain, eye PAH, cimetidine, estrone sulfate 
hOAT4 kidney, placenta  estrone sulfate 
 
PAH, p-aminohippurate; CP, choroid plexus; BBB, blood-brain barrier; r, rat; h, human. Adapted from Lee et al. (2001). 
 
From the subclass of organic anion transporter polypeptides the oatp1 and oatp2 are expressed in 
the brain. Oatp1, a bi-directional organic anion/HCO3- and/or organic anion/glutathione exchanger, is 
expressed at the apical membrane of the choroid plexus (Li et al., 1998). It possesses a broad 
substrate specificity and mediates the transport of bile salts, steroid hormones and a variety of organic 
anions and cations (Sekine et al., 2000). Oatp2 is expressed in the choroid plexus as well as in brain 
capillaries (Gao et al., 1999). This transporter is localised along both the luminal and abluminal 
membranes of the blood-brain barrier (Gao et al., 1999). Moreover, oatp2 is expressed in conditionally 
immortalised mouse brain capillary endothelial cells (TM-BBB4) (Asaba et al., 2000). Recently, OATP 
was shown to be expressed in cultured human brain endothelial cells (Gao et al., 2000). This 
transporter was found to transport two opioid peptides, deltorphin II and an enkephalin analog. 
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The organic anion transporter family is primarily responsible for the elimination of organic anions 
from the kidney. While all four isoforms are expressed in the kidney, only OAT1 and OAT3 are also 
expressed in the brain (Sekine et al., 2000). The organic anion transporters are devided into three 
classes depending on their energy requirements: sodium-dependent OATs, sodium-independent 
facilitators or exchangers and active OATs that require ATP. The active and sodium-independent 
OATs possess broad substrate specificity and are primarily involved in the secretion of organic anions 
into both kidney and liver. The sodium-dependent OATs on the other hand, have a narrow substrate 
specificity and play a major role in the reabsorption of essential anionic substances into the proximal 
tubules of the kidney (Sekine et al., 2000). In the brain, the expression of OAT1 is very low (Sekine et 
al., 1997). Recently, a new member, OAT3, was isolated from rat brain by RT-PCR cloning methods 
(Kusuhara et al., 1999). Acidic metabolites of neurotransmitters (dopamine, epinephrine, 
norepinephrine and serotonin) inhibited the uptake of estrone sulfate by OAT3 expressed in Xenopus 
oocytes, suggesting its role in the excretion/detoxification of endogenous anionic substrates from the 
brain (Kusuhara et al., 1999). 
 
In summary, although localisation and transport mechanisms in the brain need further clarification, the 
multispecific OAT systems, predominantly OAT3 and to a lesser extent Oatp1, Oatp2 and OAT1 have 
been identified in the choroid plexus and at the blood-brain barrier. So far, the in vivo and in vitro 
kinetic studies have suggested the presence of efflux transport pathways for organic anions in the 
blood-brain and blood-cerebrospinal fluid barrier. The choroid plexus was shown to mediate the 
removal of organic anions from the cerebrospinal fluid into the blood for their subsequent elimination 
by liver and kidney (Lee et al., 2001). But recently, it has been established that multidrug resistance-
associated protein (MRP) homologues belonging to the ATP-binding cassette (ABC) transporters (see 
section 2.2.4.2) are responsible for the cellular extrusion of organic anions from various organs 
including the central nervous system via the blood-brain and blood-cerebrospinal fluid barrier 
(Kusuhara et al., 1998). Thus, a vectorial transfer of organic anions is mediated by a concerted action 
of members of both the OAT and the ABC families of multispecific transporters. 
 
 
 
2.2.3 Nucleoside transport systems (NT) 
 
Purine and pyrimidine nucleosides and their metabolic products are biosynthetic precursors of the 
nucleic acids, DNA and RNA, and participate in numerous physiological CNS processes. For example, 
the nucleoside adenosine modulates neuronal and cerebral vascular functions by interacting with 
specific receptors on brain cells and blood vessels. In general, nucleosides are synthesised 
endogenously via de novo synthetic pathways. However, a number of tissues including brain are 
deficient in de novo nucleotide synthetic pathways and rely on the salvage of exogenous nucleosides 
to maintain nucleoside pools and to meet their metabolic demands. Therefore, the brain is dependent 
on a continuous and balanced supply of purine and pyrimidine nucleoside constituents. Moreover, 
nucleosides and their analogs form the basis of a wide variety of clinical agents that are used in the 
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treatment of brain cancers, disorders, parasitic and viral diseases. Most nucleosides and their analogs 
exert their biological activity intracellularly, but due to their hydrophilic nature do not readily permeate 
the lipid bilayer. Therefore, the uptake or release of nucleosides and/or nucleosides analogs in 
mammalian cells is mediated by multiple distinct transporters (Cass et al., 1998). Currently, eight 
functionally distinct nucleoside transporters have been identified (Table 2-3). Their classification is 
based on functional and pharmacological characteristics including transport mechanism 
(e = equilibrative, c = concentrative) and sensitivity to nitrobenzylmercapto-purine riboside 
(s = sensitive, i = insensitive). While equilibrative bidirectional processes are driven by chemical 
gradients, inwardly directed concentrative processes are driven by the sodium electrochemical 
gradient and thus, described as Na+/nucleoside symporters (Cass et al., 1998). 
 
Table 2-3 Nucleoside transport systems, their tissue distribution and substrate specificity.  
 
transport processes tissue expression substrate specificity 
equilibrative transporters   
es widely expressed Pur and Pyr Nuc 
ei widely expressed Pur and Pyr Nuc 
concentrative transporters   
cif/N1 macrophages, liver, leukemic cells Pur Nuc, uridine 
cit/N2 enterocytes, kidney, BBB Pyr Nuc, adenosine 
cit/N4 brush border kidney cells Pyr Nuc, adenosine, guanosine 
cib/N3 colorectum, leukemic cells, CP Pur and Pyr Nuc 
cs/N5 leukemic cells adenosine analogs 
csg/N6 acute promyelotic leukemic cells guanosine 
 
CP, choroid plexus; BBB, blood-brain barrier; Pur, purine; Pyr, pyrimidine; Nuc, nucleosides. Adapted from Lee et al. (2001). 
 
The predicted topology of concentrative nucleoside transporters is distinct from equilibrative 
nucleoside transporters. The first type contains 13 transmembrane domains with glycosylation sites at 
the extracellular carboxyl terminus, whereas the equilibrative nucleoside transporters possess only 11 
transmembrane domains with large hydrophobic loops between the first and second and the sixth and 
seventh domain. N-glycosylation sites are predicted on the hydrophobic loop between the first and 
second transmembrane domain (Cass et al., 1998). 
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The equilibrative nucleoside transport processes are found in most mammalian cell types and exhibit 
broad substrate selectivity, whereas the concentrative nucleoside transport processes are present 
primarily in specialised epithelia. Evidence suggests that six subclasses of concentrative transporters 
exist that display a complex pattern of overlapping substrate specificity, which may be the basis for a 
complex phenotype with one nucleoside simultaneously transported by more than one transporter 
within one cell or tissue (Lee et al., 1988). 
Several nucleoside transport systems have been identified in the blood-brain and blood-cerebrospinal 
fluid barrier. Early in vivo studies revealed that at the blood-brain barrier, purine ribonucleosides move 
from blood to brain by facilitated diffusion, whereas pyrimidine deoxyribonucleosides do not show 
significant uptake into the brain (Cornford and Oldendorf, 1975; Spector and Berlinger, 1982; Spector 
and Huntoon, 1983). Further experiments using cultured endothelial cells and isolated brain capillaries 
demonstrated the expression of N2, es and ei nucleoside transport systems at the blood-brain barrier 
(Kalaria and Harik, 1986; Thomas and Segal, 1997). The low blood-brain barrier transport of 
deoxyribonucleosides suggests that the saturable entry of these solutes occurs predominantly via the 
choroid plexus. By in vitro studies using isolated choroid plexus several nucleoside transport systems 
including an es, ei and a concentrative N3 type transporter mediating the transport of both 
ribonucleosides and deoxyribonucleosides have been identified (Kalaria and Harik, 1986; Spector and 
Berlinger, 1982; Wu et al., 1994; Wu et al., 1992). In vivo, both N3 and ei systems have been shown to 
transport nucleosides from blood to cerebrospinal fluid (Spector and Berlinger, 1982). The wide 
distribution of es systems in human and rat adult brains has been verified using RT-PCR, northern blot 
and in situ hybridisation methods (Anderson et al., 1999a). Similarly, ei transcript expression has been 
recently detected in several regions of the rat brain suggesting that adenosine levels in brain are 
achieved by multiple transport processes (Anderson et al., 1999b). However the actual membrane 
localisation of these facilitative and active nucleoside transport systems has not been clarified, so far. 
 
 
 
2.2.4 ABC transport systems 
 
As presented in the previous sections (2.1.2.2 and 2.2.1-2.2.3), the specific transport of molecules 
across lipid membranes is an unconditional requirement for all living organisms and a large number of 
specific transporters have evolved to carry out this function. The largest transporter gene family is the 
ATP-binding cassette (ABC) transporter superfamily. These proteins bind ATP and use the energy of 
its hydrolysis to translocate a wide variety of substrates including sugars, amino acids, metal ions, 
peptides, proteins and a large number of hydrophobic compounds and metabolites across extra- and 
intracellular membranes. ABC pumps are mostly unidirectional, and in eukaryotes most ABC gene 
products move compounds either within the cell as part of a metabolic process or from the cytoplasm 
to the outside of the cell for transport to other organs or secretion from the body. Thus, ABC 
transporters are essential for many processes in the cell. Mutations in the according genes cause or 
contribute to several human genetic disorders including cystic fibrosis, neurological diseases, retinal 
degeneration, cholesterol and bile transport defects, anemia and drug response. 
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Most ABC transporters comprise four domains (see Figures 2-3 and 2-5): two hydrophobic membrane-
spanning domains, that form the transmembrane channel responsible for translocation of the substrate 
across the membrane, and two hydrophilic domains located at the cytosolic surface of the plasma 
membrane, which bind and hydrolyse ATP to activate the transporter (Higgins, 1992). In eukaryotes, 
the transporter is generally expressed as a single polypeptide consisting of two homologous parts, 
each half comprising one transmembrane domain (TMD) and one nucleotide (ATP) binding domain 
(NBD). Each TMD contains 5 to 6 membrane-spanning α-helices and provides the specificity for the 
substrate. The ATP-binding regions contain three conserved domains: Walker A and B domains, found 
in all ATP-binding proteins and separated by 90-120 amino acids, and a signature motif C, a stretch of 
~12 residues usually starting with LSGGQ located just upstream of the Walker B site. This signature 
motif is specific to ABC transporters and distinguishes them from other ATP-binding proteins (Hyde et 
al., 1990). ABC genes are organised as either full transporters containing two TMDs and two NBDs or 
as half transporters containing one of each domain. The half transporters assemble as either 
homodimers or heterodimers to create a functional transporter (Hyde et al., 1990). 
 
ABC genes are dispersed widely in eukaryotic genomes and are highly conserved between species, 
indicating that most of these genes have existed ever since the beginning of eukaryotic evolution. The 
genes can be divided into subfamilies based on similarity of gene structure (half versus full 
transporters), order of the domains and on sequence homology in the NBDs and TMDs. To date, 48 
human ABC genes have been characterised which can be divided into seven distinct ABC subfamilies. 
A comprehensive description of all ABC genes goes beyond the scope of this chapter, therefore, only 
a concise summary of each subfamily will be provided here. 
ABCA 
This subfamily comprises 12 full transporters and contains some of the largest ABC genes. So far, two 
members of this subfamily have been studied extensively. The ABCA1 protein is involved in disorders 
of cholesterol transport and high-density lipoprotein biosynthesis. The ABCA4 protein transports 
vitamin A derivatives in the outer segments of photoreceptor cells and therefore performs a crucial 
step in the visual cycle. 
ABCB 
The ABCB subfamily is unique in that it contains both full transporters (4) and half transporters (7). 
ABCB1 (also called MDR1 = Pgp) is the first human ABC transporter cloned and characterised by its 
ability to confer a multidrug resistance phenotype to cancer cells. The functional sites of ABCB1 
include the blood-brain barrier and therefore, this transporter will be discussed in more detail in the 
following section 2.2.4.1. ABCB4 and ABCB11 proteins are both located in the liver and are involved 
in the secretion of bile acids. The ABCB2 and ABCB3 (also called TAP) genes are half transporters 
that form a heterodimer to transport peptides into the endoplasmic reticulum. The ABCB9 half 
transporter has been localised within lysosomes and the remaining four half-transporters ABCB6, 7, 8 
and 10 have been found in mitochondria, where they function in iron metabolism and transport of Fe/S 
protein precursors. 
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ABCC 
The ABCC subfamily contains 12 full transporters with a diverse functional spectrum that includes ion 
transport, cell surface receptor and toxin secretion activities. The ABCC7 protein is a chloride ion 
channel that has a role in all exocrine secretions and mutations in ABCC7 cause cystic fibrosis. 
ABCC8 and 9 proteins bind sulfonylurea and regulate potassium channels involved in modulating 
insulin secretion. The rest of the subfamily is composed of nine multidrug resistance-associated 
protein (MRP) related genes. Of these ABCC1, 2 and 3 (also called MRP1, 2 and 3) transport drugs 
conjugated to glutathione and other organic anions. ABCC4, 5, 11 and 12 proteins are smaller than 
the other MRP1-like genes and lack an amino-terminal domain which is not essential for transport 
function. The ABCC4 and ABCC5 (also called MRP4 and 5) proteins confer resistance to nucleoside 
analogues. 
ABCD 
The ABCD subfamily makes up four genes within the human genome. All of the genes encode half 
transporters that are located in peroxisomes, where they function as homo- and/or heterodimers in the 
regulation of very long chain fatty acid transport. 
ABCE and ABCF 
The ABCE and ABCF subfamilies contain genes that have ATP-binding domains that are clearly 
derived from ABC transporters but have no TMDs and are not known to be involved in any membrane 
transport functions. The ABCE subfamily is comprised solely by the oligo-adenylate binding protein, a 
molecule that recognises oligo-adenylate that is produced in response to infection by certain viruses. 
The three known ABCF genes contain a pair of NBDs each. The human ABCF1 gene is associated 
with the ribosome and appears to mediate the activation of the eIF-2 α-kinase. 
ABCG 
The human ABCG subfamily is comprised of six ‘reverse’ half transporters that have an NBD at the 
amino terminus and a TMD at the carboxyl terminus. The mammalian ABCG1 gene is involved in 
cholesterol transport and transport regulation. Other ABCG genes include ABCG2 (a drug resistance 
gene), ABCG5 and ABCG8 (transporters of sterols in the intestine and liver), ABCG3 (to date found 
exclusively in rodent) and ABCG4 gene that is expressed predominantly in the liver. 
 
From the ABC genes presented above, at least seven ABC transporters (ABCB1, ABCC1-5, ABCG2) 
are involved in multidrug resistance (MDR), in which the cell exhibits broad cross-resistance to a 
number of structurally diverse compounds. ABCB1 (Pgp) and the ABCC1-5 genes (MRP1-5) are 
expressed in the brain and will thus be presented in the following sections 2.2.4.1 and 2.2.4.2. 
 
 
2.2.4.1 P-glycoprotein (Pgp) 
 
P-glycoprotein is a 170-kDa plasma membrane, energy-dependent efflux pump that belongs to the 
ABC superfamiliy of transporters. It is the best characterised ABC drug transport system originally 
discovered in Chinese hamster ovary cells selected for colchicine resistance (Juliano and Ling, 1976). 
Together with three other full transporters and seven half transporters the Pgp gene (ABCB1) product 
belongs to the ABCB subfamily of ABC transporters. Cells that overexpress this protein display 
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multidrug resistance to a broad spectrum of hydrophobic compounds. Pgp substrates include a wide 
variety of naturally occurring antineoplastic agents such as anthracyclines (doxorubicin, daunorubicin, 
mitoxantrone), vinca alkaloids (vincristine, vinblastine), epipodophyllotoxins (etoposide, teniposide) 
and taxanes (taxol, taxotere) as well as hydrophobic drugs (colchicine, VP16, adriamycin), 
immunosuppressive agents (cyclosporin A and its analog PCS833), cardiac glycosides (digoxin), 
antibiotics (rifampin), pesticides (ivermectin), protease inhibitors (saquinavir, indinavir, ritonavir, 
nelfinavir), lipids, steroids, xenobiotics and peptides. Currently identified Pgp transport inhibitors 
include calcium channel blockers (verapamil, PSC833, GG918), calmodulin antagonists 
(trifluoperazine), quinolines (quinidine), cyclosporin A and protease inhibitors (Dean et al., 2001; Lee 
et al., 2001). Many of these compounds function as both Pgp substrates and inhibitors and may 
interact with Pgp at more than one binding site (Ford, 1995). 
 
Pgp is the product of the MDR gene. In humans, two MDR genes, MDR1 and MDR2 (also called 
MDR3), have been cloned and sequenced (Chen et al., 1986; Roninson et al., 1986). The MDR1 
protein actually is involved in the multidrug resistance phenotype (Gros et al., 1986; Ueda et al., 1987), 
whereas the protein encoded by the human MDR2 gene functions as a phosphatidyl translocase in the 
liver (Ruetz and Gros, 1994). In addition to the human Pgp homologues, hamster pgp1, 2 and 3 
(Gerlach et al., 1986) and mouse mdr1a, 1b and 2 (Gros et al., 1986) also exist (Table 2-4). Similar to 
their human counterparts, murine Pgp encoded by mdr1a/1b confers the MDR phenotype (Gros et al., 
1986; Schinkel et al., 1994; Schinkel et al., 1995; Ueda et al., 1987) whereas the mdr2 gene product 
serves in the transport of hepatic phospholipids into the bile (Smit et al., 1993). In general, class I and 
II substrates include organic cations and lipophilic compounds whereas class III substrates are 
primarily phosholipids (Schinkel, 1997). 
 
Table 2-4 The P-glycoprotein family.  
 
species 
P-glycoprotein 
human mouse/rat hamster 
tissue specificity 
class I MDR1 mdr1a pgp1 intestine, brain, heart, kidney 
class II MDR1 mdr1b pgp2 uterus, adrenal gland, kidney, heart, brain 
class III MDR2 (MDR3) mdr2 pgp3 liver, adrenal gland, spleen, heart, muscle 
 
Adapted from Lee et al. (2001). 
 
Pgp is a single polypeptide of two homologous parts, connected by a flexible linker polypeptide. Each 
half of the protein is composed of an amino-terminal hydrophobic transmembrane domain (TMD) 
followed by a hydrophilic intracytoplasmic nucleotide (ATP) binding domain (NBD) (Figure 2-3) (Fardel 
et al., 1996). The topology of the TMD in each half of Pgp was originally predicted from the hydropathy 
plot to consist of six membrane-spanning α-helices (Gros et al., 1986). In a 25 Å resolution structure 
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by electron microscopy Pgp appears as a roughly hexagonal toroidal ring, which surrounds a large 
aqueous pore (Rosenberg et al., 1997). Cysteine cross-linkage studies demonstrated that TM helices 
6 and 12 are in close proximity to one another (Loo and Clarke, 1996). Mutations on one or both 
nucleotide-binding consensus sequences result in failure to confer MDR, suggesting that both ATP-
binding sites are required for substrate transport (Rothenberg and Ling, 1989). Three putative 
glycosylation sites are located within the first extracellular loop of the protein but do not appear to be 
involved in the transport of substrates (Beck and Cirtain, 1982). In addition, Pgp is phosphorylated at 
several sites (Hamada et al., 1987) by cAMP-dependent protein kinase A and by protein kinase C 
(Chambers et al., 1992) and several studies suggest that Pgp activity is modulated by phosphorylation 
(Bates et al., 1993; Fine et al., 1988).  
 
 
Figure 2-3 Putative membrane topology of MDR1 P-glycoprotein (Borst et al., 2000b). The position 
of carbohydrate side chains is indicated by little trees, the nucleotide binding domains 
by black ellipses. 
 
Although several models for Pgp function have been proposed, there is still no clear understanding at 
the molecular-level about substrate binding and transport mechanism. Substrates may bind to a 
cytoplasmic region of Pgp resulting in an energy-dependent conformation change that shuttles the 
drug to the outside of the plasma membrane. This classical model of a transporter resembles a 
typical substrate-enzyme interaction. The current models for Pgp function are either based on a direct 
or indirect involvement of Pgp in the transport mechanism (Ambudkar et al., 1999). The altered 
partitioning model by Roepe et al. proposes that overexpression of Pgp leads to alterations of the 
electrical membrane potential, intracellular pH and other biophysical characteristics of the cell (Roepe, 
1995; Wadkins and Roepe, 1997). These alterations in the biophysical parameters of the cell then 
decrease the intracellular level of anticancer drugs. Thus, according to this model, Pgp indirectly 
promotes decreased intracellular drug accumulation. According to the pump model (Gottesman and 
Pastan, 1988) (Figure 2-4 a), the energy of ATP hydrolysis by Pgp is spent on the removal of drugs 
that have entered the cell by passive diffusion from the cytoplasm. It is hypothesised that Pgp forms a 
hydrophilic pathway and recognises substrates by one or more complex substrate recognition sites 
and then directly pumps the drugs out of the cell through the middle of the pore by using molecular 
mechanisms that are not yet well understood. The majority of experimental data strongly support the 
direct drug pump model. Evidence for a direct interaction between many of the substrates or reversing 
agents with the transporter has been gathered (reviewed in Ambudkar et al., 1999) but the nature of 
these interactions is still unknown.  
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Figure 2-4 Possible mechanisms of action for drug efflux by P-glycoprotein (Johnstone et al., 
2000). (a) pump model; (b) hydrophobic vacuum cleaner model (left side) and flippase 
model (right side). 
 
But because of the unusual kinetics of drug uptake and efflux, which suggest that drugs are detected 
and collected before they reach the cytoplasm and because of some experiments indicating that 
substrates can be removed directly from the plasma membrane, it is proposed that Pgp is a 
hydrophobic vacuum cleaner (Figure 2-4 b, left part), whose primary mode of action is to bind and 
remove its hydrophobic substrates directly from the lipid bilayer (Ambudkar et al., 1999; Gottesman 
and Pastan, 1993; Raviv et al., 1990). Another version of this model suggests that Pgp acts as a 
flippase (Figure 2-4 b, right part) carrying membrane-bound substrates from the inner leaflet of the 
lipid bilayer to the outer leaflet (Higgins and Gottesman, 1992; Sharom, 1997). The drug intercalates 
into the inner leaflet of the lipid bilayer, is flipped into the outer leaflet and released into the 
extracellular space. Movement of drug from the inner to the outer leaflet is a relatively quick process, 
whereas drug movement from the inner membrane leaflet through the hydrophilic headgroup region 
into the cytosol is relatively slow (Johnstone et al., 2000). Furthermore, a partition equilibrium is built 
up at both phase boundaries cytoplasm/inner leaflet and outer leaflet/extracellular space in favour of a 
drug transport out of the cell. This model is supported by the finding that the MDR2 gene product acts 
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as a phosphatidylcholine translocase (flippase) (Romsicki and Sharom, 2001; Ruetz and Gros, 1994; 
Smit et al., 1993). Pgp, the MDR1 gene product, also transports phospholipids such as phosphatidyl-
ethanolamine or phosphatidylcholine (Bosch et al., 1997). In addition to accounting for the known 
experimental observations regarding the action of Pgp, this model may explain the rather broad 
substrate specificity of Pgp based on the different rules governing hydrophobic interactions in a lipid 
bilayer environment. Whether Pgp transports substrates by a combination of several different methods 
remains to be elucidated (Ambudkar et al., 1999).  
 
The identification of Pgp as an energy-dependent pump, which could confer resistance to hydrophobic 
compounds cytotoxic to cancer cells, raised the question of the normal functions of Pgp. The first hint 
as to what these functions might be arose from studies in which monoclonal antibodies to Pgp were 
used to localise the protein in frozen sections of human tissues (Thiebaut et al., 1989). In all tissues 
Pgp expressing cell types show plasma membrane localisation. In epithelial cells of the lower 
gastrointestinal tract (jejunum, ileum and colon) high levels of Pgp are located only on the mucosal 
surface of these tissues, which suggests a function of Pgp in preventing the uptake of substrates and 
perhaps in facilitating excretion across the mucosa of the gut. In kidney and liver, Pgp is present on 
the brush border and biliary face, respectively, of proximal tubule cells and hepatocytes, consistent 
with a role of Pgp in excretion of xenobiotics and endogenous metabolites into the urine and bile. One 
of the most interesting localizations of Pgp is on the luminal surface of capillary endothelial cells in the 
brain (Cordon-Cardo et al., 1989) and testis, consistent with a role for Pgp in supporting the blood-
brain and blood-testis barriers. Apart from the mentioned tissues Pgp expression was found in heart, 
uterus, renal epithelia and adrenal gland (Borst et al., 1993; Croop et al., 1989; Fojo et al., 1987; 
Schinkel, 1997; Thiebaut et al., 1987; Thiebaut et al., 1989). A second hint for the physiological role 
was obtained by studies using knock-out mice. Pgp deficient mice are viable, fertile and healthy 
compared to wild type, but exhibit significantly elevated drug levels, particularly in the brain (Schinkel, 
1997; Schinkel et al., 1994) suggesting in some cases almost complete abrogation of the blood-brain 
barrier for these drugs and in other cases partial elimination of this barrier. These results are entirely 
consistent with the previously observed high expression levels of MDR1 on the luminal surface of 
capillary endothelial cells in the human brain (Cordon-Cardo et al., 1989). Drugs tested so far include 
ivermectin that normally does not enter the rodent brain in significant amounts. It is however enriched 
approximately 100-fold in the brain of mdr1 defective mice and that is lethal in mdr1 knockout mice at 
concentrations that do not affect wild-type mice. Digoxin also appears to be a substrate for the Pgp at 
the blood-brain barrier (Ambudkar et al., 1999). Although immunohistochemical studies and luminal 
membrane isolation have localised Pgp to the luminal surface of the brain endothelium (Beaulier et al., 
1997; Cordon-Cardo et al., 1989; Jette and Beliveau, 1993; Jette et al., 1993; Sugawara et al., 1990), 
the localisation of Pgp along the brain endothelial microvessels remains debatable, as Pgp has also 
been identified at the abluminal surface of endothelial cells on neighbouring astrocyte foot processes 
(Golden and Pardridge, 1999). The primary Pgp isoform detected in brain microvessels is mdr1a 
whereas mdr1b mRNA is the main isoform detected in brain parenchyma (Regina et al., 1998). Apart 
from the function at the blood-brain barrier, Pgp is also expressed at the apical side of the choroid 
plexus epithelia (Rao et al., 1999) (see Figure 2-7 at the end of section 2.2.4.2). 
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2.2.4.2 Multidrug resistance-associated proteins (MRPs) 
 
The multidrug resistance-associated proteins (MRPs) belong to the ABCC subfamily of ABC 
transporters. They became known with respect to drug resistance in 1992 when Cole et al. (1992) 
cloned the multidrug resistance-associated protein gene, now known as MRP1. MRP2 followed in 
1996 (Büchler et al., 1996; Flens et al., 1996; Taniguchi et al., 1996) and notion of an MRP family with 
five members was introduced in 1997 by Kool et al. (1997). MRP6 was added in 1999 (Kool et al., 
1999a) and the existence of MRP7 (Hopper et al., 2001) and MRP8 (Bera et al., 2001) has been 
inferred from a database search. Some of these MRPs are also known by other names, as 
summarised in Table 2-5 (Borst et al., 1999). For example, MRP2 was characterised as the canalicular 
multispecific organic anion transporter (cMOAT) long before its cloning (Jansen et al., 1985), because 
this transporter is missing in rats with an inborn error in the biliary secretion of organic anions, 
including the conjugated bilirubins. Hence, the term MOAT has also been used for other members of 
the MRP family. 
 
Table 2-5 The human MRP family, some of the alternative names used in the literature and their 
tissue distribution. 
 
members other names used tissue distribution 
MRP1 ABCC1 and MRP ubiquitous 
MRP2 ABCC2, cMOAT and cMRP liver, kidney, gut 
MRP3 ABCC3, MOAT-D and cMOAT-2 liver, adrenals, pancreas, kidney, gut 
MRP4 ABCC4 and MOAT-B prostate, lung, muscle, pancreas, testis, ovary, bladder, gallbladder 
MRP5 ABCC5, MOAT-C and pABC11 ubiquitous 
MRP6 ABCC6, MOAT-E and MLP-1 liver, kidney 
MRP7 ABCC10 ubiquitous at very low levels 
MRP8 ABCC11 breast, testis, liver, brain, placenta 
 
Adapted from Borst et al. (2000a). MOAT, multispecific organic anion transporter. 
 
The eight MRPs studied so far contain two transmembrane domains of six α-helices each (Pgp-like 
core) connected to a cytoplasmic linker (L0) region (Figure 2-5) (Borst et al., 1999; Borst et al., 2000a; 
Konig et al., 1999). In addition, MRP1, MRP2, MRP3, MRP6 and MRP7 contain up to six additional 
membrane-spanning helices (TMD0) at the N-terminus (Borst et al., 1999; Klein et al., 1999; Lautier et 
al., 1996). Although this extra N-terminal domain is not required for drug transport, the linker region 
(L0) is absolutely necessary to maintain the protein transport properties (Bakos et al., 1998; Gao et al., 
1996).  
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Figure 2-5 Two-dimensional membrane topology models (Borst et al., 2000a) for 190 kDa MRP1 
(MRP2, MRP3, MRP6, MRP7) and 160 kDa MRP5 (MRP4, MRP8). NBD, nucleotide 
binding domain; L0, linker domain zero; TMD, transmembrane domain. 
 
The MRPs are organic anion transporters, i.e., they transport anionic drugs, exemplified by 
methotrexate and neutral drugs conjugated to acidic ligands, such as glutathione (GSH), glucuronate 
or sulfate (Borst et al., 1999). However, MRP1, MRP2 and MRP3 can also cause resistance to neutral 
organic drugs that are not known to be conjugated to acidic ligands by transporting these drugs 
together with free GSH (Jedlitschky et al., 1996). For example, the most extensively characterised 
MRP familiy member MRP1 can confer resistance to vinca alkaloids (vincristine and vinblastine), to 
epidophyllotoxins (etoposide and epirubicin), to anthracyclines (doxorubicin and daunorubicin), to 
camptothecin derivatives (CPT11 and SN38) as well as paclitaxel. This substrate specificity of MRP1 
initially seemed to be similar to that of Pgp (Borst et al., 2000a), however more in-depth work showed, 
that the preferred substrates for MRP1 are organic anions (Leier et al., 1996; Muller et al., 1994), e.g., 
drugs conjugated to glutathione (GSH), glucuronate, or sulfate (Hipfner et al., 1999; Konig et al., 
1999), whereas Pgp has a low affinity for such negatively charged compounds. In fact, MRP1 is one of 
the elusive glutathione-S-conjugate (GSX) pumps, a transporter able to transport drugs conjugated to 
GSH out of the cell. This explains the ability of MRP1 to transport substrates such as methotrexate or 
arsenite. Methotrexate is an organic anion and arsenite (H3AsO3) can form a complex with three GSH 
molecules to give As(SG)3 and 3 H2O. Moreover, it is presumably this complex that is transported by 
MRP1, as indicated by the ability of H3AsO3 to induce increased GSH export from cells with elevated 
levels of MRP1 [Zaman, 1995 #180]. In summary, most high affinity substrates for MRP1 are organic 
anions with a substantial hydrophobic moiety and at least one, but preferably two, negative charges. 
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Examples of potent competitive inhibitors are high-affinity substrates, such as leukotriene C4 and S-
decylglutathione. Other inhibitors for MRP1 are organic acids that were originally developed to inhibit 
transport of uric acid, like sulfinpyrazone, benzbromarone and probenecid. The substrate spectrum of 
MRP2 may eventually turn out to be similar to that found for MRP1 with one exception: MRP2 includes 
cis-platin resistance, which has never been seen in cells overexpressing MRP1 (Borst et al., 2000a). 
Unlike MRP1 and MRP2, MRP3 prefers glucuronate conjugates as substrates over GSH conjugates 
(Hirohashi et al., 1999; Kool et al., 1999b). Resistance was also shown for etoposide and 
methotrexate. MRP4 overexpression is associated with high-level resistance to nucleoside analogues 
and azidothymidine, both of which are used as anti-human immunodeficiency virus drugs. MRP4 might 
however be specific for phosphate conjugates and it remains to be determined whether MRP4 can 
also transport GSH, glucuronide, or sulfate conjugates. For MRP5 the transport of GSH conjugates 
has already been shown and appears to be a nucleoside analogue pump like MRP4 (Borst et al., 
2000a). The potential involvement of MRP6, MRP7 and MRP8 in drug resistance is still unclear. 
 
Although the exact mechanism by which GSH enhances MRP substrate transport is currently 
unknown, MRP may contain bipartite binding sites that would allow for direct binding of drug-GSH 
complexes or sequential binding of GSH and drug (Loe et al., 1996b). It has been suggested that one 
of these binding sites may have a high affinity for a particular drug and low affinity for GSH, whereas 
the second binding site is of the opposite conformation (Borst et al., 1999). Whether GSH may elicit a 
conformational change in the MRP protein that might favour transport of selected compounds remains 
unknown (Loe et al., 1996b). GSH itself appears to be a poor substrate of MRP and is transported only 
marginally in the absence of a proper MRP substrate (Leier et al., 1996). Thus, it appears that there 
are two mechanisms of transport for MRP substrates: anionic compounds are transported directly, 
whereas some cationic and neutral compounds require the presence of GSH, likely via cotransport. 
Enhancement of substrate transport (aflatoxin, vincristine) by GSH does not appear to be a 
consequence of an alteration in the redox state of MRP since other reducing agents (2-
mercaptoethanol, dithiothreitol) have not been able to alter the transport of these substrates in a 
similar manner (Loe et al., 1997). Whether GSH and unconjugated substrates interact molecularly for 
the purpose of cotransport is presently unclear.  
 
Physiologically, MRP1 appears to play an important role in the transport of several GSH, glucuronide 
and sulfate conjugates, including conjugated leukotriene C4 (Lautier et al., 1996; Leier et al., 1996; Loe 
et al., 1996b), which is an important signalling molecule for the migration of dendritic cells from 
peripheral tissue to lymph node (Dean et al., 2001), steroid glucuronides (Loe et al., 1996a) and GSH 
disulfide (Leier et al., 1996). Thus, MRP1 may also play a role in the regulation of intracellular redox 
potential, flux of ions (Rappa et al., 1999), inflammatory mediation and elimination of potentially toxic 
endo- and xenobiotics (Deeley and Cole, 1997). Furthermore, MRP1 transport of heavy metal 
oxyanions such as sodium arsenate and antimony potassium tatrate suggests that MRP1 may play a 
protective role against environmental toxins. MRP2 is the major transporter responsible for the 
secretion of bilirubin glucuronides into bile (Konig et al., 1999; Paulusma et al., 1996). Humans without 
MRP2 develop a mild liver disease known as the Dubin-Johnson syndrome (Paulusma et al., 1997; 
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Toh et al., 1999). The physiological functions of the remaining MRP family members is currently 
unknown, however, a role for MRP3 in the normal uptake of bile salts from the gut has been 
postulated (Borst et al., 2000a) and recent studies demonstrating the ability of MRP4 and MRP5 to 
transport nucleotide analogues suggest that these two MRP homologues may be involved in 
nucleotide/nucleoside transport in vivo (Wijnholds et al., 2000). 
 
The Mrp1 (-/-) mice show no alteration concerning viability, fertility and/or biochemical profile versus 
wild-type mice (Rappa et al., 1999). Indeed, no decreased disposal of drugs has been observed in 
Mrp1 (-/-) mice (Wijnholds et al., 1997). Nevertheless, they are hypersensitive to etoposide (Wijnholds 
et al., 1997) and this is especially manifested in bone marrow, testis, kidney and the oropharyngeal 
mucosa, i.e. in cells which normally have a substantial amount of Mrp1 (Wijnholds et al., 1998). As 
MRP1 is located at the basolateral side of epithelial cells (Evers et al., 1996), it tends to pump drugs 
into the body, rather than into bile, urine or gut for disposal, as Pgp does. Nevertheless, MRP1 can 
protect vital cell layers from destruction, for instance, the basal stem cell layer in the oral mucosa 
(Wijnholds et al., 1998). There are also important organs in the body that require a basolateral 
transporter for protection. A good example are the testicular tubes. The male germ cells are protected 
by a ring of Sertoli cells with their apical surface towards the lumen. The high concentration of MRP1 
in the basal membrane of the Sertoli cells helps to protect the germ cells by pumping out drug from the 
testicular tubule (Wijnholds et al., 1998). Another position in the body where a basolateral transporter 
is useful for protecting a vital organ is the choroid plexus. This structure protrudes into the 
cerebrospinal fluid and is essential for exchange of metabolites between blood and cerebrospinal fluid. 
The epithelial cell layer of the plexus contains a high amount of MRP1 (Rao et al., 1999) and absence 
of MRP1 results in considerable accumulation of intravenously administered etoposide in the 
cerebrospinal fluid (Wijnholds et al., 2000). Whether MRP2 to MRP8 also play a role in protection 
against exogenous toxic compounds remains to be investigated. 
 
The tissue distribution of the MRPs (Table 2-5) provides further indications for their physiological 
function. While MRP1, MRP4, MRP5 and MRP7 mRNAs are widely distributed in the body, MRP2, 
MRP3 and MRP6 appear mainly to function in liver, kidney and gut (Borst et al., 2000a; Lee et al., 
2001). Most cells appear to express multiple MRP family members, with one MRP generally 
dominating (Keppler, 1999). Within polarised cells MRP2 is the only homologue located in the apical 
membrane (similar to Pgp) (Schaub et al., 1997) whereas MRP1, MRP3 and MRP5 are all routed to 
the basolateral membrane (Evers et al., 1996; Flens et al., 1996; König, 1999; Kool et al., 1999a) 
(Figure 2-6). The localisation of the other members has not been clarified so far. 
 
 
 
 
 
Figure 2-6 Schematic representation of the localisation 
of MDR1 (Pgp), MRP1, MRP2, MRP3 and MRP5 in 
transfected polarised epithelial cells (Borst et al., 1999). 
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However, the expression and localisation within the brain of the multidrug resistance-associated 
proteins (MRPs) is only beginning to be understood and quite complex due to the existence of several 
different homologues of MRP. MRP1 expression in the brain is widely confirmed for the choroid 
plexus. High levels of MRP1 have been detected in the choroid plexus using RT-PCR and western blot 
techniques [Nishino, 1999 #352]. Using a combination of fluorescence confocal and electron 
microscopy, (Rao et al., 1999) determined the localisation of MRP1 to be primarily basolateral within 
cultured choroid plexus. The high level of MRP1 in these cells plays a crucial role in preventing the 
entry of a drug into the cerebrospinal fluid (Rao et al., 1999; Wijnholds et al., 2000)[Nishino, 1999 
#352]. Meanwhile MRP1 expression has also been found in rat (Kusuhara et al., 1998; Miller et al., 
2000; Regina et al., 1998) and bovine (Zhang et al., 2000) cerebral capillaries as well as in isolated 
human brain capillary endothelial cells (Dombrowski et al., 2001) indicating a functionality at the blood-
brain barrier. In Figure 2-9 the localisation of MRP1 and Pgp at both barriers of the central nervous 
system is summarised. In more recently studies, blood-brain barrier localisation is reported for MRP2 
in fish and rat brain capillaries (Miller et al., 2002; Miller et al., 2000) and human brain capillary 
endothelial cells (Dombrowski et al., 2001). MRP3, MRP4 and MRP6 have been detected in bovine 
capillaries by RT-PCR analysis (Zhang et al., 2000) as well as MRP5 which has additionally been 
found in human brain capillary endothelial cells (Dombrowski et al., 2001). MRP7 and MRP8 have 
only been characterised in total human brain tissue, so far (Bera et al., 2001; Hopper et al., 2001). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-7 Pgp and MRP1 efflux systems in the blood-brain barrier (BBB) and choroid plexus (CP) 
(Lee et al., 2001). Arrows indicate the direction of transport. 
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2.3 Objectives of the project 
 
A cell culture model of porcine brain capillary endothelial cells that closely mimics the blood-brain 
barrier phenotype has been established in our group as described in section 2.1.3 (Hoheisel et al., 
1998). The typical blood-brain barrier characteristics of a low paracellular permeability and high 
transendothelial electrical resistance have been induced by supplementing serum-free culture with 
hydrocortisone.  
 
In order to identify genes which are responsible for this improved blood-brain barrier phenotype a 
differential screening of a subtracted cDNA library was the aim of this work. Beside others one gene 
was found to be considerably up-regulated by hydrocortisone treatment of brain capillary endothelial 
cells and was characterised on the cDNA and the amino acid level by sequence analysis. This gene 
was identified as a member of the ATP-binding cassette (ABC) transporter family with high homology 
to the multidrug resistance protein BCRP (breast cancer resistance protein; Doyle et al., 1998) and 
therefore named brain multidrug resistance protein (BMDP).  
 
As gained from sequence analysis, its possible physiological role as a multidrug resistance protein at 
the blood-brain barrier had to be tested in further experiments. Thereby, we focussed on the 
expression and subcellular localisation of BMDP within different cells of the central nervous system on 
transcriptional and protein level. Furthermore, BMDP expression had to be characterised in various 
other tissues in order to assess the importance of its expression in relation to the blood-brain barrier. 
Since BMDP was found to be an ABC transport protein, its expression had to be compared to other 
ABC transporters known to be localised at the blood-brain barrier and thought to be responsible for 
drug exclusion from the brain like P-glycoprotein and multidrug resistance protein 1 (MRP1).  
 
To reveal the transport properties of BMDP, specific substrates were selected to analyse the 
directionality for substrate transport of this new drug transporter at the blood-brain barrier in vitro. 
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3 Identification of a new multidrug resistance protein  
 
3.1 Aims and rationale 
 
Hydrocortisone (HC) is known to induce the barrier forming phenotype in cultured porcine brain 
capillary endothelial cells (PBCEC) (Hoheisel et al., 1998) which is one of the most prominent features 
of the blood-brain barrier (BBB). The aim of the present work was to find out which genes are 
regulated by hydrocortisone and thus probably involved in this improvement of the BBB phenotype by 
differential screening of a subtracted cDNA library. 
 
 
3.2 Results 
 
3.2.1 Differential screening of a subtracted cDNA library  
 
The establishment of the subtracted cDNA library was performed by the subtractive suppression 
hybridisation (SSH) technique using Clontech PCR-SelectTM cDNA Subtraction Kit (for details see 
section 7.2.13.1). First, cDNA was synthesised from hydrocortisone treated (tester) and untreated 
(driver) PBCEC. Tester and driver cDNAs were then subtracted by two hybridisation steps. While the 
concentrations of high- and low-abundance sequences were equalised differentially expressed 
sequences were selectively enriched. Next, only the desired differentially expressed sequences were 
amplified by PCR and directly cloned to create the subtracted library. The PCR-Select Differential 
Screening Kit (Clontech) was used to prescreen clones before confirming differential expression by 
northern blot analysis (for details see section 7.2.13.2). Clones from the subtracted library were 
arrayed on four nylon membranes and hybridised with four different probes (Figure 3-1): one probe 
prepared from the subtracted cDNA, another probe made from reverse-subtracted cDNA, and 
nonsubtracted probes synthesised directly from tester and driver cDNAs. To generate the reverse-
subtracted probe, subtractive hybridisation was performed with the original tester cDNA as a driver 
and the driver cDNA as a tester. Clones hybridising to tester but not to driver were expected to be 
differentially expressed. However, nonsubtracted probes are not sensitive enough to detect rare 
messages, while subtracted probes are greatly enriched for rare differentially expressed sequences 
and therefore can detect rare transcripts. Thus, clones representing mRNAs that are truly differentially 
expressed were expected to hybridise only with the forward-subtracted probe, while clones that 
hybridise with the reverse-subtracted probe were considered as background.  
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Figure 3-1 Differential screening of a subtracted cDNA library. 
 
Subtraction was performed using hydrocortisone treated PBCEC cDNA as tester and untreated PBCEC cDNA as driver; for the 
reverse subtraction, tester and driver were switched. Clone C8 (accentuated by boxes) was expected to be differentially 
expressed and further analysed. 
 
 
 
 
Using this method approximately 600 cDNA clones were screened and about 150 cDNA clones were 
found to be potentially up-regulated in PBCEC after hydrocortisone treatment. 104 cDNA clones were 
sequenced and 16 cDNA clones were analysed by northern blot analysis, so far. In Figure 3-1 
clone C8 is expected to be differentially expressed because hybridisation occurred only with tester and 
forward-subtracted but not with driver and reverse-subtracted probes. This clone was isolated and the 
cDNA insert was sequenced. Comparison of the 116 bp cDNA fragment (Figure 3-2) to sequences in 
the data base using the software BLASTX revealed high homology to a large number of multidrug 
resistance proteins. Therefore, we named the expected gene product brain multidrug resistance 
protein (BMDP). 
 
 
 
Figure 3-2 Nucleotide sequence of cDNA clone C8. 
 
 
 
 
ACTTCAGCATTCCTCGATACGGCTTTTCGGCTTTGCAGTATAATGAGTTT
TTGGGACAAAACTTCTGCCCTGGACTCAACGTCACAACAAACAATACCTG
TAGCTTCGCAATATGT
50
100
116
Screening with subtracted cDNA probes
forward-subtracted probe reverse-subtracted probe
Screening with nonsubtracted cDNA probes 
tester probe driver probe
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3.2.2 Analysis of a putative differentially expressed cDNA clone  
 
3.2.2.1 Northern blot analysis for the expression of cDNA clone C8 (BMDP) 
 
In order to confirm the up-regulation of BMDP in hydrocortisone treated porcine brain endothelial cells 
the expression was analysed by standard northern blot analysis. Total RNA from hydrocortisone 
treated and untreated PBCEC was blotted and probed with the isolated 116 bp cDNA fragment of 
clone C8 (Figure 3-2). Figure 3-3 confirms a fivefold overexpression of a 2.1 kb mRNA transcript upon 
hydrocortisone treatment as determined by laserdensitometric scanning. These data underline that 
BMDP is significantly up-regulated in cerebral endothelium. Thus, unrevealing its role in determining 
the characteristics of the blood-brain barrier phenotype was then the aim of this PhD work. 
 
 
Figure 3-3 Northern blot analysis for the expression of cDNA clone C8 (BMDP). 
 
Northern blot analysis was performed on 20 µg of total RNA of each sample isolated from hydrocortisone treated (+HC) and 
untreated (-HC) porcine brain capillary endothelial cells and probed for BMDP (clone C8). Same northern blot was hybridised 
with α-32P-labelled GAPDH probe to show loading of RNA. Signal intensities were analysed and calculated by 
laserdensitometric scanning. 
 
 
 
3.2.2.2 Genomic Southern blot analysis of cDNA clone C8 (BMDP) 
 
Southern blot analysis of genomic DNA isolated from porcine liver tissue was performed to investigate 
the genomic organisation of BMDP. The number of visible bands will correspond to the number of 
BMDP genes in the porcine genome unless the genomic sequence to which the probe hybridises has 
been cut by a restriction enzyme. To eliminate this option the genomic DNA was digested by three 
different hexanucleotide-recognising restriction enzymes. As shown in Figure 3-4 the genomic 
Southern blot displays three (HindIII, BamHI) and four (EcoRI) signals, indicating that the gene 
corresponding to BMDP is either represented with a maximum of three or four copies in the porcine 
genome or other related genes that cross-hybridise with the probe may exist in the genome. 
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Figure 3-4 Southern blot analysis of cDNA clone C8 (BMDP). 
 
Genomic Southern blot analysis of 10 µg genomic porcine liver DNA digested with 
HindIII (H), BamHI (B) and EcoRI (E) and hybridised with the radiolabelled insert of 
cDNA clone C8 (BMDP). 
 
 
 
Figure 3-5 Isolation of the full-length cDNA sequence of BMDP by RACE-PCR tenchnology. 
 
A 2% Agarosegel of 3’-RACE-PCR product generated with the primers BMDP_C8-F and 3’RACE-R. cDNA was synthesized 
from 5 µg of total RNA using SUPERSCRIPTTM II RNase H- Reverse Transcriptase (Life Technologies). 
B 1% Agarosegel of 5’-RACE-PCR product using the SMARTTM RACE cDNA Amplification Kit (Clontech). cDNA was 
synthesized from 500 ng mRNA according to the manufacturer’s instructions. BMDP_5’RACE-R and 
BMDP_Nested5’RACE-R primer were used as gene-specific primers together with the applied universal primers . 
C 1% Agarosegel of Long-Distance-PCR product using same cDNA as in B as template and BMDP_complete-F and 
BMDP_complete-R as primers. 
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3.2.3 Isolation of the full-length cDNA sequence by RACE-PCR technology 
 
Based on the known sequence of the 116 bp fragment of clone C8 the full-length cDNA of BMDP was 
obtained by 3’- and 5’-RACE-PCR and finally Long-Distance-PCR (LD-PCR). Figure 3-5 A shows one 
3’-RACE-PCR product of 350 bp in length and Figure 3-5 B the 5’-RACE-PCR product of 1.9 kb. Both 
PCR products were sequenced and identified as parts of the BMDP gene. Overlapping parts of the 
sequences are schematically shown in Figure 3-6. Finally, the full-length cDNA clone was generated 
by LD-PCR with 5’- and 3’-end flanking primers being specific for BMDP. In Figure 3-5 C the LD-PCR 
product of 2.1 kb in length confirms the result of the transcript length observed in the northern blot 
analysis (see Figure 3-3). 
 
Figure 3-6 Schematic description of PCR reactions to obtain the full-length cDNA of BMDP. 
 
Based on cDNA clone C8 with the known sequence length of 116 bp (position 1797-1912) stepwise sequencing finally led to the 
full-length cDNA sequence: 3’-RACE-PCR product from position 1803 to 2112, 5’-RACE-PCR product from 1 to 1945 and LD-
PCR product from 1 to 2112. 
 
 
 
3.2.4 Analysis of the cDNA sequence 
 
The full-length cDNA of BMDP generated by LD-PCR comprises 2112 bp (Figure 3-7) and is published 
under GenBank accession AJ420927. A single large open reading frame (ORF) was found starting 
with ATG at position 86 and ending with an in-frame termination codon TAA at position 2054. The 
ORF codes for a protein of 656 amino acids with a calculated molecular weight of 72,391 Daltons. The 
5’ non-translated region consists of 85 nucleotides. The methionine coding ATG triplet at position 86 is 
the first ATG at the 5’ terminus and thus the starting signal for protein biosynthesis by the ribosomes 
which bind to the 5’ CAP of mRNAs and then start with translation at the first AUG. The environment of 
the AUG codon is also important for the exact recognition by ribosomes but not as conserved as the 
Shine-Dalgarno sequence in bacterial systems. The starting sequence 82-CCAGAUG-88 of BMDP 
mRNA resembles the known Koszak sequence for eukaryotic systems which is CCAAUGG (Alberts et 
al., 1997b). The 3’ non-translated region consists of 59 nucleotides abundant in adenine and the 
characteristic polyadenylation signal of 2088-ATTAAA-2093, which is involved in the formation of 
mature mRNAs in vertebrates. Generally, the cleavage and polyadenylation of the pre-mRNA occurs 
10-30 nucleotides downstream of an AAUAAA or AUUAAA signal sequence (Beaudoing et al., 2000). 
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Figure 3-7 Nucleotide sequence and the deduced amino acid sequence of BMDP. 
 
1  ACGCGGGGGA GCATAAGAGT TCCTGAGATT GGAGCCCTTG GTTGAACTGA ACCGTTATTA AGCTGAAAAG GCAGAAACAC  TCCAG  ATG TCC 
Met Ser 
92  TCC AAT AGT TAC CAA GTT TCA ATC CCG ATG TCA AAA AGG AAC ACC AAT GGC CTG CCG GGG TCC AGC TCC AAT GAG CTG  
Ser Asn Ser Tyr Gln Val Ser Ile Pro Met Ser Lys Arg Asn Thr Asn Gly Leu Pro Gly Ser Ser Ser Asn Glu Leu  
170  AAG ACG TCT GCT GGG GGA GCT GTG TTA AGC TTT CAT GAC ATC TGC TAT CGA GTG AAA GTG AAG AGT GGC TTT CTT TTT  
Lys Thr Ser Ala Gly Gly Ala Val Leu Ser Phe His Asp Ile Cys Tyr Arg Val Lys Val Lys Ser Gly Phe Leu Phe  
248  TGT CGG AAA ACG GTT GAG AAG GAA ATA CTG ACG AAC ATC AAT GGG ATC ATG AAA CCT GGC CTC AAT GCC ATT CTG GGA  
Cys Arg Lys Thr Val Glu Lys Glu Ile Leu Thr Asn Ile Asn Gly Ile Met Lys Pro Gly Leu Asn Ala Ile Leu Gly  
326  CCC ACA GGT GGA GGC AAA TCT TCG TTG TTA GAT GTC TTA GCT GCA AGG AAA GAT CCG CAT GGA TTA TCT GGA GAT GTT  
Pro Thr Gly Gly Gly Lys Ser Ser Leu Leu Asp Val Leu Ala Ala Arg Lys Asp Pro His Gly Leu Ser Gly Asp Val  
404  TTG ATC AAT GGA GCA CCT CGA CCT GCC AAT TTT AAA TGT AAC TCA GGT TAC GTG GTA CAG GAT GAC GTC GTG ATG GGA  
Leu Ile Asn Gly Ala Pro Arg Pro Ala Asn Phe Lys Cys Asn Ser Gly Tyr Val Val Gln Asp Asp Val Val Met Gly  
482  ACG CTG ACA GTG AGA GAA AAC TTA CAG TTC TCG GCA GCT CTT CGG CTT CCG ACC ACC ATG ACA AAT CAT GAA AAA AAT  
Thr Leu Thr Val Arg Glu Asn Leu Gln Phe Ser Ala Ala Leu Arg Leu Pro Thr Thr Met Thr Asn His Glu Lys Asn  
560  GAG CGG ATT AAC ATG GTC ATT CAA GAG TTG GGT CTG GAT AAA GTG GCC GAT TCC AAG GTG GGA ACC CAG TTT ATC CGT  
Glu Arg Ile Asn Met Val Ile Gln Glu Leu Gly Leu Asp Lys Val Ala Asp Ser Lys Val Gly Thr Gln Phe Ile Arg  
638  GGT GTG TCT GGA GGA GAA AGA AAA CGG ACT AGT ATT GCA ATG GAG CTT ATT ACT GAC CCG TCT ATC TTG TTC CTG GAT  
Gly Val Ser Gly Gly Glu Arg Lys Arg Thr Ser Ile Ala Met Glu Leu Ile Thr Asp Pro Ser Ile Leu Phe Leu Asp  
716  GAG CCC ACG ACT GGC TTA GAC TCC AGC ACA GCA AAT GCT GTC CTT TTG CTC CTG AAG AGG ATG TCT AAA CAA GGA CGG  
Glu Pro Thr Thr Gly Leu Asp Ser Ser Thr Ala Asn Ala Val Leu Leu Leu Leu Lys Arg Met Ser Lys Gln Gly Arg  
794  ACC ATC ATC TTC TCC ATT CAT CAG CCT CGT TAC TCC ATC TTT AAG TTG TTT GAT AGC CTC ACC TTG TTG GCC TCA GGA  
Thr Ile Ile Phe Ser Ile His Gln Pro Arg Tyr Ser Ile Phe Lys Leu Phe Asp Ser Leu Thr Leu Leu Ala Ser Gly  
872  AGA CTC ATG TTC CAT GGA CCT GCT CGG GAG GCC TTG GGA TAC TTT GCC TCC ATC GGT TAC AAC TGT GAG CCC TAC AAC  
Arg Leu Met Phe His Gly Pro Ala Arg Glu Ala Leu Gly Tyr Phe Ala Ser Ile Gly Tyr Asn Cys Glu Pro Tyr Asn  
950  AAC CCC GCA GAC TTC TTC CTG GAC GTC ATT AAC GGC GAC TCC TCC GCT GTG GTG TTA AGC AGA GCG GAC AGA GAC GAG  
Asn Pro Ala Asp Phe Phe Leu Asp Val Ile Asn Gly Asp Ser Ser Ala Val Val Leu Ser Arg Ala Asp Arg Asp Glu  
1028  GGA GCC CAA GAG CCC GAA GAG CCT CCC GAG AAA GAT ACT CCC CTC ATA GAC AAA CTT GCT GCG TTT TAT ACC AAC TCC  
Gly Ala Gln Glu Pro Glu Glu Pro Pro Glu Lys Asp Thr Pro Leu Ile Asp Lys Leu Ala Ala Phe Tyr Thr Asn Ser  
1106  TCC TTC TTC AAG GAC ACG AAG GTT GAG TTA GAT CAG TTC TCA GGG GGT CGG AAG AAG AAG AAG AGC TCG GTG TAC AAG  
Ser Phe Phe Lys Asp Thr Lys Val Glu Leu Asp Gln Phe Ser Gly Gly Arg Lys Lys Lys Lys Ser Ser Val Tyr Lys  
1184  GAG GTC ACC TAC ACC ACC TCC TTC TGT CAT CAG CTC CGA TGG ATT TCC AGG CGT TCC TTC AAA AAC TTA CTG GGT AAT  
Glu Val Thr Tyr Thr Thr Ser Phe Cys His Gln Leu Arg Trp Ile Ser Arg Arg Ser Phe Lys Asn Leu Leu Gly Asn  
1262  CCC CAG GCG TCC GTA GCC CAG ATA ATT GTG ACG ATC ATC CTG GGC CTG GTT ATA GGT GCC ATT TTC TAT GAT CTG AAA  
Pro Gln Ala Ser Val Ala Gln Ile Ile Val Thr Ile Ile Leu Gly Leu Val Ile Gly Ala Ile Phe Tyr Asp Leu Lys  
1340  AAT GAT CCC TCA GGA ATC CAG AAC AGA GCC GGA GTG CTC TTC TTC CTG ACA ACC AAC CAG TGT TTC AGC AGC GTC TCG  
Asn Asp Pro Ser Gly Ile Gln Asn Arg Ala Gly Val Leu Phe Phe Leu Thr Thr Asn Gln Cys Phe Ser Ser Val Ser  
1418  GCC GTG GAG CTC CTT GTG GTG GAG AAG AAA CTC TTT ATA CAT GAA TAT ATC AGT GGA TAC TAC AGA GTG TCA TCT TAT  
Ala Val Glu Leu Leu Val Val Glu Lys Lys Leu Phe Ile His Glu Tyr Ile Ser Gly Tyr Tyr Arg Val Ser Ser Tyr  
1496  TTC TTC GGA AAA CTG TTA TCG GAT TTA CTA CCC ATG AGG ATG TTA CCA AGC ATT ATC TTT ACT TGT ATA ACG TAC TTC  
Phe Phe Gly Lys Leu Leu Ser Asp Leu Leu Pro Met Arg Met Leu Pro Ser Ile Ile Phe Thr Cys Ile Thr Tyr Phe  
1574  TTG TTA GGA CTG AAG CCC GCG GTG GGG TCC TTC TTC ATC ATG ATG TTT ACC CTG ATG ATG GTG GCG TAC TCA GCC AGT  
Leu Leu Gly Leu Lys Pro Ala Val Gly Ser Phe Phe Ile Met Met Phe Thr Leu Met Met Val Ala Tyr Ser Ala Ser  
1652  TCC ATG GCC CTG GCC ATA GCC GCC GGT CAG AGC GTG GTC TCC GTG GCA ACA CTT CTC ATG ACC ATC TCG TTT GTG TTC  
Ser Met Ala Leu Ala Ile Ala Ala Gly Gln Ser Val Val Ser Val Ala Thr Leu Leu Met Thr Ile Ser Phe Val Phe  
1730  ATG ATG ATC TTT TCG GGG CTG TTG GTG AAT CTC AAA ACG GTC GTG CCT TGG CTC TCG TGG TTA CAG TAC TTC AGC ATT  
Met Met Ile Phe Ser Gly Leu Leu Val Asn Leu Lys Thr Val Val Pro Trp Leu Ser Trp Leu Gln Tyr Phe Ser Ile  
1808  CCT CGA TAC GGC TTT TCG GCT TTG CAG TAT AAT GAG TTT TTG GGA CAA AAC TTC TGC CCG GGA CTC AAC GTC ACA ACA  
Pro Arg Tyr Gly Phe Ser Ala Leu Gln Tyr Asn Glu Phe Leu Gly Gln Asn Phe Cys Pro Gly Leu Asn Val Thr Thr  
1886  AAC AAT ACC TGT AGC TTC GCA ATA TGT ACT GGC GCC GAG TAT TTG GAA AAC CAG GGC ATC AGT CTC TCC GCT TGG GGC  
Asn Asn Thr Cys Ser Phe Ala Ile Cys Thr Gly Ala Glu Tyr Leu Glu Asn Gln Gly Ile Ser Leu Ser Ala Trp Gly  
1964  CTG TGG CAG AAT CAC GTG GCC TTG GCG TGC ATG ATG GTC ATT TTC CTG ACG ATC GCC TAC CTG AAA CTG CTA CTC CTC  
Leu Trp Gln Asn His Val Ala Leu Ala Cys Met Met Val Ile Phe Leu Thr Ile Ala Tyr Leu Lys Leu Leu Leu Leu  
2042  AAA AAA TAC TCC TAA ATTCCCCTCT AGGTTACACC ACTTACCCCC CATTAAAGAG AAAGCATTCT GGTTTC
Lys Lys Tyr Ser --- polyadenylation signal
Koszak sequence
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Searching the nucleotide sequence data base of the National Centre for Biotechnology Information 
(NCBI) using BLASTX for homologies to the BMDP cDNA a number of related sequences were 
identified. All sequences were identified as members of the superfamily of ATP-binding cassette (ABC) 
transporter. The highest degree of homology was found to human breast cancer resistance protein 
(BCRP; GenBank accession AF098951; Doyle et al., 1998) with a nucleotide identity of 80%, to 
human placenta-specific ABC protein (ABCP; GenBank accession AF103796; Allikmets et al., 1998) 
with 80% nucleotide identity, to mouse BCRP (GenBank accession AF140218; Allen et al., 1999) with 
75% nucleotide identity and to the human mitoxantrone resistance proteins 1 and 2 (MXR1 and MXR2; 
GenBank accession AF093771 and AF093772; Miyake et al., 1999) with 58% and 76% identity, 
respectively (Table 3-1).  
 
Table 3-1 Nucleotide identities of the porcine BMDP cDNA sequence. 
 
complete 5’ non-translated translated 3’ non-translated 
gene acc no 
length identitiy length identitiy length identitiy length identitiy 
pBMDP AJ420927 2112 bp  85 bp  1968 bp  59 bp  
hBCRP AF098951 2418 bp 80% 238 bp 49% 1965 bp 82% 215 bp 42% 
hABCP AF103796 2719 bp 80% 204 bp 49% 1965 bp 82% 550 bp 42% 
mBCRP AF140218 2025 bp 75% 19 bp 74% 1971 bp 76% 35 bp 41% 
hMXR1 AF093771 1469 bp 58%   1049 bp 79% 420 bp 46% 
hMXR2 AF093772 1141 bp 76%   1085 bp 78% 59 bp 46% 
 
Nucleotide sequence of porcine BMDP cDNA was compared to human BCRP, ABCP, MXR1 and MXR2 as well as to mouse 
BCRP cDNA sequences (software MegAlign, Dnastar Lasergene). Presented are the identity values given in percent and the 
lengths in bp for the complete, 5’ non-translated, translated and 3’ non-translated regions of each cDNA sequence. For human 
MXR1 and MXR2 only partial cDNA sequences are published, yet.  
 
 
The comparison in Table 3-1 shows high correspondence between 76% and 82% nucleotide identity 
in the translated region of the presented genes and a much lower similarity of only approximately 45% 
in the 3’ and 5’ non-translated regions. The length of transcripts especially differs up to 515 
nucleotides in the 5’ and 3’ non-translated regions. The coding regions with 1965 bp to 1971 bp are 
very similar in length indicating the close relation of the proteins. The sequence data for MXR1 and 
MXR2 are not completely published so far. 
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Figure 3-8 Sequence alignment of pBMDP, hBCRP and mBCRP. 
 
Amino acid sequence alignment (program MegAlign, Dnastar Lasergene) of porcine BMDP (GenBank accession AJ420927), 
human BCRP (GenBank accession AF098951) and mouse BCRP (GenBank accessionAF140218). Putative features are 
marked: bars, transmembrane regions; light shading, ATP-binding domain; boxes, Walker A and B motifs; dark shading, N-
linked glycosylation sites. 
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3.2.5 Analysis of the cDNA-deduced amino acid sequence 
 
Analysis of the BMDP cDNA revealed one large open reading frame encoding a protein of 656 amino 
acids with a calculated molecular weight of 72,391 Daltons. Further amino acid analysis demonstrated 
a large ATP-binding domain from position 61 to 270 as presented by light shading in Figure 3-8. This 
domain includes the Walker A and B motifs at positions 80-88 (GPTGGGKS) and 206-211 (ILFLD) 
respectively, which are characteristic of all ATP-hydrolysing domains (Walker A: GxxGxGKS, x can 
be varied; Walker B: hhhhD, h stands for hydrophobic; Walker et al., 1982). The hydrophobicity plot 
according to Kyte-Doolittle (Figure 3-10) shows that this domain is located within the hydrophilic part at 
the N-terminus of the protein (aa 1 to 395) followed by the highly hydrophobic C-terminus (aa 396 to 
656). The latter consists of six putative transmembrane domains (TMD1: aa 395-415, TMD2: aa 428-
446, TMD3:aa 479-501, TMD4: aa 507-528, TMD5: aa 540-560 and TMD6: aa 630-647) shown by 
straight lines in Figure 3-8 as well as in Figure 3-10. Two potential sites for N-linked glycosylation are 
assigned by dark shading in Figure 3-8. One is located in the loop between the fifth and sixth putative 
transmembrane domain at amino acid position 597-599 (NVT) and is probably extracellular. The 
second putative N-linked glycosylation site is located at amino acid position 339-341 (NSS) which is 
likely to be the cytosolic part of the protein. Neglecting these putative glycosylation sites a membrane 
topology model of BMDP can be proposed as demonstrated in Figure 3-9. 
 
 
Figure 3-9 Putative membrane topology model of BMDP. 
 
As shown in chapter 3.2.4 for the cDNA sequence similarities, on amino acid level BMDP also highly 
resembles to the human breast cancer resistance protein (BCRP; Doyle et al., 1998), the human 
mitoxantrone resistance protein (MXR; Miyake et al., 1999) and the human placenta-specific ABC 
protein (ABCP; Allikmets et al., 1998) which were described independently by the three different 
groups. As BCRP, MXR and ABCP share amino acid homology of 100% only human BCRP will be 
taken into consideration, here. 
On the amino acid level porcine BMDP shows identities of 80% to human BCRP and of 76% to mouse 
BCRP (Table 3-2). Figure 3-8 illustrates that the conservation of the amino acid sequence is 
particularly high in the ATP-binding domain (aa 61 to 270) and within transmembrane domains (aa 396 
to 656). The cytosolic part (aa 305 to 395) between ATP-binding and transmembrane domains is less 
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conserved. The homology between pBMDP, hBCRP and mBCRP is even higher with 86% for human 
and 84% for mouse BCRP (Table 3-2). This correspondence among the three species is also 
illustrated by the hydrophobicity plots in Figure 3-10 showing three almost identical plots. Porcine 
BMDP, human and mouse BCRP slightly differ in their peptide lengths with 656 aa for the porcine, 655 
aa for the human and 657 aa for the mouse protein (Table 3-2). They also show differences in the 
number and positions of their potential sites for N-linked glycosylation (Figure 3-8). While peptide 
analysis predicts four putative sites for human and mouse BCRP, only two sites are proposed for 
porcine BMDP. Only the one located in the loop between the fifth and sixth putative transmembrane 
domain (aa 597-599) is conserved in all three species and is probably extracellular.  
 
Table 3-2 Identities and homologies of the amino acid sequence of porcine BMDP. 
 
gene acc no length homologies identitites 
pBMDP AJ420927 656 aa   
hBCRP AF098951 655 aa 86% 80% 
mBCRP AF140218 657 aa 84% 76% 
 
The amino acid sequence of porcine BMDP was compared to human BCRP as well as to mouse BCRP amino acid sequence 
(BLASTX, NCBI). In this comparison it was distinguished between homology and identity values. Homology values include 
amino acids which are not identical but have similar properties and should not change protein function in an essential manner. 
Apart from the identity and homology values in percent, the table also shows the different lengths of the proteins in aa. 
 
 
 
 
Figure 3-10 Hydrophobicity plots of pBMDP, hBCRP and mBCRP. 
 
Hydrophobicity plots determined of the amino acid sequences of porcine BMDP (GenBank accession AJ420927), human BCRP 
(GenBank accession AF098951) and mouse BCRP (GenBank accessionAF140218) by Kyte-Doolittle method using a window-
length of 17 amino acids (program Protean, Dnastar Lasergene). Putative features are marked: bars, transmembrane regions; 
light shading, ATP-binding domain. 
Mouse BCRP
Human BCRP
Porcine BMDP
50 100 150 200 250 300 350 400 450 500 550 600 650
0
4.5
-4.5
50 100 150 200 250 300 350 400 450 500 550 600 650
0
4.5
-4.5
50 100 150 200 250 300 350 400 450 500 550 600 650
0
4.5
-4.5
3  Identification of a new multidrug resistance protein 38 
As porcine BMDP is assumed to belong to the superfamily of ABC transport proteins, its phylogenetic 
relationship to other representative members of this protein family is shown in Figure 3-11. This 
analysis again indicates the very close relationship of porcine BMDP to mouse (76% aa identity) and 
human BCRP (80% aa identity). Furthermore, it reveals that BMDP is only distantly related to P-
glycoprotein (Pgp) (e.g. human MDR1: 13% aa identity) and to the multidrug resistance-associated 
protein 1 (e.g. human MRP1: 12% aa identity) which are ABC-transporters that have been considered 
to be expressed at the blood-brain barrier and to be responsible for the multidrug resistance 
phenotype of brain capillary endothelial cells so far. In this PhD thesis BMDP could be identified as a 
new transport protein expressed at the BBB as described in this chapter. Characterisation of BMDP in 
terms of expression and transport studies will be the subject of the following sections 4 and 5. 
 
 
 
Figure 3-11 Phylogenetic tree showing the relationship of BMDP to representative ABC transporters. 
 
The phylogram was created by using the multiple-sequence alignment program MegAlign, which is part of the Dnastar 
Lasergene software, using Clustal method with a gap penalty and a gap length penalty of 10. The length of each pair of 
branches represents the distance between sequence pairs, while the units at the bottom of the tree indicate the number of 
amino acid substitution events. Following amino acid identities compared to porcine BMDP have been calculated: human MRP1 
12%, rat MRP1 11%, human MRP3 12%, rat MRP3 12%, human MRP6 12%, rat MRP6 13%, human MRP5 12%, human MRP2 
11%, rat MRP2 13%, human MDR1 13%, rat MDR1 12%, human MDR3 13%, rat MDR2 11%, human BCRP 80%, mouse 
BCRP 76% and mouse ABC-2 12%. 
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3.3 Discussion 
 
By screening a subtracted cDNA library the clone C8 was found to be differentially expressed in 
hydrocortisone treated porcine brain endothelial cells as confirmed by conventional northern blot 
analysis. Because of its homology to other multidrug resistance proteins it was named brain multidrug 
resistance protein (BMDP). Genomic Southern blot analysis revealed BMDP to be present with a 
maximum of four copies in the genome. Full-length cDNA sequence could successfully be obtained by 
RACE-PCR technology and subsequently analysed with the help of specialised software in the same 
way as the deduced amino acid sequence. 
 
In order to find differentially expressed genes in hydrocortisone treated porcine brain endothelial cells, 
which closely mimic the blood-brain barrier phenotype, a differential screening of a subtracted library 
was performed by using the subtractive suppression hybridisation technique (SSH) (Clontech) 
(Diatchenko et al., 1996; Thoenes, 1996). Compared with other common fingerprinting techniques like 
differential display RT-PCR (DDRT-PCR) (Liang and Pardee, 1992; Liang et al., 1996), RNA arbitrary 
primed PCR (RAP-PCR) (Welsh et al., 1995) and restriction fragment differential display-PCR (RFDD-
PCR) (DisplayProfileTMKit, 1998) screening a subtracted library established by the SSH method 
seemed to be the most promising way to isolate differentially expressed genes. Its main advantages 
with respect to the other fingerprinting techniques as listed above and conventional differential 
screening methods of cDNA libraries (Hubank and Schatz, 1994; Kimmel and Berger, 1987; 
Lönneberg et al., 1993; Wang and Brown, 1991) are a very straightforward and time-saving procedure 
and a high sensitivity even to very rare transcripts because of its equalisation step. From 
360,000 mRNA molecules per cell approximately 45% belong to the very low abundant transcripts with 
5 to 15 copies, further 40% to the low abundant messages with up to 300 copies per cell and only 15% 
belong to the high abundant class molecules (Alberts et al., 1997). That means that most genes are 
represented by very low numbers of mRNA transcripts and that their proportion of total mRNA amount 
per cell is less than 0.1 % (0.08% for rare and 0.004% for very rare transcripts) indicating the 
importance of a very sensitive method to detect even those rare messages. From about 600 cDNA 
clones that were subjected to a pre-screening 450 cDNA clones could be eliminated as false positives 
by the differential screening technique with four subtracted and nonsubtracted probes (Clontech) 
(Figure 3-1). Approximately 150 cDNA clones were sequenced and 16 “interesting” clones were 
analysed by standard northern blot analysis, so far. Three (19%) cDNA clones could not be detected 
by northern blot analysis at all, ten (62%) cDNA clones showed neither up- nor down-regulation and 
three (19%) cDNA clones could be confirmed to be differentially expressed in hydrocortisone treated 
PBCEC. With its high homology to other multidrug resistance transporters and with multidrug 
resistance being a highly discussed topic at the blood-brain barrier clone C8 (Figure 3-2) was the most 
relevant candidate for further examination, named BMDP hereafter. Its up-regulation in PBCEC 
representing the BBB phenotype could be reproducibly confirmed by laserdensitometric scanning of 
northern blots. The degree of up-regulation varied between three and five fold (Figure 3-3). 
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Genomic Southern blot analysis was then performed to investigate the genomic organisation of 
BMDP. Three to four signals of different intensity could be detected for each digestion (Figure 3-4) 
indicating that other related BMDP genes that cross-hybridise with the probe may exist in the genome 
rather than that BMDP is represented with more than one copy. In the latter case signal intensity 
should have been equal for each copy as hybridisation conditions would have been the same. For P-
glycoprotein, which belongs to the superfamily of ABC-transporters like BMDP, five different porcine 
Pgp genes (pgp1A, pgp1B, pgp1C, pgp1D, pgp3) could be identified by such Southern blot analysis 
(Childs and Ling, 1996) supporting the probability that further two to three BMDP genes do exist in the 
porcine genome. Isolating the genomic DNA fragments from the gel, cloning and sequencing will give 
more information on possible isoforms of BMDP. When differences occur in transcribed but may be 
non-translated regions RT-PCR analysis with specific primers will provide further hints on organ 
specific expression of different BMDP transcripts. Possible variations in intron sequences may result in 
alternate splicing products. 
 
To obtain the full-length cDNA from BMDP 3’- and 5’-RACE-PCR SMARTTM technology developed by 
Clontech (Chenchik et al., 1998) was applied instead of time-consuming screening of a cDNA library. 
3’- and 5’-RACE-PCR products as well as Long-Distance-PCR product were isolated and sequenced 
(Figures 3-5 and 3-6). The sequence of the BMDP transcript of 2112 bp in length (Figure 3-7) seemed 
to be complete as this length corresponds to the hybridisation signal observed in northern blot 
analysis, having in mind that transcript lengths could only be approximated by a magnitude of 100 bp 
in northern blot experiments. The absolute 5’-end has to be determined by sequencing genomic DNA 
upstream of the known 5’-end into the promoter region of the BMDP gene. cDNA and deduced amino 
acid analysis revealed numerous information on potential BMDP features. Searching the nucleotide 
sequence data base of the NCBI (BLASTX) very high homology of BMDP cDNA as well as amino acid 
sequence was found for human breast cancer resistance protein (BCRP; Doyle et al., 1998), for 
human placenta-specific ABC protein (ABCP; Allikmets et al., 1998) and for human mitoxantrone 
resistance protein (MXR; Miyake et al., 1999). BCRP was discovered and found to be upregulated in 
the adriamycin and verapamil selected human breast cancer cell line MCF-7 AdrVp, while at the same 
time Miyake et al. (1999) isolated the MXR protein from mitoxantrone selected human colon cancer 
cell line S1-M1-80. Based on searches in the expressed sequence tags (EST) database for human 
ATP-binding cassette (ABC) genes, Allikmets et al. (1998) could identify one gene to be highly 
expressed in placenta tissue which was therefore named ABCP. Comparison of these three 
independently discovered genes showed differences in the length and sequence of the 3’ non-
translated cDNA region and only one polymorphism in the amino acid sequence at position 482 
(BCRP: T; ABCP: R and MXR: G) (Honjo et al., 2001; Komatani et al., 2001). As these proteins belong 
to the second member of the G (white) subfamily of ABC transport proteins the Human Gene 
Nomenclature Committee has suggested BCRP/MXR/ABCP to be renamed as ABCG2 (http://www. 
gene.ucl.ac.uk/nomenclature/genefamiliy/abc.html); but in this work it will be referred to as human 
BCRP throughout. The corresponding mouse BCRP sequence was published in 1999 by Allen et al.. 
The cDNA analysis data presented in this work showed that porcine BMDP cDNA mainly differs in 
length and sequence identity of the 5’ and 3’ non-translated regions to human BCRP/ABCP/MXR and 
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mouse BCRP cDNA (Table 3-1). These kind of differences are due to species dependent features 
and/or different splicing. Very high correspondence in length and high conservation in nucleotide 
sequence is found for the coding DNA regions differing by up to six nucleotides and porcine BMDP 
showing 82% identity to human BCRP and 76% to mouse BCRP cDNA. 
Furthermore, amino acid analysis confirmed the high correspondence of porcine BMDP to human and 
mouse BCRP in particular shown for the potential ATP-binding domains and the six putative 
transmembrane domains (Figure 3-8). However, the number and position of potential sites for N-linked 
glycosylation is different among the species (mouse and human: 4; porcine: 2). Only one is conserved 
in all three species located in the potentially extracellular loop between the fifth and sixth putative 
transmembrane domain. The second porcine N-linked glycosylation site is only in agreement with 
human BCRP and is located in the proposed cytosolic part of the protein. As glycosylation only occurs 
extracellular this site together with two other potential sites of mouse BCRP are probably not relevant. 
Nevertheless, both human and mouse peptide sequences reveal a second potentially extracellular N-
linked glycosylation site. For human BCRP it is placed between transmembrane domain one and two 
and for mouse again between five and six. Whether these differences in glycosylation reflect 
discrepancies in protein features, remains to be investigated. However, Maliepaard et al. found 
different levels of glycosylation in topotecan- and mitoxantrone-selected human ovarian carcinoma 
cells indicating that substrate specificity might be influenced by glycosylation (Maliepaard et al., 2001).  
 
The results presented so far indicate that newly isolated porcine BMDP cDNA codes for an equivalent 
protein as human and mouse BCRP cDNA sequences do. This hypothesis is supported by the very 
similar hydrophobicity plots of these peptides (Figure 3-10) which are like a fingerprint of each protein 
and by the close relationship shown in the phylogenetic tree (Figure 3-11). It is further supported by 
the degree of homology which is for porcine BMDP compared to human (86%) and mouse (84%) 
BCRP in the same magnitude as it is for human to mouse (86%) BCRP (Table 3-2). Apart from these 
considerations RT-PCR analysis of mouse and human brain tissue with porcine specific BMDP primer 
revealed cDNA sequences with 100% identity to the published mouse and human BCRP cDNA 
sequences (see Section 4.2.1.7). Taken together, porcine BMDP is a protein with equal structure 
properties as mouse and human BCRP. Differences in nucleotide and amino acid sequences analysed 
in this section are due to species discrepancies. Neglecting the N-linked glycosylation their common 
membrane topology model predicts an ATP-binding domain at the hydrophilic amino-terminus and one 
highly hydrophobic carboxyl-terminal domain consisting of six membrane-spanning α-helices 
(Figure 3-9). 
 
The phylogenetic relationship of BMDP to other representative members of the superfamily of ABC 
transport proteins indicated only a very distant relationship to P-glycoprotein and Multidrug Resistance 
Associated Protein MRP1 (Figure 3-11), both commonly discussed to be responsible for the multidrug 
resistance of the brain. Thus, further characterisation of novel BMDP concerning its functions at the 
blood-brain barrier in particular was of prime interest and indispensable and has been performed as 
presented in the following sections. 
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4 Expression and localisation of BMDP  
 
4.1 Aims and rationale 
 
The brain multidrug resistance protein (BMDP) was found to be differentially expressed in primary 
cultured porcine brain capillary endothelial cells (PBCEC). Although belonging to the superfamily of 
ATP-binding cassette transporter proteins phylogenetic analysis revealed that BMDP is only distantly 
related to P-glycoprotein (Pgp) and the multidrug resistance-associated protein (MRP1). Both, Pgp 
and MRP1, have been shown to be expressed at the blood-brain barrier. In order to assess the 
features of BMDP especially at the blood-brain barrier, expression and localisation studies both on 
RNA and protein level were performed as presented in this section. 
 
 
4.2 Results 
 
4.2.1 Expression analysis of BMDP on RNA level 
 
4.2.1.1 BMDP expression at different days during cell cultivation process 
 
So far, the expression of BMDP was only investigated at day six in vitro when porcine brain capillary 
endothelial cells reach the highest level of blood-brain barrier phenotype with respect to 
transendothelial resistance and permeability. To exclude the possibility that BMDP expression occured 
as an in vitro artefact rather than reflecting the in vivo situation a time course of BMDP expression was 
examined by northern blot analysis. Total RNA was isolated from endothelial cells directly after 
preparation from brain tissue (0 day in vitro) up to day 9 in vitro. 10 µg of each sample were separated 
by denaturing agarose gel electrophoresis, blotted and hybridised with a BMDP specific probe. 
Loading differences were identified by the amount of 18 S rRNA on the ethidiumbromide stained gel. 
As seen in Figure 4-1 BMDP expression is approximately constant along the time course of culture. 
The weaker hybridisation signal at the day of preparation (day 0 in vitro) is due to a reduced amount of 
loaded RNA.  
 
 
4.2.1.2 BMDP expression in vivo compared to primary cultured and immortalised cells 
 
BMDP expression is proven not to be an in vitro artefact since BMDP has also been detected in 
freshly isolated brain capillary endothelial cells. To confirm the expression in vivo the presence of 
BMDP transcripts was analysed for brain tissue and isolated brain capillaries (Figure 4-2).  
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Figure 4-1 Time course of BMDP expression in vitro. 
 
Northern blot analysis was performed using 10 µg of total RNA isolated from porcine brain capillary endothelial cells directly 
after preparation at day 0 and up to day 9 in culture. Amount of loading is shown by the 18 S rRNA in the ethidiumbromide 
stained gel. 
 
 
Both northern blot analysis (A) and RT-PCR (B) confirmed the in vivo expression and furthermore 
indicated that BMDP is located in the endothelial cells of the cerebral capillaries. This is shown by 
increasing band intensities comparing brain tissue with isolated capillaries and endothelial cells. To 
examine whether the frequently used BBB in vitro model RBE4, an immortalised rat brain endothelial 
cell line, reflects this expression phenotype of brain capillary endothelial cells, BMDP expression in 
these cells (RBE4) was controlled (Figure 4-2). Neither by northern blot analysis nor by RT-PCR 
BMDP mRNA could be detected in RBE4 cells underlining that immortalised cells may not reflect the 
original BBB phenotype but showing another differentiation status as commonly expected. 
 
 
 
 
Figure 4-2 BMDP expression in vivo, primary cultured cells and immortalised cells. 
 
A Northern blot analysis was performed using 20 µg of total RNA isolated from porcine brain and capillary tissue, porcine 
brain capillary endothelial cells (PBCEC) and immortalised rat brain endothelial cells (RBE4). The same northern blot was 
hybridised with α-32P-labelled GAPDH probe to show loading of RNA. 
B 2% Agarosegel of RT-PCR products generated with the primers BMDP_C8-F and BMDP_5’RACE-R (see Appendix E) 
giving a product of 176 bp. cDNA was synthesized from 5 µg total RNA of each sample, as listed above. 
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4.2.1.3 BMDP expression at the blood-brain and blood-cerebrospinal fluid barrier 
 
Besides the blood-brain barrier the entry of xenobiotics into the brain is controlled by the blood-
cerebrospinal fluid barrier. In contrast to the blood-brain barrier forming endothelial cells the blood-
cerebrospinal fluid barrier is located in the epithelial cells of the plexus chorioideus. Both barrier 
systems are responsible for the multidrug resistance of the brain and are, thus, of particular interest 
concerning the expression of BMDP. As shown in Figure 4-3, expression of BMDP in plexus epithelial 
cells could only be detected by RT-PCR. Standard northern blot analysis was not sensitive enough to 
clearly detect BMDP transcripts although GAPDH probing showed equal loading of mRNA compared 
to PBCEC. These data provide evidence that brain multidrug resistance protein is mainly expressed in 
the endothelial cells of the blood-brain barrier rather than in the epithelial cells of the blood-
cerebrospinal fluid barrier. 
 
 
Figure 4-3 BMDP expression at the blood-brain and blood-cerebrospinal fluid barrier. 
 
A Northern blot analysis was performed with 1 µg mRNA of porcine brain capillary endothelial cells (blood-brain barrier) and 
plexus epithelial cells (blood-CSF barrier). The same northern blot was hybridised with α-32P-labelled GAPDH probe to 
show equal loading of RNA.  
B 1.5% Agarosegel of RT-PCR products generated with the primers BMDP_C8-F and BMDP_5’RACE-R (see Appendix E) 
giving a product of 176 bp and GAPDH-F and GAPDH-R (see Appendix E) giving a product of 405 bp. cDNA was 
synthesized from 5 µg of total RNA of PBCEC and plexus epithelial cells. 
 
 
 
4.2.1.4 BMDP expression in different types of brain specific cells 
 
As shown above BMDP is much higher expressed in the capillary endothelial cells than in the 
epithelial cells of the choroid plexus. Its expression in other brain specific cells needed to be compared 
in order to understand more about possible functions. The results of northern blot and RT-PCR 
studies, presented in Figure 4-4, clearly prove and confirm that BMDP expression is high in blood-
brain barrier forming endothelial cells, much lower in plexus epithelial cells and pericytes and not 
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detectable in astrocytes. These results again indicate the potentially physiological importance of 
BMDP expression at the blood-brain barrier and its minor significance at the blood-cerebrospinal fluid 
barrier. 
 
 
Figure 4-4 BMDP expression in different types of brain specific cells. 
 
A Northern blot analysis was performed with 20 µg of total RNA of porcine brain capillary endothelial cells (PBCEC), choroid 
plexus epithelial cells and pericytes as well as astrocytes. The same northern blot was hybridised with α-32P-labelled 
GAPDH probe to show loading of RNA.  
B 2% Agarosegel of RT-PCR products generated with the primers BMDP_C8-F and BMDP_5’RACE-R (see Appendix E) 
giving a product of 176 bp. cDNA was synthesized from 5 µg of total RNA of the same samples listed above. 
 
 
 
4.2.1.5 BMDP expression in different types of endothelial cells 
 
To prove whether BMDP expression is a feature of brain capillary endothelium or can also be found in 
macrovascular endothelium, its expression in aortic endothelial and umbilical vein endothelial cells 
was analysed (Figure 4-5). In human umbilical vein endothelial cells (HUVEC) BMDP could not be 
detected neither by northern blot nor RT-PCR analysis. BMDP expression in porcine aortic endothelial 
cells (PAEC) is much lower than in microvascular endothelial cells (PBCEC) proven by the much 
weaker signal intensity of the BMDP probe. Therefore, expression of BMDP is characteristic for 
cerebral microvessel endothelial cells. 
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Figure 4-5 BMDP expression in different types of endothelial cells. 
 
A Northern blot analysis was performed using 20 µg of total RNA isolated from porcine brain capillary endothelial cells 
(PBCEC), porcine aortic endothelial cells (PAEC) and human umbilical vein endothelial cells (HUVEC). The same northern 
blot was hybridised with α-32P-labelled GAPDH probe to show loading of RNA.  
B 1.5% Agarosegel of RT-PCR products generated with the primers BMDP_C8-F and BMDP_5’RACE-R (see Appendix E) 
giving a product of 176 bp and GAPDH-F and GAPDH-R (see Appendix E) giving a product of 405 bp. cDNA was 
synthesized from 5 µg of total RNA of each sample listed above. 
 
 
 
4.2.1.6 BMDP expression in selected porcine tissues 
 
So far, BMDP was mainly investigated with respect to the brain as it was originally found in brain 
capillary endothelial cells. Its expression in selected tissues is now shown in Figure 4-6. All tissue 
samples were obtained from freshly slaughtered pigs and total RNA was isolated. The results of RT-
PCR prove that BMDP can generally be found in each of the investigated tissues (Figure 4-6 B). 
According to the signal intensities of northern blot analysis (Figure 4-6 A) BMDP expression is highest 
in brain, kidney and lung and lowest in heart, skeletal muscle, spleen, stomach and pancreas while 
liver, colon and small intestine show moderate expression. As GAPDH probing of different tissues 
does not reflect the actual loading the amount of 18 S rRNA shown in the ethidiumbromide stained gel 
is additionally presented.  
 
 
 
4.2.1.7 BMDP expression in human, mouse and porcine brain tissue 
 
BMDP was discovered in porcine brain endothelial cells. To examine its expression in other species 
equal amounts of total RNA of human (H), mouse (M) and porcine (P) brain were separated by 
denaturing agarose gel electrophoresis, blotted and hybridised with species specific probes that 
means human (mouse, porcine) RNA was hybridised with human (mouse, porcine) BMDP or GAPDH 
probes, respectively (Figure 4-7 A).  
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Figure 4-6 BMDP expression in selected porcine tissues. 
 
A Northern blot analysis was performed with 30 µg mRNA of selected porcine tissues. The same northern blot was 
hybridised with α-32P-labelled GAPDH probe. Ethidiumbromide staining of the 18 S rRNA is presented to show loading of 
RNA.  
B 2% Agarosegel of RT-PCR products generated with the primers BMDP_C8-F and BMDP_5’RACE-R (see Appendix E) 
giving a product of 176 bp. cDNA was synthesized from 5 µg of total RNA of each sample. 
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This procedure became necessary in order to avoid different signal intensities just because of species 
dependent mismatches between RNA and labelled probe that are due to differences in hybridisation 
kinetics rather than due to different transcript amounts. Prior hybridisation probe intensities were 
equalised by using a scintillation counter. This northern blot analysis clearly show that BMDP 
expression in porcine brain is much higher than in mouse brain and that BMDP expression in human 
brain is lowest and only detected by RT-PCR analysis as shown in Figure 4-7 B, thus, demonstrating 
that species dependant differences in the expression pattern must be taken into account when 
working with mouse and porcine BBB model systems. 
 
 
Figure 4-7 BMDP expression in human, mouse and porcine tissue. 
 
A Northern blot analysis were performed with 20 µg of total RNA isolated from human (H), mouse (M) and porcine (P) brain 
tissue each and hybridised with either human, mouse or porcine BMDP probes. The same northern blots were afterwards 
hybridised either with α-32P-labelled human, mouse or porcine GAPDH probe to show loading of RNA.  
B 1.5% Agarosegel of RT-PCR products generated with the primers BMDP_763-F and BMDP_1018-R see Appendix E) 
giving a product of 295 bp. cDNA was synthesized from 5 µg of total RNA of human (H), mouse (M) and porcine (P) brain 
tissue. 
 
 
 
4.2.1.8 BMDP expression compared to Pgp and MRP1 expression 
 
So far, the multidrug resistance of the brain was almost exclusively assigned to the most prominent 
member of the ATP-binding cassette transporter family P-glycoprotein (Pgp), which is located in the 
luminal membrane of brain capillary endothelial cells (Schinkel, 1999). The importance of a second 
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ABC-transporter referred to as multidrug resistance-associated protein MRP1 in porcine brain tissue is 
still controversially discussed (Gutmann et al., 1999). With BMDP a new putative multidrug resistance 
protein was discovered at the blood-brain barrier as described so far. Its expression compared to Pgp 
and MRP1 was investigated by northern blot analysis as presented in Figure 4-8.  
 
 
Figure 4-8 BMDP expression compared to Pgp and MRP1. 
 
Northern blot analysis were performed each with 1 µg of mRNA isolated from brain capillaries and PBCEC each and hybridised 
with either BMDP, Pgp or MRP1 probes. The same northern blots were hybridised with α-32P-labelled GAPDH probe to show 
equal loading of RNA compared between each blot. 
 
 
BMDP expression in PBCEC is approximately 30 times stronger than Pgp expression as determined 
by laserdensitometric scanning. MRP1 transcripts could not be detected at all. This tendency is the 
same for freshly isolated brain capillaries underlining that these results reflect the in vivo situation 
rather than being due to culture conditions. Thus, BMDP might be much more relevant at the blood-
brain barrier than Pgp, which, so far, is discussed to be the protein that is predominantly responsible 
for the cerebral multidrug resistance. 
 
 
 
4.2.2 Subcellular localisation of BMDP on protein level 
 
4.2.2.1 Three independent ways to obtain an antibody against BMDP 
 
In order to investigate the expression and localisation of BMDP at the blood-brain barrier on the 
protein level either specific antibodies had to be generated or commercially available ones had to be 
tested. Three independent ways were followed in parallel.  
Dr. Hubert Kalbacher (University Tübingen) synthesized two peptides of the N-terminal BMDP amino 
acid sequence (aa 13-30 and aa 10-21, indicated in grey in Figure 4-9) that were supposed to be 
highly antigenic by computer analysis. The peptides were conjugated to KLH (keyhole limpet 
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hemocyanin) by glutaraldehyde and were used for immunisation of rabbits (Charles River Coorp.). 
Although the obtained sera were tested to be positive in ELISA assays neither positive 
immunostaining nor positive western blot analysis results were obtained.  
 
 
 
Figure 4-9 Positions of antigenic sites for antibodies. 
 
Antigenicity plot by (Jameson and Wolf, 1988) (Protean software, Dnastar Lasergene) of BMDP peptide. Peaks of a positive 
arbitrary unit present potential antigenic determinants. Grey coloured amino acid sequence used for peptide antibodies, purple 
coloured amino acids overexpressed as a fusion protein in E. coli and blue coloured homologous porcine sequence to which the 
anti-humanBCRP antibody (BXP-21) is directed. 
 
 
The second way to generate anti-BMDP antibodies was based on recombinant BMDP as an antigen to 
immunise rabbits. A fusion construct of 144 amino acids of BMDP (aa 91 to 235, indicated in purple in 
Figure 4-9) and the maltose-binding protein (MBP) was successfully overexpressed in E. coli and 
purified. In Figure 4-10 lane 2 the expression of the BMDP-MBP fusion protein with a molecular weight 
of 60 kDa is shown 2 h after induction with IPTG compared to the situation prior to IPTG induction 
(lane 1). As indicated in lane 3 the BMDP-MBP fusion was enriched in the soluble crude extract after 
cell lysis and centrifugation. The purification was performed using amylose resin and the single 
purification steps are demonstrated in lane 4 to 9 of Figure 4-10. In lane 4 the supernatant fraction of 
non bound protein during amylose incubation is loaded onto the gel, whereas in lane 5 an aliquot of 
the washing solution is applied to gel electrophoresis. Lanes 6 to 8 show the eluted and purified 
BMDP-MBP fractions which were afterwards successfully cleaved by thrombin to yield 60 mg/l 
bacterial culture of 16.5 kDa BMDP fragment (lane 10) which are used for immunisation.  
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Figure 4-10 MBP-BMDP-fusion protein expression in E.coli. 
 
10% SDS-PAGE of bacterial suspension before IPTG induction (lane 1), 2 h after IPTG induction (lane 2) and the soluble crude 
extract (lane 3). Supernatant of non bound protein during amylose purification (lane 4), washing solution (lane 5), elution 
fractions 1-3 (lanes 6 to 8) and remaining fusion protein bound to the amylose matrix (lane 9). Products after thrombin digestion 
(lane 11): 16.5 kDa purified BMDP, 37 kDa thrombin, 43.5 kDa MBP. Molecular weight marker (lane 10). 
 
 
As described previously the porcine BMDP is a homologous protein to the human BCRP, thus the 
commercially available anti-hBCRP monoclonal antibody BXP-21 (Alexis) was tested in 
immunocytochemical experiments of brain endothelial cells as described in the following section. This 
antibody was raised in Balb/C mice by injection of a fusion protein consisting of the E. coli maltose-
binding protein and a 126 amino acids fragment of the human BCRP peptide (Maliepaard et al., 2001) 
that corresponds to porcine amino acids 271 to 396 shown in blue in Figure 4-9. 
 
 
 
4.2.2.2 Immunocytochemical detection of BMDP in PBCEC 
 
The subcellular localisation of BMDP in cultured porcine brain capillary endothelial cells was studied 
by immunocytochemical analysis. BMDP is localised most prominently at the plasma membrane with a 
homogenous distribution over the whole cell surface as shown in Figure 4-11 A. At the cell borders of 
adjacent cells the immunofluorescent signal is enhanced due to overlapping signal intensities. By 
means of confocal laser scanning microscopy the polarised localisation of BMDP at the basolateral or 
apical site of the cells was checked. Optical xz-sections revealed clear indications that BMDP is 
preferentially targeted to the luminal membrane domain as demonstrated in Figure 4-11 C. However, 
since PBCEC have a very flat morphology with cell heights that only exceed 0.5 µm in regions close to 
the nucleus, these studies were hampered by the diffraction limited optical resolution. Figure 4-11 B 
and D show the corresponding negative controls to Figure 4-11 A and C, respectively, in which the 
primary antibody has been omitted. 
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Figure 4-11 Fluorescence micrographs of immunocytochemical stainings of BMDP in PBCEC. 
 
A PBCEC stained with anti-BXP21      B PBCEC stained with secondary antibody only 
C xz-section of A          D xz-section of B 
 
 
 
 
4.3 Discussion 
 
By mRNA expression analyis BMDP was found to be highly expressed in brain tissue at the blood-
brain barrier rather than at the blood-cerebrospinal fluid barrier. Compared to P-glycoprotein and 
MRP1 BMDP is much higher expressed at the blood-brain barrier. Protein localisation by 
immunocytochemistry indicated that BMDP is predominantly localised at the apical plasma membrane.  
 
 
BMDP is expressed in the blood-brain barrier forming cerebral endothelial cells 
 
BMDP cDNA was isolated from cultured porcine brain capillary endothelial cells. To exclude that 
BMDP expression in cerebral endothelial cells is due to a culture artefact rather than reflecting the in 
vivo situation, the time course of BMDP expression was investigated by northern blot analysis 
(Figure 4-1). The data underline that BMDP is not up-regulated during culture and is also present in 
freshly isolated cerebral endothelial cells. For comparison, the expression of the ABC-transporter 
MRP1 was found to be upregulated along the culture of porcine brain capillary endothelial cells for a 
period of 10 days and furthermore, the presence of MRP1 could not be shown in the freshly isolated 
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cells (Gutmann et al., 1999). Interestingly, MRP1 expression was enhanced considerably not only in 
primary cultures of brain capillary endothelial cells (Huai-Yun et al., 1998; Gutmann et al., 1999) but 
also in immortalised brain endothelial cell lines (Seetharaman et al., 1998; Regina et al., 1998). Thus, 
the level of MRP1 expression in vitro seems to be dependent on the isolation procedure and on the 
applied cell culture model (Seetharaman et al., 1998; Gutmann et al., 1999; Sugiyama et al., 1999). 
Regina et al. (1998) noted that MRP1 is overexpressed in rat brain endothelial cell cultures, with 
primary cultures having higher expression levels compared to immortalised cell lines. In the same way 
the level of Pgp expression varies depending on the isolation procedure and between immortalised 
endothelial cell lines and isolated brain microvessels (Regina et al., 1999). These studies indicate that 
both MRP1 and Pgp expression is very variable in different cell systems and hardly reflects the in vivo 
situation in most cases. Therefore, the expression of the new ABC-transporter BMDP in brain tissue, 
isolated brain capillaries, primary cultured endothelial cells and immortalised rat brain endothelial cells 
(RBE4) was compared (Figure 4-2) and transcripts are shown to be present in all but in the 
immortalised cell line. Thus, our porcine brain capillary endothelial cells reflect the in vivo situation with 
respect to BMDP expression, whereas the in vitro model of immortalised rat brain endothelial cells 
does not. Considerations of species discrepancies rather than immortalisation will be discussed later. 
 
Apart from the blood-brain barrier the blood-cerebrospinal fluid barrier also prevents the central 
nervous system from the entry of xenobiotics. For both barriers the expression of the ABC-transporters 
P-glycoprotein and multidrug resistance-associated protein MRP1 has been reported to be responsible 
for drug transport (Rao et al., 1999; Regina et al., 1999). Figure 4-3 shows that BMDP is expressed in 
the choroid plexus of the blood-cerebrospinal fluid barrier but at a much lower level compared to the 
capillary endothelial cells. This indicates that its physiological function at the blood-cerebrospinal fluid 
barrier is possibly similar but less significant than at the blood-brain barrier. Recently, the functional 
expression of Pgp and MRP1 within glial cells such as astrocytes has been reported (Declèves et al., 
2000; Dallas et al., 2001; Lee et al., 2001b; Lee et al., 2001a) providing evidence that microglia might 
be important for drug transport and distribution in brain parenchyma as well. However, so far drug 
transfer in and out of the CNS has been assigned to the blood-brain barrier and the choroid plexus 
and little information existed on the role of the brain parenchyma. MRP1, for example, was found to be 
expressed in higher levels in total brain homogenate as opposed to isolated microvessels (Regina et 
al., 1998). This finding is not surprising since MRP1 expression was detected in rat astrocyte cultures 
(Declèves et al., 2000). For BMDP the increasing signal intensities from brain tissue to isolated 
capillaries and cultured endothelial cells (Figure 4-2) underlines its major expression in cerebral 
endothelial cells rather than in other brain specific cells. Furthermore, the expression study including 
pericytes, choroid plexus epithelial cells and astrocytes in Figure 4-4 indicates that BMDP might be 
involved in transport activities predominantly at the blood-brain barrier, whereas according to our 
results the choroid plexus and brain parenchyma may play a minor or no role. It has to be mentioned, 
however, that rat astrocytes have been used in the experiments and species discrepancies have to be 
taken into account as well. This will be discussed in detail later.  
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Summing up the results of BMDP expression so far, BMDP appears to be a feature of the brain 
capillary endothelium. In order to elucidate whether it is also expressed in macrovascular endothelium 
northern blot analysis of porcine aortic and human umbilical vein endothelial cells have been 
performed (Figure 4-5). No expression was found for umbilical vein endothelium and little for aortic 
endothelium indicating that BMDP expression is not a phenomena of endothelium in general but 
special for cerebral endothelial cells and thus, probably important at the blood-brain barrier. As 
described in detail in chapter 3, BMDP is an equivalent transporter to BCRP/MXR/ABCP (ABCG2) 
(Allikmets et al., 1998; Doyle et al., 1998; Miyake et al., 1999). Immunostaining of normal tissues with 
the anti-BCRP monoclonal antibodies (BXP-21 and –34) also revealed endothelial BCRP expression 
(Maliepaard et al., 2001). In almost all of the tissues tested, staining of the venous and capillary 
endothelial cells was observed, whereas only sporadic staining for BCRP was observed in arterial 
endothelium. Apart from the results for venous BCRP expression these data correspond nicely to the 
BMDP results obtained by northern blot analysis. At this moment it is not known if BCRP contributes to 
transport across the endothelium and whether BCRP is expressed somewhere in the brain especially 
in cerebral endothelium to protect the central nervous system. However, in this study it could be 
shown that BMDP is highly expressed in porcine brain capillary endothelial cells. 
 
 
BMDP: its tissue expression profile and putative physiological functions 
 
In order to unravel the physiological function of BMDP apart from the blood-brain barrier its tissue 
distribution was investigated by northern blot analysis (Figure 4-6). The high expression levels in brain 
underline the data previously reported and predict a possible role in protecting the brain against 
xenobiotics. Furthermore, BMDP is highly expressed in lung and kidney, whereas BMDP expression in 
heart, skeletal muscle, spleen, stomach and pancreas was only minor. A moderate expression could 
be shown for colon, small intestine and liver tissue. The expression in the liver indicates that BMDP 
might be involved in excretion processes in the liver, similar to many other ABC transporters, e.g. Pgp 
and MRP2 (Borst et al., 1997). The presence of BMDP in the small intestine and colon suggests that 
BMDP is involved in the uptake regulation of orally administered BMDP substrates from the 
gastrointestinal tract by back-transport of substrates entering from the gut lumen. In agreement with 
the presented data, human BCRP (Doyle et al., 1998; Maliepaard et al., 2001) and mouse BCRP 
(Jonker et al., 2000) revealed to be moderately expressed in small intestine, liver and colon, as well 
(Table 4-1). Comparing the published data on the ABC-transporters ABCG2 (human BCRP (Doyle et 
al., 1998), human ABCP (Allikmets et al., 1998) and mouse BCRP (Jonker et al., 2000)) with the 
similar expression profile of BMDP speculations about a role of BMDP like Pgp or MRPs in the 
regulation of transport of chemicals through cellular barriers are very reasonable. Some diifferences of 
the tissue expression profiles can not only be observed between the ABCG2 gene and BMDP but 
among the ABCG2 genes themselves. For example, Allikmets et al. (1998) found human ABCP to be 
highly expressed in placenta but only a very weak ABCP expression in heart and no expression at all 
in brain, lung, liver, muscle, kidney and pancreas. Whereas Doyle et al. (1998) detected highest 
human BCRP expression in placental tissue with considerably lower expression levels in brain, 
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prostate, small intestine, testis, ovary, colon and liver. Human BCRP transcripts were below the level 
of detection in heart, lung, skeletal muscle, kidney, pancreas, spleen and thymus. Jonker et al. (2000) 
detected high expression of mouse BCRP in kidney and moderate levels in liver, colon, heart, spleen 
and placenta. Especially, the moderate levels of BCRP expression in mouse placenta (Jonker et al., 
2000) contrast with the very high levels of BCRP/ABCP expression observed in human placenta 
(Allikmets et al., 1998; Doyle et al., 1998) indicating that a hypothetical protective role of ABCG2 for 
the fetus in humans might be stronger than that observed in mice. Therefore, applying murine models 
for characterization of multidrug resistance substrates and for extrapolation to human organism is not 
necessarily straight forward and needs careful judgement. In the case of the ABC-transporter MRP1 
differences have also been identified for example in the transport characteristics of anthracyclines by 
murine and human MRP1 (Lee et al., 2001a). For the transport protein P-glycoprotein expression was 
found to vary among the species in brain capillaries, as well, showing highest expression in human, 
moderate levels in bovine and lowest expression in rat tissue (Jette and Beliveau, 1993; Jette et al., 
1993). 
 
 
Table 4-1 mRNA tissue expression profile of the human, murine and porcine half-transporters. 
 
  hABCG2     hABCG2  
tissue pBMDP hBCRP hABCP mBCRP  tissue pBMDP hBCRP hABCP mBCRP 
brain +++ ++ - +  colon ++ ++  ++ 
liver ++ ++ - ++  small intestine ++ ++  ++ 
kidney +++ - - +++  pancreas + - -  
lung +++ - - +  placenta  +++ +++ ++ 
heart + - + ++  prostate  ++   
skeletal 
muscle + - - +  testis  ++   
spleen + -  ++  ovary  ++ +  
stomach +   +  thymus  -  - 
 
Symbols used: +++ high expression; ++ moderate expression; + low expression; - expression is below the level of detection; 
p, porcine; h, human; m, murine. Data published by: hBCRP (northern blot analysis) (Doyle et al., 1998); hABCP (northern blot 
analysis) (Allikmets et al., 1998); mBCRP (RNase protection assay) (Jonker et al., 2000). 
 
 
In order to elucidate this kind of species discrepancies BMDP expression in porcine brain tissue has 
been compared to human and mouse brain tissue (Figure 4-7). Northern blot analysis revealed that 
porcine expression is much higher than murine. BMDP expression in human brain could only be 
detected by RT-PCR. These findings correlate with the weak or missing expression of ABCG2 in 
human and mouse brain (Allikmets et al., 1998; Doyle et al., 1998; Jonker et al., 2000). Nevertheless, 
RT-PCR analysis clearly shows that the new ABC-transporter BMDP is expressed in human brain and 
thus, is possibly involved in drug transport in the human central nervous system. Both mice and 
vertebrate in vitro models have to be considered with care, always taking into account that expression 
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differences might exist. These species dependent discrepancies can thus be the reason why no 
BMDP expression could be detected in the immortalised rat brain endothelial cells, in rat astrocytes 
and finally human umbilical vein endothelial cells as discussed earlier.  
 
 
BMDP is much higher expressed than P-glycoprotein 
 
To investigate the importance of BMDP with respect to the multidrug resistance of the brain its 
expression has been compared to that of P-glycoprotein and MRP1 (Figure 4-8). Both ABC-
transporters are widely discussed to be of physiological importance at the blood-brain barrier. Northern 
blot analysis of porcine brain capillaries and porcine brain capillary endothelial cells revealed that 
BMDP expression is 30-fold higher than Pgp expression. MRP1 was not detected neither by northern 
blot analysis nor by RT-PCR (data not shown). Pgp expression at the blood-brain barrier is generally 
expected (Schinkel, 1999) and was also published for porcine brain capillary endothelial cells (Childs 
and Ling, 1996; Huwyler et al., 1996), whereas MRP1 expression is controversially discussed. In 
agreement with these data, Gutmann et al. (1999) found no MRP1 expression in porcine brain 
homogenate and freshly isolated PBCECs by western blot analysis. They only demonstrated an up-
regulation of MRP1 expression during culture indicating that MRP1 is an in vitro artefact rather than a 
feature of the BBB in vivo. Nevertheless, the level of MRP1 expression has been found to be variable 
in other species. By western blot analysis no expression was detected in human brain tissue (Flens et 
al., 1996), while small amounts of transcripts could be observed by northern blot analysis and RNAse 
protection assay (Kruh et al., 1995; Zaman et al., 1993). Anyway, in isolated human brain capillaries 
MRP1 expression was neither detected by western blot analysis (Flens et al., 1996) nor by RT-PCR 
and immunostaining (Seetharaman et al., 1998). On the other hand bovine brain microvessels show 
moderate MRP1 expression by RT-PCR (Zhang et al., 2000). The same is true for rodents where 
Regina et al. (1998) detected high levels in rat brain tissue and low levels in rat brain capillaries and 
Kusuhara et al. (1998) as well as Paul et al. (1996) who found low MRP1 expression in mouse brain. 
To sum up, missing MRP1 expression at the porcine blood-brain barrier seems to correlate with no 
MRP1 expression in human brain capillaries (Flens et al., 1996; Seetharaman et al., 1998). The low 
levels of MRP1 transcripts detected in human brain homogenate (Kruh et al., 1995; Zaman et al., 
1993) can be due to MRP1 expression in other cerebral cells rather than capillary endothelial cells, 
especially since it is known that MRP1 is expressed in astrocytes and microglia (Dallas et al., 2001; 
Declèves et al., 2000). 
 
P-glycoprotein is hitherto the most intensively investigated efflux pump at the blood-brain barrier. As 
already discussed BMDP is much higher expressed and thus, possibly more involved in drug efflux out 
of the brain than P-glycoprotein. A similar result was published for the expression of the human 
homologous protein BCRP compared to eight related ABC-transporters in human jejunum 
(Taipalensuu et al., 2001). BCRP was found to be much higher expressed than P-glycoprotein and 
MRP1 suggesting that the role of BCRP in intestinal drug efflux has been underestimated so far. 
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Therefore, localisation and functional analysis of this new BMDP in porcine brain capillary endothelial 
cells might additionally reveal its features. 
 
 
BMDP is expressed at the plasma membrane of cerebral endothelial cells 
 
Immunocytochemical studies revealed a clear plasma membrane staining of endogenous BMDP in 
isolated porcine brain endothelial cells (Figure 4-11 A). This kind of plasma membrane localisation 
was also found for human BCRP in various drug selected or BCRP transfected carcinoma cells 
(Rocchi et al., 2000; Scheffer et al., 2000; Maliepaard et al., 2001). As described in chapter 3 in detail, 
BMDP consists of only one transmembrane domain and one ATP-binding domain. This kind of ABC-
transporters is assigned to the group of half-transporters compared to the full-transporters with two 
transmembrane and ATP-binding domains like P-glycoprotein and MRP1. Generally full-transporters 
are found in the plasma membrane as shown for example for P-glycoprotein (Flens et al., 1994) and 
MRP1 (Hipfner et al., 1994), whereas half-transporters are usually found in intracellular membranes 
such as the mitochondria (M-ABC1 and ABC7), the endoplasmatic reticulum (TAP1, 2) and the 
peroxisomes (ALD subfamily) (reviewed in Klein et al., 1999; Higgins, 1992). Therefore, plasma 
membrane localisation of BMDP is somewhat surprising in light of the generally intracellular 
localisation of the other known half-transporters, but commensurates with the potential BMDP function 
as a drug exporter which will be further described in chapter 5. Though the exact mechanisms for 
targeting of full- and half-transporters to their respective membrane localisation are not known, it may 
be noteworthy that BMDP has a domain arrangement in which the ATP-binding cassette-fold precedes 
the transmembrane region, an arrangement which it shares with the human BCRP, the Drosophila 
white gene (also classified as ABCG2 gene) and the ABCG8 gene. In contrast, all other human ABC 
proteins containing both domains have an arrangement in which the ATP-binding fold is carboxy-
terminal to the transmembrane region. Models for the Drosophila white protein predict it to be localised 
in the plasma membrane of the eye pigment cells (Ewart et al., 1994). Recent evidence, however, 
suggests that the human ABCG8 protein is expressed both on the cell surface and in intracellular 
compartments (Klucken et al., 2000). Thus, it appears that BMDP and human BCRP are the first ABC 
half-transporters with a predominant plasma membrane localisation, indicating that the BMDP 
transporter is more likely to be involved in active transport from the cell into blood at the blood-brain 
barrier than in transport into internal vesicles. In agreement to the potential role of this new ABC-
transporter BMDP to function as a drug efflux pump at the blood-brain barrier, luminal staining in 
PBCEC was detected taking into account the limited optical resolution using a laser scanning 
microscope (Figure 4-11 C). Therefore, drugs that have entered brain capillary endothelial cells can 
possibly be pumped into the circulating blood at the luminal membrane by BMDP and thus be 
hindered to enter the brain. This potential protective function of BMDP in porcine brain capillary 
endothelial cells has further been investigated by transport studies as will be presented in the following 
chapter.  
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5 Characterisation of BMDP transport  
 
5.1 Aims and rationale 
 
The brain multidrug resistance protein (BMDP) was found to be localised at the apical plasma 
membrane of brain capillary endothelial cells (PBCEC). Its high homology to the human ATP-binding 
cassette half-transporter BCRP that actively transports certain chemotherapeutic drugs out of cancer 
cells suggests a transport activity at the blood-brain barrier. To reveal its substrate specificity porcine 
BMDP was stably transfected into human embryonic kidney cells (HEK 293) and cytotoxicity studies 
were performed. Furthermore, endogenous transport activity of BMDP in PBCEC was investigated to 
assess its protective function at the blood-brain barrier. Results of both exogenous and endogenous 
transport analysis will be the topic of this section. 
 
 
5.2 Results 
 
5.2.1 Exogenous expression of BMDP in HEK 293 cells 
 
5.2.1.1 Generating a stable cell line 
 
In order to characterise substrate specificity of porcine BMDP HEK 293 cells were transfected with 
pcDNA3/BMDP and pEGFP/BMDP by using the calcium phosphate precipitation method, selected by 
supplementing the culture medium with geneticin and subcloned. As a control, HEK 293 cells were 
stably transfected with the empty pcDNA3 vector. Isolated clones were tested for expression of BMDP 
mRNA by northern blot analysis and results of 13 pcDNA3/BMDP, 4 pcDNA3 and 5 pEGFP/BMDP 
clones are presented in Figure 5-1. 
All pcDNA3/BMDP clones revealed expression of the 2.1 kb mRNA of BMDP but with considerably 
different expression levels when normalised to the signal of GAPDH probes. The expression of BMDP 
mRNA in clones 3, 10, 11 and 13 was higher than in clones 1, 2, 4, 5, 7, 8 and 12, while clones 6 and 
9 showed extremely low levels of BMDP mRNA expression. In order to investigate the localisation of 
BMDP in transfected HEK 293 cells BMDP cDNA was cloned into the pEGFP vector (Clontech) to 
yield a fusion of BMDP and the green fluorescent protein when expressed by the cells. The resulting 
mRNA transcript of 2.8 kb was successfully expressed in all selected clones (Figure 5-1). 
Nevertheless, the fusion protein could not be detected in the transfected cells neither by fluorescence 
microscopy nor by immunostaining with anti-GFP antibody (data not shown). As expected, cells 
transfected with the empty vector showed no BMDP expression thus being a valuable control in 
transport studies of BMDP.  
For further studies of BMDP function the four BMDP-overexpressing clones 7, 9, 11 and 13 were 
selected in comparison to cells transfected with empty vector (HEK 293/pcDNA3 clone 1) only.  
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Figure 5-1 BMDP expression in subclones of HEK 293 cells. 
 
Northern blot analysis was performed using 20 µg of total RNA isolated from HEK 293 cells stably transfected with expression 
vectors pcDNA3/BMDP or pEGFP/BMDP and with empty vector pcDNA3 (uncloned-vector control) after selection in medium 
containing geniticin. The same northern blot was also hybridised with α-32P-labelled GAPDH probe to show loading of RNA. 
 
 
 
5.2.1.2 Cytotoxicity studies 
 
To evaluate BMDP function, the sensitivity of transfected HEK 293 cells to the chemotherapeutic 
agents mitoxantrone, daunorubicin, doxorubicin, cis-platin, paclitaxel and vincristine was tested by the 
formazan cytotoxicity assay as will be explained in section 7. The absorbance of cells not treated with 
any drug was set to 100%. 
Cell survival data was statistically evaluated using the Data Analysis software Microcal Origin. In order 
to quantify the drug concentration of half-maximal activity (EC50), the data were analysed by non-linear 
least square techniques using the following transfer function: 
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In this expression parameters a and b denote the extrapolated percentage of cell survival at low and 
high drug concentration, respectively. The parameter EC50 stands for the drug concentration (cdrug) of 
half-maximal activity and corresponds to the turning point of the dose-response curve. The parameter 
d is a measure for the slope of the transfer function at cdrug = EC50. During the fitting procedure cell 
survival data were weighted with their respective standard deviations. All parameters are given in the 
figure captions or are summarised in the tables. 
 
The BMDP-overexpressing clone 13 displayed no resistance to any tested cytotoxic drug compared 
with pcDNA3 control clone 1 as shown in a typical experiment for mitoxantrone in Figure 5-2. The pool 
of experiments is summarised in Table 5-1 for all other drugs demonstrating that the EC50 values for 
BMDP-overexpressing and non-expressing clones were not significantly different.  
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Figure 5-2 Representative formazan cytoxoxicity studies for mitoxantrone. 
 
Representative cytoxocity analysis of HEK 293/pcDNA3/clone 1 (control) or HEK293/BMDP/clone 13 cells upon exposure to 
mitoxantrone. These data are typical for those used to obtain EC50 values summarised in Table 5-1. The vertical bars for each 
data point represent the standard deviation of four replicate determinations. control: a (110 ± 7)%; b (20 ± 2)%; EC50 (22 ± 4) 
nM; d (2 ± 0.3). clone 13: a (109 ± 8)%; b (10 ± 1)%; EC50 (18 ± 3) nM; d (1.4 ± 0.2). 
 
 
 
Table 5-1 Summarised cytotoxicity analysis of transfected HEK 293 cells. 
 
cells HEK 293/pcDNA3/clone 1 (control) HEK 293/pcDNA3/BMDP/clone 13 
drug a [%] b [%] EC50 [nM] d a [%] b [%] 
EC50 
[nM] d 
mitoxantrone 110 ± 7 20 ± 2 22 ± 4 2 ± 0.3 109 ± 8 10 ± 1 18 ± 3 1.4 ± 0.2 
daunorubicin 105 ± 6 27 ± 6 113 ± 29 1.3 ± 0.4 100 ± 4 9 ± 5 84 ± 15 2 ± 0.5 
doxorubicin 97 ± 8 19 ± 2 25 ± 4 1 ± 0.3 89 ± 7 11 ± 2 35 ± 10 1.2 ± 0.3 
cis-Platin 107 ± 2 -2 ± 4 9900 ± 1400 2 ± 0.7 108 ± 2 7 ± 4 
10500 ± 
1500 2 ± 1.1 
paclitaxel 117 ± 10 -3 ± 21 5 ± 2 0.8 ± 0.4 126 ± 4 1 ± 12 10 ± 2 1.9 ± 0.9 
vincristine 118 ± 6 -5 ± 10 5 ± 1 1.1 ± 0.3 108 ± 4 7 ± 4 4 ± 1 4 ± 1.3 
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To make sure that this missing resistance is not due to the selected HEK293/BMDP/clone 13, the 
sensitivity to mitoxantrone of three more BMDP-expressing clones 7, 9 and 11 was analysed. As 
demonstrated in Figure 5-3, again no differences of the EC50 value between pcDNA3 control clone 1 
and pcDNA3/BMDP/clone 7, 9 and 11 could be determined. Thus, no functionality of BMDP protein 
could be detected by cytotoxicity studies. 
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Figure 5-3 Formazan cytoxoxicity studies for four different HEK 293 clones. 
 
Cytoxocity analysis of HEK 293/pcDNA3/clone 1 (control), HEK293/BMDP/clone 7, HEK293/BMDP/clone 9, HEK293/BMDP/ 
clone 11 cells upon exposure to mitoxantrone. The vertical bars for each data point represent the standard deviation of four 
replicate determinations. control: a (104 ± 6)%; b (14 ± 4)%; EC50 (18 ± 6) nM; d (0.7 ± 0.2). clone 7: a (125 ± 11)%; b (16 ± 
4)%; EC50 (19 ± 6) nM; d (0.9 ± 0.2). clone 9: a (103 ± 13)%; b (20 ± 6)%; EC50 (24 ± 15) nM; d (0.9 ± 0.5). clone 11: 
a (104 ± 5)%; b (15 ± 3)%; EC50 (21 ± 10) nM; d (0.9 ± 0.2). 
 
 
 
5.2.2 Endogenous expression of BMDP in PBCEC 
 
5.2.2.1 Active transport of daunorubicin 
 
In order to evaluate the functional relevance of BMDP at the blood-brain barrier its capability to 
transport 3H-daunorubicin across a monolayer of porcine brain capillary endothelial cells was 
measured. PBCECs cultured on filter inserts express a polarised morphology with the upper (apical) 
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chamber corresponding to the luminal (blood) and the lower (basolateral) chamber corresponding to 
the abluminal (brain) side in vivo (see Figure 7-1). Same concentration of 3H-daunorubicin was applied 
to both compartments and the concentration of 3H-daunorubicin in each compartment was measured 
after 0.5, 6, 12, 24, 36, 48 and 72 hours. The values at time point 0.5 h were set to 100%. As shown in 
Figure 5-4 within 72 hours the concentration of 3H-daunorubicin increases up to 205% in the apical 
chamber and correspondingly decreases at the basolateral side (81%). Thus, 3H-daunorubicin is 
actively transported from the basolateral to the apical side.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-4 Transendothelial transport of 3H-daunorubicin in PBCECs. 
 
Concentrations of 3H-daunorubicin were measured after 0.5, 6, 12, 24, 36, 48 and 72 hours and normalised to measurements at 
0.5 h. Apical (100%, 108%, 123%, 144%, 161%, 182%, 205%) and basolateral (100%, 96%, 94%, 90%, 85%, 84%, 81%). The 
vertical bars for each data point represent the standard deviation of three replicate determinations. 
 
 
 
5.2.2.2 Inhibition studies of daunorubicin transport 
 
As 3H-daunorubicin is also a substrate of other ABC-transporters like P-glycoprotein which is 
expressed in porcine brain capillary endothelial cells (see Figure 4-8) inhibitors were used to elucidate 
whether the new transporter BMDP is responsible for the observed drug transport rather than P-
glycoprotein. The inhibitors GF120918, verapamil, cyclosporin A and PSC833 are known to inhibit P-
glycoprotein mediated drug transport. Added at concentrations of 1 µM to the medium one hour before 
3H-daunorubicin measurements following changes of transport rates were observed (Figure 5-5): 
Apical concentration of 3H-daunorubicin increased up to 205% without treatment with inhibitors, 
whereas 3H-daunorubicin concentrations increased only to 177% after verapamil addition, to 135% by 
cyclosporin A and to 138% by PSC833 treatment. GF120918 incubation only led to an apical increase 
up to 116% within 72 hours. As demonstrated for the active transport in Figure 5-4 the concentration of 
3H-daunorubicin in the basolateral chamber decreases correspondingly in each case (data not shown). 
Summing up these results, 3H-daunorubicin transport across PBCECs is inhibited by GF120918 and to 
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a minor extend by PSC833 and cyclosporin A but hardly affected by verapamil. Considering published 
data these findings indicate that BMDP mediates the active daunorubicin transport as discussed in 
detail lateron. 
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Figure 5-5 Inhibition studies of 3H-daunorubicin transport in PBCECs. 
 
1 µM of verapamil (V), GF120918 (G), PSC833 (P) or cyclosporin A (C) were added one hour prior to the measurement. Apical 
concentrations of 3H-daunorubicin were measured after 0.5, 6, 12, 24, 36, 48 and 72 hours and normalised to readings at 0.5 h. 
Verapamil (100%, 101%, 115%, 126%, 146%, 146%, 159%, 177%); GF120918 (100%, 91%, 94%, 96%, 100%, 106%, 116%); 
PSC833 (100%, 95%, 102%, 111%, 121%, 126%, 138%); cyclosporin A (100%, 95%, 102%, 111%, 115%, 128%, 135%) and 
without inhibitor (100%, 108%, 123%, 144%, 161%, 182%, 205%). The vertical bars for each data point represent the standard 
deviation of three replicate determinations. 
 
 
 
5.3 Discussion 
 
Although porcine BMDP was successfully transfected into HEK 293 cells proven by northern blot 
analysis no functionality could be detected in cytoxocity studies. However, functionality of 
endogenously expressed BMDP in porcine brain capillary endothelial cells could be demonstrated by 
the active transport of daunorubicin. 
 
 
BMDP exogenously expressed in HEK 293 cells 
 
To disclose the functional properties of porcine BMDP its cDNA was transfected into HEK 293 cells 
and exogenous expression of BMDP mRNA was confirmed by northern blot analysis (Figure 5-1). The 
construct pEGFP/BMDP was used to visualise the localisation of BMDP in the transfected cells by 
means of fusion to the green fluorescent protein. Although all selected and tested clones showed 
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BMDP-GFP mRNA transcripts, no protein expression could be observed by fluorescence microscopy 
indicating that the fusion protein was either not properly expressed, degraded or the fluorescence 
properties of the GFP were destroyed by the fusion to the transmembrane protein BMDP. In order to 
exclude the latter, immunofluorescence studies using anti-GFP antibodies were performed. But the 
fusion protein could not be detected by this method either.  
Regardless of these findings functional properties of pcDNA3/BMDP transfected HEK 293 cells were 
tested by cytotoxicity tests (Figure 5-2 and Table 5-1). In agreement with published data for the 
homologous human BCRP (Doyle et al., 1998) the following six chemotherapeutic agents were chosen 
for a basic test: doxorubicin, daunorubicin and mitoxantrone as examples to which human BCRP 
confers resistance to and vincristine, paclitaxel and cis-platin for which human BCRP does not render 
protection. However, the porcine BMDP overexpressing clone 13 does not display resistance to any of 
the tested drugs. In Table 5-2 the EC50 values determined for BMDP transfected HEK 293 cells are 
compared to the data for the human BCRP overexpressing breast cancer cell line MCF-7 (Doyle et al., 
1998).  
 
 
Table 5-2 Comparison of measured EC50 values to published data. 
 
 HEK 293/ MCF-7/ 
drug pcDNA3/clone 1 BMDP/clone 13 pcDNA3 BCRP/clone 8 
mitoxantrone 22 ± 4 18 ± 3 40 1300 
daunorubicin 113 ± 29 84 ± 15 68 350 
doxorubicin 25 ± 4 35 ± 10 49 1050 
cis-Platin 9900 ± 1400 10500 ± 1500 3900 3700 
paclitaxel 5 ± 2 10 ± 2 5.1 3.0 
vincristine 5 ± 1 4 ± 1 0.39 0.28 
 
Effects of chemotherapeutic drugs on BMDP-transfected HEK 293 cells compared to BCRP-transfected MCF-7 cells (Doyle et 
al., 1998). EC50 values are given in nM. 
 
 
Whereas the EC50 values determined for BMDP are not significantly different to the empty vector 
control, the BCRP clone 8 displays resistance to mitoxantrone, daunorubicin and doxorubicin 
compared with the empty vector-transfected control which is shown by an increase of the EC50 value 
in one to two orders of magnitude. The BCRP-overexpressing clone 8 is sensitive to cis-platin, 
paclitaxel and vincristine. 
As the degree of BMDP overexpression in the transfectant clones varied, three more clones of 
different BMDP expression levels were selected in order to correlate expression levels with their 
degree of resistance to selected cytotoxic drugs (Figure 5-3). The degree of BMDP overexpression in 
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clone 11 was as high as in clone 13, while clone 7 revealed moderate and clone 9 weak BMDP mRNA 
expression (Figure 5-1). As shown in Table 5-3 neither of the three clones confers resistance to 
mitoxantrone. 
 
 
Table 5-3 EC50 values of chemotherapeutic drugs in different clones of BMDP transfected cells. 
 
clones pcDNA3/clone 1 BMDP/clone 7 BMDP/clone 9 BMDP/clone 11 
EC50 values [nM] 18 ± 6 19 ± 6 24 ± 15 21 ± 5 
 
 
 
In conclusion, the results demonstrate that BMDP expression does not confer resistance to 
mitoxantrone and the other tested chemotherapeutic agents when transfected into HEK cells. This is in 
contrast with previous findings for the homologous human BCRP. BCRP/ABCP/MXR was reported to 
confer resistance to mitoxantrone when it was introduced into breast cancer cell lines (Doyle et al., 
1998) and its mRNA overexpression was detected in several mitoxantrone-resistant cell lines (Allen et 
al., 1999; Doyle et al., 1998; Miyake et al., 1999; Ross et al., 1999). However, Komatani et al. (2001) 
reported that a lung cancer cell line PC-13 transfected with BCRP was also not resistant to 
mitoxantrone. Several explanations are possible for these contradictory observations: 
 
First, a different resistance pattern might be explained by putative cellular factors affecting the 
transport activity of BMDP. In this work, porcine BMDP was transfected into human embryonal kidney 
cells, whereas human BCRP was transferred into the human breast cancer cell line MCF-7 where it 
originally had been derived from (Doyle et al., 1998). Thus cellular factors that are present in porcine 
brain capillary endothelial cells and that might be necessary to render BMDP functionality might be 
missing in the HEK cell system. The cellular factors might be either endogeneous small molecules to 
be co-transported with the substrates (Loe et al., 1996) or another half-transporter that functions by 
forming heterodimers with BMDP. The translocation pathway of typical ABC transporters consists of 
two ATP-binding domains and two highly hydrophobic domains that contain membrane-spanning 
regions. This configuration is realised in a single amino acid chain. Alternatively, the active complex of 
certain ABC transporters can be formed by the heterodimerisation of two non-identical proteins, each 
containing a single ATP-binding and hydrophobic region. The white and brown proteins of Drosophila 
melanogaster (Ewart and Howells, 1998) and the Tap-1 and Tap-2 proteins that transport major 
histocompatibility class I peptides (Townsend and Trowsdale, 1993) are examples of ABC-transport 
protein family members that exhibit such a cooperative interaction. Although various transfection 
studies suggest that the enforced overexpression of human BCRP cDNA is sufficient to confer drug 
resistance to the transfected cells (Doyle et al., 1998; Jonker et al., 2000; Ozvegy et al., 2001; 
Rabindran et al., 2000; Volk et al., 2000) it is still possible that another transporter might be necessary 
in a dimeric or multimeric complex with porcine BMDP that is missing in HEK 293 cells but probably 
present in PBCECs. Furthermore, alterations of protein stability, localisation or both in different cell 
types may contribute to the different phenotype observed for BMDP compared to BCRP and finally the 
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different genetic background of the two cell lines and/or different cellular metabolism. Metabolic 
modifications of the drug are also likely to cause different resistance patterns.  
 
Second, the difference in substrate specificity might be explained by the differences in the amino acid 
composition. The isolated porcine BMDP differed from human BCRP isolated from MCF-7/AdrVp by 
the amino acid at codon 482. As previously reported (Honjo et al., 2001; Komatani et al., 2001), codon 
482 varies in human BCRP/ABCP/MXR clones isolated in different laboratories. BCRP isolated from 
MCF-7/AdrVp cells, which was previously shown to confer resistance to mitoxantrone, carries 
threonine (T) at codon 482 (Doyle et al., 1998). On the other hand the ABCP clone carries arginine (R) 
at codon 482, as detected in a clone from normal placenta (Allikmets et al., 1998). Sequencing 
genomic DNA revealed wild-type MXR/BCRP/ABCP to have an arginine (R) at position 482 (Honjo et 
al., 2001). Studying 11 cell lines that express MXR/BCRP/ABCP (Honjo et al., 2001) revealed that all 
demonstrated mitoxantrone transport, whereas only 2 effluxed rhodamine 123, those who have an 
threonine (T) or glycine (G) at position 482. Those having an arginine like the wild-type did not efflux 
rhodamine 123. These results suggest that amino acid 482 has a crucial role in MXR/BCRP/ABCP 
function and that mutation of a single amino acid residue significantly changes substrate specificity, 
thus altering the drug resistance phenotype. Codon 482 is located in the putative transmembrane-3-
region (Allikmets et al., 1998), and analysis of MDR1 (Pgp) suggested that transmembrane regions of 
ABC transporters are likely to participate in substrate recognition (Gottesman and Pastan, 1993). 
Therefore, it is possible that amino acid substitution at this position alters the substrate specificity. 
Especially, when transmembrane domains for MXR/BCRP/ABCP were identified using computer 
software (Honjo et al., 2001), the third transmembrane domain was predicted to span amino acids 
483-499 for wild type (R482) but was predicted to span amino acids 478-497 for R482G mutation and 
478-499 for the R482T mutation. Thus, the observed differences in drug efflux and resistance may 
result from a change in the size and/or conformation of the third transmembrane domain. This in turn 
may result in an altered interaction with other transmembrane domains. This view envisions the 
changes in aa 482 as resulting in structural changes beyond its immediate vicinity and considers the 
transmembrane domain to be adaptable. Or, residue 482 may be the site of drug binding, and 
mutations at this site may result in altered affinity for different drugs or the mutation impacts on the 
dimerisation or oligomerisation process. Although these substitutions may reflect the occurrence of 
natural polymorphism, they may also be mutations occurring in the course of drug selection of the 
cultured cells. Such mutations were reported in the case of MDR1 (Pgp) and were shown to affect 
substrate specificity (Choi et al., 1988). To clarify this point, Komatani et al. (2001) performed 
sequence analysis of the BCRP/MXR/ABCP transcript in human tissues and demonstrated that the 
BCRP/MXR/ABCP expressed in human tissue carries arginine at codon 482 indicating arginine to be 
the wild-type amino acid. Furthermore, he reported that BCRP containing arginine at position 482 
confers no mitoxantrone resistance. As porcine BMDP cDNA also contains arginine at this position, at 
least this difference of the peptide sequence to human BCRP with threonine at position 482 might be 
responsible for a different drug resistance phenotype.  
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To sum up, BMDP was successfully transfected into HEK 293 cells to generate a stable cell line but 
revealed no functionality in cytotoxicity studies so that substrate characterisation was not possible. 
Therefore, endogenous BMDP transport activity was investigated in porcine brain capillary endothelial 
cells. 
 
 
BMDP endogenously expressed in PBCEC 
 
In order to evaluate the physiological role of BMDP, porcine brain capillary endothelial cells (PBCEC) 
were used to determine the direction of endogenous BMDP drug transport. Transport activity and 
direction was measured using the human BCRP substrate daunorubicin (Doyle et al., 1998). 
Unfortunately, the multidrug-resistance phenotype due to human BCRP expression is overlapping with 
the properties of P-glycoprotein and MRP1 which also accept daunorubicin as a transport substrate 
(reviewed in Litman et al., 2001). However, to assess the specific role of BMDP in protecting the brain 
against drugs, various inhibitors characterised for P-glycoprotein and/or human BCRP had been 
applied to PBCEC before active daunorubicin transport was measured. Specific MRP1 inhibitors were 
not used in these first studies as MRP1 is not expressed in porcine brain capillary endothelial cells 
(see Figure 4-8). 
 
As demonstrated in Figure 5-4 daunorubicin is transported from the basolateral to the apical side 
across a monolayer of PBCECs within 72 hours. This transport is accomplished against the 
establishing concentration gradient and thus requires energy. The increase of daunorubicin in the 
apical (upper) chamber indicates that the responsible ATP-dependent transporter is localised at the 
apical plasma membrane mediating a directed transport of this drug out of the cell into the apical 
compartment. The decrease of daunorubicin in the basolateral chamber corresponds to this proposed 
mechanism, since daunorubicin diffuses into the cell at the basolateral membrane and is then actively 
transported to the apical side. As the apical side of polarised PBCECs corresponds to the luminal 
(blood) side and the basolateral side to the abluminal (brain) side in vivo, this transporter actively 
translocates daunorubicin from the brain to the blood side and thus prevents the central nervous 
system from this cytotoxic drug. As mentioned before, daunorubicin is a substrate of both human 
BCRP and P-glycoprotein and both expressed in PBCECs (see Figure 4-8). Therefore, only specific 
inhibition studies can elucidate whether BMDP or P-glycoprotein or both are responsible for 
daunorubicin transport in these cells. Furthermore, results must be scrutinised with respect to possible 
other transport mechanisms that are not yet known. In this work the inhibitors verapamil, cyclosporin 
A, PSC 833 and GF120918 were used to investigate the transport mechanism.  
Verapamil is known to be an inhibitor of P-glycoprotein mediated drug transport, first described by 
Tsuruo et al. (1981) and confirmed in numerous Pgp studies (Drion et al., 1996; Letrent et al., 1999; 
Ozvegy et al., 2001; Sarkadi et al., 1992) (for an overview see Table 5-4). Meanwhile its inhibitory 
effect on human BCRP has been investigated by several independent groups. Two groups have 
reported a slight inhibition (Nielsen et al., 2000; Rabindran et al., 1998), whereas a majority found no 
effect on BCRP mediated drug transport, so far (Lee et al., 1997; Litman et al., 2000; Maliepaard et al., 
5  Characterisation of BMDP transport  68 
1999; Ozvegy et al., 2001). Cyclosporin A, however, is known to inhibit both human BCRP (Doyle et 
al., 1998; Nielsen et al., 2000; Ozvegy et al., 2001) and P-glycoprotein (Ford and Hait (1990); Kochi et 
al., 1999; Lee et al., 1994; Letrent et al., 1999; Ozvegy et al., 2001).  
 
Table 5-4 Effect of several inhibitors on BCRP, P-glycoprotein and BMDP activity. 
 
inhibitors BCRP P-glycoprotein BMDP 
verapamil - + - 
cyclosporin A + + - / + 
PSC833 - / + + - / + 
GF120918 + + + 
fumitremorgin C + - n. d. 
 
 
Both verapamil and cyclosporin A belong to the first-generation multidrug resistance modulators and 
require to be applied by high doses. However, side effects and drug interactions limit their clinical 
applications (Tan et al., 2000). In the second generation PSC833 (Valspodar) was developed as a 
potent and non-immunosuppressive cyclosporin analogue that is ten times more potent than 
cyclosporin and interacts specifically with P-glycoprotein, shown by various laboratories (Drion et al., 
1996; Jonker et al., 2000; Lee et al., 1994; Mayer et al., 1997; Muzzammil et al., 2001; Smith et al., 
1998; Tai, 2000). Since BCRP has been found to be responsible for multidrug resistance in several 
tumor cell lines derived from breast, colon, stomach and leukemic cells (Doyle et al., 1998; Miyake et 
al., 1999) PSC833 has been tested as a resistance reversing agent for BCRP as well. Although one 
group described non inhibitory effect of PSC833 on mouse BCRP transfected into polarised pig kidney 
epithelial cells (Jonker et al., 2000), Muzzammil et al. (2001) found PSC833 to inhibit doxorubicin 
transport in human BCRP overexpressing and transfected human breast cancer cells. In 1997 Mayer 
et al. already proposed that PSC833 inhibits not only Pgp but also other drug transporters when they 
investigated digoxin transport in mice and found extensive but not complete inhibition at the blood-
brain barrier. Thus, transporters like the new protein BMDP that is described in this work to be highly 
expressed at the blood-brain barrier have to be taken into account in further preclinical studies. 
Therefore, the inhibitory effect of PSC833 on the daunorubicin transport in brain capillary endothelial 
cells has been investigated during this project, as well. Finally, the effect of the synthetic third 
generation modulator GF120918 was tested, since it was described to be a very effective inhibitor of 
both P-glycoprotein and human BCRP (Hyafil et al., 1993; Letrent et al., 1999; de Bruin et al., 1999; 
Jonker et al., 2000; Maliepaard et al., 2001; van Loevezijn et al., 2001). The four latter groups also 
reported that BCRP can effectively be inhibited by this modulator, as further supported by Allen et al. 
(1999) and Brangi et al. (1999). 
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Inhibition studies of daunorubicin transport across a monolayer of porcine brain capillary endothelial 
cells demonstrated in Figure 5-5 clearly indicate that daunorubicin transport is almost completely 
inhibited by GF120918, whereas cyclosporin A and its analogue PSC833 reveal only moderate 
inhibition. However, verapamil shows hardly any effect on daunorubicin transport even if used in ten 
times higher concentrations (data not shown). These findings are in agreement with data published by 
Ozvegy et al. (2001) who functionally characterised the human BCRP in insect cells and found that 
BCRP-ATPase activity was inhibited by cyclosporin A but not by verapamil. A slight inhibition of BCRP 
by verapamil has been reported in BCRP overexpressing but non-Pgp expressing Ehrlich ascite tumor 
cells (Nielsen et al., 2000) and in BCRP overexpressing human colon carcinoma cells (Rabindran et 
al., 1998). Nevertheless, P-glycoprotein mediated daunorubicin transport should have been inhibited 
by verapamil as demonstrated in Pgp overexpressing insect cells by measuring its ATPase activity 
(Ozvegy et al., 2001) and as confirmed by many further studies (Drion et al., 1996; Letrent et al., 1999; 
Sarkadi et al., 1992). The moderate inhibitory effect of PSC833 on daunorubicin transport corresponds 
to the results for sestamibi and doxorubicin transport in BCRP overexpressing human breast cancer 
cells (Muzzammil et al., 2001). GF120918 has been reported to be a potent inhibitor of BCRP in 
several studies (Allen et al., 1999; Brangi et al., 1999; de Bruin et al., 1999; Maliepaard et al., 2001; 
van Loevezijn et al., 2001) and one group has directly shown that GF120918 effectively inhibited 
mouse BCRP and Pgp whereas PSC833 only inhibited Pgp completely (Jonker et al., 2000) 
underlining the findings for daunorubicin transport in PBCEC. Taken together published data for BCRP 
inhibition nicely correspond to the findings of daunorubicin transport inhibition in porcine brain capillary 
endothelial cells indicating that the new half-transporter BMDP might be responsible for drug transport 
rather than P-glycoprotein. However, Pgp-mediated transport cannot be excluded by this study since 
some laboratories have reported similar orders of inhibitory strength for Pgp transport mechanism. 
Both PSC833 (Drion et al., 1996; Tai, 2000) and GF120918 (Letrent et al., 1999; Maliepaard et al., 
2001) have been found to be more effective inhibitors for Pgp transport than verapamil similar to the 
findings for BMDP. 
 
This work suggests that the transport activity of the ABC half-transporter BMDP is a potent new 
mechanism for conferring multiple drug resistance in the brain and thus needs further examination. 
Recently, a new inhibitor has been characterised to be specific for human BCRP in comparison to both 
P-glycoprotein and MRP1 (Robey et al., 2001a; Robey et al., 2001b), named fumitremorgin C. 
Fumitremorgin C is a natural product from fungal origin and belongs to a class of diketopiperazines, 
which are potent mycotoxins. Final transport studies with this inhibitor will clarify whether daunorubicin 
transport in PBCEC is mediated by BMDP and thus inhibited by fumitremorgin C or mediated by P-
glycoprotein and thus not effected by fumitremorgin C. Our lab is in contact with the company that 
produces this compound to obtain a sample for clarifying experiments. 
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6 General discussion 
 
Primary cultures of porcine brain capillary endothelial cells (PBCEC) have proven to be a validated 
in vitro model of the blood-brain barrier (BBB) with a highly differentiated cerebral endothelial 
phenotype. A new brain multidrug resistance protein (BMDP) was found to be expressed in these cells 
and be up-regulated in presence of hydrocortisone. cDNA and amino acid sequence analysis revealed 
a very close relationship of BMDP to the breast cancer resistance protein (BCRP) with a predicted 
topology of a reverse ABC half-transporter characterised by one N-terminal ATP-binding domain and 
one C-terminal transmembrane domain. Northern blot analysis of porcine brain tissue and isolated 
capillaries showed that BMDP is expressed at the BBB in vivo and that expression at the blood-
cerebrospinal fluid barrier is minor. Furthermore, BMDP mRNA could be detected at much higher 
levels in cerebral rather than in macrovascular endothelial cells supporting a potential physiological 
importance in brain capillaries. The subcellular localisation of BMDP in PBCEC was studied by 
immunocytochemical analysis. In contrast to the common localisation of ABC half-transporters BMDP 
protein was found to be predominantly localised at the plasma membrane. By means of confocal laser 
scanning microscopy clear indications for an apical localisation have been gathered suggesting a 
BMDP transport activity out of the cell into the blood in vivo. In order to evaluate a possible transport 
activity of BMDP, translocation of the human BCRP substrate daunorubicin was measured across a 
monolayer of PBCEC. The data clearly demonstrate that daunorubicin is transported from the 
basolateral (brain) to the apical (blood) side and is localised at the apical plasma membrane mediating 
a directed transport of this drug out of the cell into the apical compartment. Therefore, both 
immunostaining and active transport analysis provide consistent evidence that BMDP is localised at 
the blood-facing membrane of PBCEC mediating the transport of drugs from the brain into the 
circulating blood and thus, excluding the central nervous system from cytotoxic drugs. However, 
polarised immunolocalisation has to be further confirmed by electron microscopy, since PBCEC have 
a very flat morphology with cell heights around 0.5 µm in regions close to the nucleus so that confocal 
microscopy studies are hampered by the diffraction limited optical resolution. 
 
BMDP is not the only ABC transporter that has been identified at the apical side of polarised brain 
capillary endothelial cells but shares its function with at least P-glycoprotein. Therefore, the expression 
of BMDP was compared to P-glycoprotein and MRP1 both known to be expressed in blood-brain 
barrier forming endothelial cells. Northern blot analysis revealed that BMDP is 30 times higher 
expressed than Pgp, whereas MRP1 expression could not be detected in PBCEC. However, 
meanwhile all eight MRP proteins (MRP1 to MRP8) identified so far have been detected in the brain of 
various species. Blood-brain barrier localisation has been reported for MRP1 in rat, cow and human. 
MRP2 has been detected at the blood-brain barrier of fish, rat and human whereas MRP3, 4 and 6 
have only been reported for cow so far. MRP5 is expressed in bovine and human brain capillary 
endothelial cells. Solely, MRP7 and MRP8 have only been characterised in total human brain tissue 
and thus, not assigned to the blood-brain barrier yet. Therefore, the expression level of all the other 
ABC transporters in PBCEC need to be investigated and compared to BMDP expression in future 
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studies to provide a comprehensive understanding of the physiological importance of BMDP compared 
to other ABC transport systems. For instance in human jejunum BCRP has been found to be much 
higher expressed than P-glycoprotein and MRP1 to MRP6 suggesting that BCRP has been 
underestimated in intestinal drug efflux so far. Similarly, the role of P-glycoprotein at the blood-brain 
barrier might have been overestimated and other transporters like BMDP might be responsible for the 
transport of many drugs rather than P-glycoprotein. 
 
Having in mind that other transporters than BMDP and P-glycoprotein are possibly expressed in 
PBCEC additional by more comprehensive transport studies have to be performed in the future. Only 
a very specific combination of substrates and inhibitors will enable us to distinguish between the 
different known transport systems. An absolute assignment of drug transport to one particular 
transporter is hardly possible in such a complex system like primary cultured brain capillary endothelial 
cells that express many features of the blood-brain barrier phenotype. In this work, active daunorubicin 
transport was completely inhibited by GF120918 and reduced by cyclosporin A and PSC833, whereas 
verapamil showed almost no inhibitory effect. These findings nicely correspond to the published data 
for the human BCRP activity which was most effectively inhibited by GF120918, diminished by 
PSC833 and cyclosporin A, however not effected by verapamil. Thus, daunorubicin transport can be 
assigned to BMDP. On the other hand P-glycoprotein mediated transport cannot be excluded by this 
preliminary study since all the mentioned inhibitors are known to modulate P-glycoprotein as well. 
However, in connection with the very high expression levels of BMDP compared to P-glycoprotein it 
seems to be likely that the measured daunorubicin transport is mediated by BMDP rather than by P-
glycoprotein. 
 
In this work BMDP mRNA expression has also been compared between porcine, human and 
mouse brain tissue and found to be much higher expressed in porcine than in human and mouse 
brains. These species dependent differences in the BMDP expression level was similarly observed for 
other tissues when porcine BMDP expression data were compared with human and mouse BCRP 
tissue expression. For instance, BCRP was reported to be highly expressed in human placenta 
whereas murine BCRP was only detected at moderate levels in mouse placenta possibly indicating 
that a protective role of BCRP for the fetus plays a more important role in humans than in mice. Thus, 
species differences in the expression of BMDP and other ABC transporters have to be quantified by 
Real Time PCR in future experiments in order to reassess the relevance of animal in vitro models for 
the situation given in humans. In general, care has to be taken when published data concerning both 
transport and expression studies are cited and compared without special emphasis on the species 
dependent discrepancies. The controversial discussion of the MRP1 expression among the different 
species is one outstanding example for misinterpreting results since high MRP1 expression levels at 
the blood-brain barrier have only been detected in rodents while in vertebrates and humans low or no 
expression was demonstrated by standard techniques like immunostaining, western and northern blot 
analysis as well as RT-PCR. However, it is unnecessary to mention that animal model systems are 
crucial and indispensable to elucidate drug actions. Nevertheless, before results are projected to 
humans detailed information about species dependent differences have to be taken into consideration. 
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7 Experimental 
 
7.1 Cell biology 
 
7.1.1 Cell culture 
 
Special working procedures in cell culture experiments including the handling and sterilisation of 
pipettes and buffers to minimise the risk of contaminations were applied as described by 
(Freshney, 2000). Cell culture work was exclusively performed in a laminar-flow hood with sterile 
equipment, solutions and media. 75 cm2 culture flasks, 58 cm2 petri dishes, 6-well (10 cm2), 24-well 
(2 cm2) and 96-well (1/3 cm2) plates were used for cell plating. The cells were cultured at 37°C in a 
water saturated atmosphere with 5% (v/v) CO2.  
 
 
7.1.1.1 Primary culture of porcine brain capillary endothelial cells (PBCEC) 
 
Preparation. The isolation of porcine brain capillary cells (PBCEC) from 6 months old pigs was 
performed as described by (Tewes B., 1997). 
The hemispheres of porcine brains were taken from freshly slaughtered pigs and collected in ice-cold 
70% ethanol. For transport, ethanol was replaced by ice-cold PBS containing the antibiotics 
streptomycin (200 U/ml) and penicillin (200 U/ml). The storage buffer was refreshed once again in the 
laminar-flow hood. After shortly flaming the hemispheres the meninges and adhering larger vessels 
were carefully but completely removed. Secretory brain areas were dissected and the grey and white 
matter consisting of cerebral tissue was then mechanically homogenised by using scalpels and a 
sterile cutter with rolling blades. The homogenate was supplemented with preparation medium (37°C) 
to a final volume of 100 ml per brain. After addition of 1.6% (w/v) dry powdered unspecific 
protease/dispase II the suspension was stirred at 37°C for 2 h. To isolate the released capillaries 
100 ml of the digested homogenate were mixed with 150 ml of a 18% (w/v) dextran solution (4°C, 
MW ~ 160 kDa) and centrifuged (4°C, 6800 x g, 10 min). Both supernatant phases were discarded 
and the capillaries containing pellet was resuspended in 10 ml plating medium per brain. This 
microvessel-fragment suspension was filtered through a nylon mesh (180 µm pore size) to remove 
larger blood vessels. In order to improve the separation of the capillaries the filtered suspension was 
triturated up and down three to five times in a 10 ml sized pipette with the pipette tip placed directly 
onto the bottom of a petri dish. This mechanical disruption of capillary fragments to small pieces allows 
to shorten the incubation time of the second digestion: a mix of collagenase/dispase II (0.1% (w/v)) 
was added to remove the mainly collagen containing basement membrane and to release the 
endothelial cells. This digestion was performed at 37°C for 30 min in a flask with a hanging magnetic 
stirrer to avoid any cell damage. State of digestion was controlled by inverse microscopy. The isolated 
endothelial cells were collected by centrifugation (10 min, 140 x g) and resuspended in 10 ml plating 
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medium per percoll-gradient. This discontinuous percoll gradient was prepared from 15 ml percoll 
solution of a density of ρ = 1.07 g/ml and 20 ml percoll solution of ρ = 1.03 g/ml. 10 ml of the cell 
suspension were carefully placed onto the top of the gradient and centrifuged in a swing-out bucket 
rotor (1300 x g, 4°C, 10 min). The cell load of each gradient was adjusted to correspond to 1-2 brains. 
The red-stained, sharp interface containing the endothelial cells was aspired from the lower middle of 
the gradient and diluted in plating medium. After a final centrifugation (140 g, 10 min) the cell pellet 
was gently resuspended in plating medium and the cell yield of one brain was plated on a total of 
6 x 75 cm2 collagen-G coated culture substrates. 
 
Culturing. One day after cell preparation the cells were washed twice with PBS++ buffer to remove cell 
debris and non adherent cell bodies and supplied with fresh culture medium afterwards. 
 
Passage of cells. To further reduce contaminations with other cells, the cells were subcultured two 
days after preparation. Firstly, cells were washed twice with PBS and detached with trypsin solution 
(0.025% w/v) at room temperature. The displacement of endothelial cells was followed by inverse 
microscopy and trypsin digestion was stopped by addition of serum as soon as the majority of 
endothelial cells had lifted off the culture surface. The cell suspension was centrifuged (140 x g, 
10 min), the cells were resuspended in plating medium and plated on either collagen-G coated culture 
flasks, glass cover slips or alternatively on rat tail collagen coated microporous polycarbonate filter 
membranes (0.4 µm pore size, 1 cm2 growth area, TranswellTM No. 3401, Costar) with a density of 
250,000 cells/filter. 
 
Exchange of media. Two days after passage the plating-medium was replaced by hydrocortisone 
containing serum-free medium without further washing. The cells were cultured for two more days until 
they were used for RNA isolation (see section 7.2.6.1), transport studies (see section 7.1.5) or 
immunocytochemistry (see section 7.1.3).  
 
PBS    140 mM NaCl 
    2.7 mM  KCl 
    8.1 mM  Na2HPO4 
    1.5 mM  KH2PO4 
 
PBS++      PBS 
    0.5 mM  MgCl2 
    0.9 mM  CaCl2 
 
preparation medium    Earle’s Medium M199 
    0.7 mM  L-glutamine 
    1% (v/v) penicillin/streptomycin (10 mg/ml) 
    1% (v/v) gentamicin (10 mg/ml) 
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plating medium     preparation medium 
    10% (v/v) ox serum 
 
culture medium     plating medium without gentamicin 
 
serum-free medium    DMEM/Ham’s F12-Medium 
    0.7 mM  L-glutamine 
    1% (v/v) penicillin/streptomycin (10 mg/ml) 
    1% (v/v) gentamicin (10 mg/ml) 
    550 nM  hydrocortisone 
 
dextran solution  200 ml  Earle’s buffer (10 x) containing phenol red 
    4.4 g  NaHCO3 
    360 g  dextran (~ 162 kDa/mol) 
    ad 2 l  ddH2O 
 
percoll solutions 
 ρ = 1.03 g/cm3  400 ml  PBS 
    90 ml  percoll 
    10 ml  Earle’s Medium M199 (10 x) 
 
ρ = 1.07 g/cm3  200 ml  PBS 
    270 ml  percoll 
    30 ml  Earle’s Medium M199 (10 x) 
 
7.1.1.2 Culture of cells 
 
This thesis comprises experiments with the following cell types: HEK 293 (human embryonic kidney 
cells, fibroblasts, obtained from “Deutsche Sammlung für Microorganismen und Zellkulturen”), PAEC 
(porcine aortic endothelial cells, kindly provided by Sabine Hüwel), porcine brain pericytes (kindly 
provided by Sabine Hüwel), porcine choroid plexus epithelial cells (kindly provided by Matthias 
Haselbach), HUVEC (human umbilical vein endothelial cells, kindly provided by Bodo Levkau), rat 
astrocytes (kindly provided by Sabine Hüwel), C6 Glioma cells (kindly provided by Sabine Hüwel) and 
RBE4 (rat brain endothelial cells, kindly provided by Sabine Hüwel).  
 
HEK 293 cells were cultured in DMEM (1 x) containing 5-10% (v/v) FCS, 1% (v/v) L-glutamine 
(200 mM), 1% (v/v) gentamycin (10 mg/ml) and 1% (v/v) penicillin/streptomycin (10 mg/ml). The cells 
were routinely grown in culture flasks, but for transfection procedures petri dishes and 6-well plates, 
for selection of stable clones petri dishes, 6-well and 96-well plates, for immunocytochemistry 24-well 
plates with glass coverslips, for RNA isolation petri dishes and for cytotoxicity assays 96-well plates 
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were used. After 100% confluency cells were passaged using trypsin/EDTA (0.5%/0.2% (w/v)) solution 
and plated at 1:2 to 1:20 dilutions dependent on further use.  
 
7.1.1.3 Cell counting 
 
A Bürker haemocytometer was used to determine the number of cells. For each determination 2 
different cell samples were counted in 3 areas consisting of 4 times 4 squares. Average cell number of 
one area was multiplied by 10,000 to give the cell density per ml. 
 
7.1.1.4 Storage of cells 
 
For storage cells from a exponential growth phase (80% confluency) were trypsinised and pelleted as 
described before. The cell pellet was then resuspended in 1.8 ml NCS containing 10% (v/v) DMSO to 
prevent formation of ice crystals, transferred into a cryotube and immediately frozen at –20°C. After 
30 min the cryotube was placed in a –70°C freezer overnight and finally stored in liquid nitrogen. 
For thawing cells were rapidly placed in a water bath (37°C), slowly diluted with medium and replated 
at high cell density. 
 
 
 
7.1.2 Stable transfection 
 
7.1.2.1 Transient transfection of HEK 293 cells 
 
During transient transfection foreign DNA is introduced into cells. Part of it enters the cell nucleus 
during cell division and is transcribed for some days. Transcription results in expression of the protein 
coded by foreign DNA that has been introduced into the cell. But the DNA will not be integrated into 
the genome of the cell and thus, will be decomposed when a selection pressure is missing.  
In this work HEK 293 cells were transfected by a precipitate of calcium phosphate and DNA which in 
turn adsorbs to the cell surface and is taken up by endocytosis. To improve the transfection efficiency 
a glycerol shock was applied three hours after transfection. In doing so cells were exposed to an 
osmotic pressure, which strains the cell membrane and facilitates the up-take of the foreign DNA. In 
detail, one day prior to transfection HEK 293 cells were plated with a density of 2 x 105 cells per petri 
dish (58 cm2) and 5 µg DNA (prepared as described in section 7.2.4) were precipitated at –20°C 
overnight (DNA ad 150 µl dilution buffer + 600 µl 100% ethanol). Immediately before transfection, the 
DNA was pelleted (15 min, 4°C, 12000 x g) and the supernatant aspirated. The pellet was dried in a 
laminar-flow hood and then resuspended in 438 µl sterile water and 62 µl sterile 2 M CaCl2 solution. 
500 µl of sterile 2 x HBS buffer were applied into 5 ml plastic tubes and the DNA solution was added 
slowly during agitating vortex. The precipitates were then applied drop wise to the cells and incubated 
in the CO2-incubator for 3 h. Afterwards, the culture medium was removed, 3 ml shock solution were 
added per petri followed by an incubation of exactly 2 min before replacement by fresh culture 
medium. 
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dilution buffer   1 mM  EDTA 
    300 mM NaCl 
    10 mM  Tris-HCl, pH 7.8 
 
2 x HBS   50 mM  Hepes 
    280 mM NaCl 
    1.5 mM  Na2HPO4 
      adjusted exactly to pH 7.13 with NaOH 
 
shock solution     1 x HBS 
15% (v/v) glycerol 
 
7.1.2.2 Reportergene assays 
 
To estimate the transfection efficiency both β-galactosidase chemoluminescence assay and β-
galactosidase staining were performed. Hereby one utilises that the enzyme β-galactosidase catalyses 
not only the hydrolysis of various physiological important β-galactosides as lactose but also the non-
physiological substrates as galacton and X-Gal. By transient transfection of pCMVβ (Clontech) the 
enzyme β-galactosidase will be expressed in the cells and can then be used for determination of the 
transfection efficiency. 
 
For the β-galactosidase chemoluminescence assay galacton is used as a substrate. Galacton 
contains a complex organic residue that is connected to galactose by a glycosidic bond. After 
cleavage of galacton by β-galactosidase the organic residue decomposes which is accompanied by 
chemoluminescence because of deprotonation in consequence of increasing pH. The emitted light of 
475 nm wavelengths can be measured and quantified by using an autoluminometer. 
Two days after transfection of pCMVβ (and pcDNA3 as negative control) into HEK 293 cells they were 
carefully washed with PBS and 1 ml CAT Lysis Buffer (Roche) was added per petri dish. Using a 
rubber policeman the cells were collected, incubated for 5 min and finally centrifuged (2 min, 
12000 x g). 5 µl cell lysat were applied to a luminometer tube (Sarstedt). Then, 100 µl of the galacton 
containing reaction mix were added and after 30 min incubation 300 µl stop solution finished the 
enzymatic reaction and induced the pH shift for releasing chemoluminescence.  
 
reaction mix   0.1% (v/v) galacton 
    1 mM  MgCl2  
    0.1 M  Na2HPO4, pH 8 
 
stop solution   5% (v/v) enhancer (Emerald) 
    0.2 M  NaOH 
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For the β-galactosidase staining X-Gal is used as a substrate which becomes hydrolysed by β-
galactosidase. Hydrolysis releases an indoxyl derivative which will then be oxidised to the blue 
coloured dye Indigo so that successfully transfected cells will show a blue staining. 
The cells were washed as described for the chemoluminescence assay. Afterwards, they were fixed 
by adding 5 ml fixation solution and incubation at 4°C for 5 min. Before staining, cells were washed 
again with PBS. 5 ml of X-Gal containing staining solution were added and the cells were incubated at 
37°C for 30 min to allow the β-galactosidase to hydrolyse X-Gal. After further washing with PBS, 
transfection efficiency was estimated by using an inverse phase-contrast microscope.  
 
fixation solution     PBS 
2% (v/v) formaldehyde 
    0.02% (v/v) glutaraldehyde 
 
staining solution    PBS 
5 mM  K3Fe(CN)6 
    5 mM  K4Fe(CN)6 
    2 mM  MgCl2 
    1 mg/ml X-Gal in DMF 
 
7.1.2.3 Selection of stable clones 
 
In contrast to transient transfection the DNA is integrated into the genome by stable transfection. To 
select stably transfected cells the expression vector must contain an selection marker which can be 
expressed in transfected cells. Using the appropriate selection medium the cells can only survive their 
cell division cycles if expressing the resistance gene product permanently. 
To generate BMDP expressing eukaryotic cells, the HEK 293 cells were stably transfected with the 
vectors pEGFP/BMDP, pcDNA3/BMDP and pcDNA3 as negative control according to the description 
given in section 7.1.2.1. Only for monitoring the transfection efficiency pCMVβ was transiently 
transfected (see sections 7.1.2.1 and 7.1.2.2). Two days after transfection the cells were trypsinised 
and plated into selection medium (culture medium + 1 mg/ml geniticin) in different plating densities. 
Over a period of two weeks the selection medium was replaced every 2-3 days before single colonies 
of HEK 293 cells could be identified. They were separated by three different ways: 1. cells of one 
population were trypsinised within a cloning ring and plated into 96-well plates; 2. the medium around 
one cell population was completely removed by a Pasteur pipette and the cells within this circle were 
trypsinised and plated as described for method 1; 3. all surviving cells of one petri dish were 
trypsinised and diluted such that plating of theoretically one or alternatively 10 cells per well of a 96-
well plate was possible. By keeping the cells in selection medium the colonies were expanded up to 
culture flasks. 
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7.1.3 Immunocytochemistry 
 
For immunofluorescence studies porcine brain capillary endothelial cells were plated onto collagen-G 
coated glass cover slips placed in 24 well-plates and stained using mouse anti-human BCRP (BXP-21, 
Alexis) antibody. On ice PBCEC were washed twice with 1 ml PBS before fixation was performed by 
adding 500 µl of –20°C-cold methanol/acetic acid (97/3) solution and incubation for 5 min at –20°C. 
Before addition of the primary antibody fixed cells were washed five times with 1 ml PBS and 
preblocked for 30 min at 37°C in 500 µl PBS supplemented with 3% (v/v) NGS and 0.1% (v/v) Triton-
X-100. Anti-human BCRP monoclonal antibody was used in a 1:10 dilution in 0.5% (v/v) NGS 
containing PBS and the specimen incubated at 37°C for 1 h. Cover slips were washed and blocked 
again before the secondary Cy3-labelled anti-mouse antibody (Molecular Probes) was applied in a 
1:1000 dilution in 0.5% (v/v) NGS containing PBS and followed by a 30 min incubation at 37°C. After 
further washing cells were postfixed by 4% (v/v) paraformaldehyde for 10 min at room temperature. 
The fixative was removed by washing five times with PBS and the cover slips were shortly treated with 
ddH2O and dried on Kimwipes. For embedding one drop Paramount (Polysciences) was placed onto 
an optical slide and the cover slip was put face down onto the slide and allowed to settle. Furthermore, 
the slides were stored in darkness to prevent bleaching of the fluorophores. Normally, the detection 
was performed 12 h after embedding of the cover slips either by epifluorescence or laserscanning 
microscopy. Otherwise samples were stored at 4°C. 
 
 
 
7.1.4 Cytotoxicity assay 
 
In order to characterise the transport activity of BMDP stably expressed in HEK 293 cells the 
cytotoxicity of 6 different cytotoxic agents was probed using the CellTiter 96 AQueous Non-Radioactive 
Cell Proliferation Assay (Promega). This is a colorimetric method for determining the number of viable 
cells in chemosensitivity assays and is composed of solutions containing the tetrazolium compound 
(MTS) and an electron coupling reagent (PMS). MTS is bioreduced by viable cells into a formazan 
product that is soluble in tissue culture medium. The absorbance of the formazan at 490 nm can be 
measured directly from 96-well plates without additional processing. The conversion of MTS into 
aqueous, soluble formazan is accomplished by dehydrogenase enzymes only found in metabolically 
active cells. The quantity of formazan product as measured by the absorbance at 490 nm is directly 
proportional to the number of living cells in culture. Cell viability was always compared between BMDP 
mRNA expressing HEK 293 cells and the negative control HEK 293/pcDNA3. 
For this cytotoxicity assay 1 x 104 cells were plated in 96-well plates and allowed to adhere within 24 h 
before the different cytotoxic agents were added in following concentrations: 
 
    cis-platin  10 nM-10 mM 
    daunorubicin  0.1 nM-1 mM 
    doxorubicin  0.1 nM-10 mM 
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    mitoxantrone  1 nM-10 mM 
    paclitaxel  0.1 nM-10 nM 
    vincristine  0.1 nM-10 nM 
 
After three hours of drug exposition at 37°C in a 5% (v/v) CO2 incubator the proliferation assay was 
performed. 20 µl MTS solution were added and after 2 hours the amount of formazan was measured 
using the microplate reader (ELISA Microtec MPP 4008). The absorbance of cells not treated with any 
drug was set to 100%. 
 
 
 
7.1.5 Active transport of daunorubicin by PBCEC 
 
For active transport measurements of 3H-daunorubicin across a confluent cell monolayer of PBCEC 
the cells were prepared as described in detail in section 7.1.1.1. For filter measurements cells were 
plated on microporous polycarbonate filter membranes (0.4 µm pore size, 1 cm2 growth area, 
TranswellTM No. 3401, Costar) at a density of 250,000 cells/filter two days after preparation. After 
additional two days culture medium was replaced by DMEM/Ham´s F12 medium containing 
L-glutamine (0.7 mM), penicillin/streptomycin (100 µg/ml), gentamicin (100 µg/ml) and hydrocortisone 
(550 nM). The barrier forming endothelial phenotype was tested by readings of the transendothelial 
electrical resistance using AC impedance analysis (Wegener et al., 2000) and by measuring the 
permeability coefficient of 14C-sucrose. In transport inhibition assays the cells were incubated with 
1 µM of the inhibitors verapamil, cyclosporin A, PSC833 and GF120918 60 minutes prior to the 
experiment. The experiment was started by replacing the medium on both sides of the cell layer with 
medium containing 0.2 µM 3H-daunorubicin and 1 µM inhibitor. After 0.5, 6, 12, 24, 36, 48 and 72 
hours, 50 µl samples were taken from each compartment, and the radioactivity in each aliquot was 
measured. Radioactivity at time 0.5 h was set to 100% for each compartment. The tightness of the 
monolayer was simultaneously monitored by the paracellular flux of 1.8 µM 14C-sucrose from the 
apical to the basolateral chamber.  
 
 
Figure 7-1 
Cross-section of a brain capillary and filter 
set-up. The apical compartment corresponds 
to the blood side and the basolateral to the 
brain side. 
 
 
 
 
 
apical 
basolateral 
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7.2 Molecular biology 
 
All devices and solutions as well as pipette tips and reaction tubes were sterilised by routine 
sterilisation techniques. Exclusively chemicals of molecular biology grade were used. When working 
with RNA material, solutions were treated additionally with 0.1% (v/v) dimethylpyrocarbonate (DMPC) 
to inactivate RNases. Glassware was treated at 200°C for at least 4 h and gloves were worn during all 
RNA preparations. 
 
 
7.2.1 Quantification of nucleic acids 
 
7.2.1.1 Photometric determination of concentrations 
 
Concentrations of nucleic acids were measured with an UV-VIS recording spectrophotometer (UV-
2401PC, Shimadzu) using a wavelength of 260 nm which is most suited for RNA/DNA quantification 
due to the absorbance of purine- and pyrimidine bases. Using a 1 cm cuvette an optical density OD260 
of 1 corresponds to 40 µg/ml of ss RNA- and to 50 µg/ml of ds DNA-concentration. 
The purity of isolated nucleic acids was determined by measuring the optical density at 280 nm where 
aromatic amino acids of proteins show highest absorbance. The ratio OD260/OD280 is supported to be 
between 1.8 to 2.1 for RNA dissolved in buffer with pH > 7 and about 1.8 for DNA. 
 
7.2.1.2 Determination of concentrations by ethidiumbromide staining  
 
The quantity of DNA, especially when used for cloning, was estimated on ethidiumbromide stained 
agarose gels with the help of commercially available DNA ladders from Eurogentec. The so called 
SMART-ladders contain definite amounts of DNA in each visible band to which the intensity of 
analysed DNA sample was visually compared and thus, the amount of DNA of the sample could be 
estimated. 
 
 
 
7.2.2 Agarose gel electrophoresis 
 
Nucleic acids can be separated with respect to their size in an agarose matrix by gel electrophoresis. 
The concentration of agarose was varied according to the expected size of the DNA fragments in 
order to obtain optimal separation results as listed in Table 7-1. To guarantee that nucleic acids move 
in the electrical field to the anode the electrophoresis must be performed at a pH close to neutral pH. 
Therefore, 1 x TAE-buffer for non-denaturing gels (DNA) and 1 x MEA-buffer for denaturing gels 
(RNA) were used. In case of DNA gels variable amounts of agarose were directly dissolved in 
1 x TAE-buffer by heating in a microwave, while for RNA gels 1% (w/v) agarose was dissolved in 
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DMPC treated water, first. Afterwards 10 x MEA and formaldehyde (37%) were added to a final 
concentration of 1 x MEA and 6% (v/v) formaldehyde. Gel electrophoresis was performed at 100 V. 
Prior to electrophoresis the samples were diluted in DNA- or RNA-loading buffer. Furthermore, RNA 
samples were denatured for 10 min at 65°C and both formaldehyde and formamide present in the 
loading buffer inhibit further formation of RNA secondary structures. To determine the size of DNA 
fragments DNA-ladders (Life Technologies and Eurogentec) were used. Nucleic acid fragments were 
visualised under UV-light (254 nm) using ethidiumbromide as dye. In case of DNA separation gels 
were stained after electrophoresis in an ethidiumbromide containing solution (0.5 µg/ml in 1 x TAE-
buffer). For RNA-visualisation 1 µl of an ethidiumbromide solution (1 mg/ml) was directly added to the 
samples prior to loading.  
 
 
Table 7-1 Concentration of standard agarose used for separating DNA of different sizes. 
 
agarose concentration (% w/v) 0.3 0.6 0.8 1.0 1.2 1.5 2.0 
nucleic acid fragment range (kb) 5-60 1-20 0.8-10 0.5-10 0.4-7 0.2-3 0.1-2 
 
 
 
50 x TAE    2 M  Tris 
    2 M  sodiumacetate 
    0.05 M  EDTA 
      pH 7,4-7,8 
 
10 x MEA    0.01 M, pH8 EDTA 
    0.2 M  MOPS 
    0.05 M  sodiumacetate 
      pH 7.0 
 
10 x DNA-loading buffer 0.25% (w/v) bromophenol blue 
    0.25% (w/v) xylene cyanole 
    15% (v/v) Ficoll 
 
1 x RNA-loading buffer  50% (v/v) formamide de-ionised 
    10% (v/v) 10 x MEA 
    16% (v/v) 37% formaldehyde 
    5% (v/v) glycerol 
    0.25% (w/v) bromophenol blue 
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7.2.3 Isolation of DNA from agarose gels 
 
Gel extraction of DNA fragments was performed by using the QIAquick Gel Extraction Kit (Qiagen) 
according to the manufacturer’s instructions. The DNA fragment was excised from the agarose gel, 
weighed (1 mg ≈ 1µl) and dissolved in 3 gel volumes Buffer QG at 50°C for 10 min. Afterwards, one 
gel volume of isopropanol was added and DNA was purified by a QIAquick spin column. DNA adsorbs 
to the silica-membrane in the presence of a high concentration of chaotropic salts and pH < 7.5 while 
contaminants pass through the column and are efficiently washed away. The pure DNA was then 
eluted by 30-50 µl of 10 mM Tris/HCl and pH 8.5. Concentrations of purified DNA fragments were 
determined as described in section 7.2.1.2. 
 
 
 
7.2.4 Isolation of plasmid-DNA  
 
Plasmid DNA was isolated from E. coli cultures grown overnight in LB medium containing the 
appropriate antibiotic. Depending on further use the isolation was done by two slightly different 
methods. For plasmid analysis by PCR, restriction digestion or sequencing the QIAprep Spin Miniprep 
(Qiagen) was used. If the plasmid DNA was isolated for cell culture transfection experiments, larger 
amounts were obtained by the corresponding QIAprep Spin Maxiprep (Qiagen). In the latter case, 
plasmids were further purified and sterilised by ethanol precipitation just prior to transfection 
(see section 7.1.2.1). 
Both QIAprep methods are based on the same principle of an alkaline lysis of bacterial cells, 
precipitation of genomic DNA, proteins and cell debris followed by adsorption of plasmid-DNA onto 
silica in the presence of high salt concentrations. After removal of molecular contaminants plasmid-
DNA will be eluted by low salt buffer at pH between 7 and 8.5. The main difference between both 
methods is their scale: mini preparations are optimised for 1-5 ml bacterial culture and yield up to 
10 µg ds plasmid-DNA, while maxi preparations can be used for 500 ml bacterial culture to give 
500 µg ds DNA. Both procedures were exactly performed according to the instructions given in the 
manuals.  
 
 
 
7.2.5 Isolation of genomic DNA 
 
Genomic DNA was isolated from porcine liver as described by (Sambrook et al., 1989) with minor 
modifications. Porcine liver was obtained from freshly slaughtered pigs, rapidly frozen in liquid nitrogen 
and crushed to produce readily digestible pieces. The processed tissue was soaked in a solution of 
proteinase K and sodium dodecyl sulfate and incubated until most of the cellular proteins were 
degraded. The digest was then deproteinised by successive phenol/chloroform/isoamyl alcohol 
extractions, recovered by ethanol precipitation, and dried and resuspended in buffer. In detail, 2 g of 
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frozen tissue were ground with a prechilled mortar and pestle to a fine powder and then resuspended 
in 30 ml digestion buffer. 500 µl DNase-free RNase (1 mg/ml) were added and incubated at 37°C for 
2 h. After supplementation with 600 µl proteinase K (10 mg/ml) the sample was agitated carefully at 
37°C overnight. Next day, the viscous sample was extracted with 30 ml phenol/chloroform/isoamyl 
alcohol (25/24/1) and centrifuged (10 min, 1700 x g, 4°C). The aqueous (top) layer was transferred to 
a new tube and ½ of its volume of 7.5 M ammonium acetate and 2 volumes of 100% ethanol were 
added. The DNA immediately formed a stringy precipitate, which was rolled up on a Pasteur pipette. 
DNA was rinsed with 70% ethanol, air dried and dissolved in 5 ml 10 mM Tris/HCl (pH 8.5) at 37°C 
and careful agitation. Concentration was determined by photometric measurement as described in 
section 7.2.1.1 and the genomic DNA was stored in small aliquots at –20°C. Repeated freeze/thaw 
cycles were avoided. 
 
digestion buffer   100 mM NaCl 
    10 mM  Tris/HCl, pH 8 
    25 mM  EDTA, pH8 
    0.5% (w/v) SDS 
 
 
 
7.2.6 Isolation of RNA 
 
7.2.6.1 Isolation of total RNA from cultured cells 
 
Total RNA from cultured cells was isolated using the High Pure RNA Isolation Kit (Roche) according to 
the instructions given in the manual. 1 x 106 cells were washed twice with PBS before lysis is 
accomplished by incubating the sample with 400 µl Triton X-100 and guanidine hydrochloride 
containing lysis/binding buffer to inactivate RNases. Cell suspensions were applied to the filter tubes 
where in the presence of chaotropic salt RNA binds to the surface of glass fibers. The binding process 
is specific for nucleic acids, and here optimised for RNA. Rests of contaminating DNA were digested 
by DNase I, applied directly on the glass fiber fleece and incubated for 30 min. The bound RNA was 
then purified from salts, proteins and other cellular impurities by three washing steps and was finally 
eluted in 100 µl RNase-free water. The quality of RNA was checked by denaturing agarose gel 
electrophoresis (see section 7.2.2) and the ratio of OD260/OD280 (see section 7.2.1.1). RNA was 
quantified by measuring the OD260 (see section 7.2.1.1) and stored at –70°C. 
 
In most cases RNA was precipitated prior to further use according to the following protocol: 
0.2 volumes 2 M sodium acetate (pH 5.2) and 2.5 volumes 100% ice-cold ethanol were added and 
incubated either on ice for 1 h or at –20°C overnight. After centrifugation (20 min, 4°C, 10000 x g) the 
pellet was washed with 75% ethanol and again collected by centrifugation. The air-dried pellet was 
dissolved either in RNase-free water when used for mRNA isolation (see section 7.2.6.3) or cDNA 
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synthesis (see section 7.2.7) or in RNA-loading buffer when applied for northern blot analysis (see 
section 7.2.10.1). 
 
7.2.6.2 Isolation of total RNA from tissue 
 
Isolation of total RNA from tissue was performed using the TRIzol Reagent (Life Technologies) 
according to the following protocol. Tissues were obtained from freshly slaughtered pigs and rapidly 
frozen in small pieces of 100 mg each in liquid nitrogen. To 100 mg tissue 750 µl TRIzol Reagent 
were added and immediately homogenised using an ultraturrax (IKA Labortechnik). Samples were 
incubated for 5 min at room temperature before centrifugation (12000 x g, 4°C, 10 min). TRIzol 
Reagent is a mono-phasic solution of phenol and guanidine isothiocyanate and maintains the integrity 
of the RNA, while disrupting cells and dissolving cell components. The supernatant was then applied 
to a new tube and 300 µl chloroform were added and mixed vigorously to separate the solution into an 
aqueous and an organic phase. After centrifugation (12000 x g, 4°C, 15 min) RNA was recovered by 
addition of 375 µl isopropyl alcohol to the upper aqueous phase, while DNA and proteins were 
localised in the interphase and organic phase. Precipitation of RNA occured within 10 min at room 
temperature and RNA was subsequently collected by centrifugation (12000 x g, 4°C, 15 min). The 
pellet was washed with 750 µl 75% ethanol (7500 x g, 4°C, 5 min), briefly air-dried and resuspended in 
100 µl RNase-free water at 65°C for 10 min. The qualitiy of RNA was checked by denaturing agarose 
gel electrophoresis (see section 7.2.2) and the ratio of OD260/OD280 (see section 7.2.1.1). The amount 
of RNA was quantified by measuring the OD260 (see section 7.2.1.1). The RNA was stored at –70°C. 
Higher concentrations of RNA were provided by ethanol precipitation as described in the previous 
section. 
 
7.2.6.3 Isolation of mRNA 
 
To isolate poly-A mRNA from total RNA the Oligotex mRNA Kit (Qiagen) was used. Starting with up 
to 250 µg total RNA this preparation yielded 2.5-12.5 µg mRNA. According to the manufacturers 
instructions total RNA solution was combined with buffer OBB and Oligotex suspension and incubated 
firstly for 3 min at 70°C to disrupt secondary structures of the mRNA and secondly for 10 min at room 
temperature to allow hybridisation of poly-A tails to dT oligomers coupled to a solid-phase matrix 
present in the Oligotex suspension. In two washing steps poly-A tail missing rRNA and tRNA species 
were removed. Since hybridisation requires high-salt conditions, the poly-A mRNA was then easily 
released by lowering the ionic strength and destabilising the dT:A hybrids when eluted with 100 µl of 
Oligotex elution buffer (5 mM Tris/HCl, pH 7.5). mRNA was either stored at –70°C or precipitated for 
subsequent use as described in section 7.2.6.1. 
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7.2.7 cDNA synthesis 
 
cDNA was transcribed from either 5 µg of total RNA or 500 ng of mRNA using SUPERSCRIPT II 
RNase H- Reverse Transcriptase (Life Technologies). The reaction mix was supplemented with 
accompanied 5 x First Strand Buffer and 0.1 M DTT as well as Oligo (dT)12-18 (500 µg/ml). 1 µl Oligo 
(dT) was added to the RNA sample in a final volume of 12 µl, denatured at 70°C to dissolve secondary 
structures and immediately chilled on ice. 4 µl 5 x First Strand Buffer, 2 µl 0.1 M DTT and 1 µl dNTP 
mix (10 mM each dATP, dGTP, dCTP, dTTP) were added and incubated at 42°C for 2 min before 1 µl 
(200 units) of SUPERSCRIPT II was added. cDNA synthesis was performed at 42°C for 50 min and 
finished by inactivation of the enzyme at 70°C for 15 min. The cDNA pool was either used directly for 
PCR analysis or stored at –20°C. 
 
 
 
7.2.8 PCR methods 
 
The polymerase chain reaction (PCR) was applied to amplify DNA fragments using two specific 
primers complementary to the ends of the desired DNA fragment. As templates either plasmid-DNA or 
cDNA pools were used. The latter case was given for RT-PCR, 3’- and 5’-RACE-PCR and LD-PCR 
which will be described in more detail in the following sections. All primers and their annealing 
temperatures are listed in Appendix E and F. PCR with plasmid-DNA as template was performed to 
generate material enough for probing northern or Southern blots. In these cases the thermostable Taq 
DNA polymerase (Life Technologies) and a reaction volume of 100 µl were used as follows: 10 µl 
10 x PCR buffer and 3 µl 50 mM MgCl2 (both applied by the manufacturer’s), 2 µl dNTP mix (10 mM 
each nucleotide), 1 µl of 5’- and 3’-primer (10 µM), 0.5 µl plasmid-DNA (approx. 0.2 µg/µl), 81.5 µl 
ddH2O and finally 1 µl (5 U/µl) Taq DNA polymerase were gently mixed and incubated using the 
Mastercycler gradient (Eppendorf). The PCR was performed according to the following program: 3 min 
initial denaturation at 94°C, 25 to 30 cycles of 30 sec denaturation at 94°C, 1 min annealing of the 
primers at a primer specific temperature (50-65°C, listed in Appendix E and F) and 1.5 min elongation 
at 72°C. Afterwards the mixture was incubated for 5 min at 72°C to complete elongation and finally 
stored at 4°C. PCR-products were then analysed by agarose gel electrophoresis (see section 7.2.2), 
purified from agarose gel (see section 7.2.3), quantified (see section 7.2.1.2) and generally used for 
probing in northern and Southern blotting (see section 7.2.10.3) and for cloning (see section 7.2.11). 
 
7.2.8.1 RT-PCR 
 
RT-PCR was generally performed using the Advantage cDNA Polymerase Mix (Clontech) which 
contains KlenTaq-1 DNA Polymerase (an exo-minus, N-terminal deletion of Taq DNA polymerase), a 
proofreading polymerase to minimise the error rate and TaqStart Antibody for automatic hot start. 
The PCR-products were either investigated on agarose gels in case of various expression studies or 
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they were cloned for subsequent sequencing either directly by TA-cloning (see section 7.2.11.3) or 
after restriction in the priming sites (see sections 7.2.11.1 and 7.2.11.2). 
Generally 1 µl of cDNA (see section 7.2.7) was added to a mixture of 18 µl ddH2O, 2.5 µl 
10 x Advantage PCR buffer, 1 µl dNTP mix (10 mM of each nucleotide), 1 µl 5’- and 3’-primer (10 µM) 
and 0.5 µl 50 x Advantage cDNA Polymerase Mix. The PCR was carried out according to the 
program listed above. 
 
7.2.8.2 3’-RACE-PCR 
 
To generate the 3’-cDNA end of clone C8 (BMDP) the BMDP specific primer BMDP_C8-F, the 
oligo (dT) containing 3’RACE-R primer and the cDNA prepared from total RNA as described in section 
7.2.7 were used in the PCR with the thermostable Taq DNA polymerase (Life Technologies). For the 
reaction 18.5 µl ddH2O, 2.5 µl 10 x PCR buffer, 0.75 µl 50 mM MgCl2, 0.5 µl dNTP mix (10 mM of each 
nucleotide), 0.5 µl cDNA template, 1 µl BMDP_C8-F (10 µM), 1 µl 3’RACE-R (10 µM) and 0.25 µl Taq 
DNA polymerase (0.5 U/µl) were gently mixed and subjected to the following PCR program: 3 min 
initial denaturation at 94°C, 30 cycles of 30 sec denaturation at 94°C, 1 min annealing of the primers 
at 55°C and 1 min elongation at 72°C. Afterwards the mixture was incubated for 5 min at 72°C to 
complete elongation and then stored at 4°C. The PCR product was subjected to gel electrophoresis as 
described in chapter 7.2.2, the DNA was excised (see section 7.2.3), quantified (see section 7.1.1.2), 
used for TA-cloning (see chapter 7.2.11.3) and finally sequenced (see section 7.2.12). 
 
7.2.8.3 5’-RACE-PCR 
 
To obtain full-length cDNA sequence information of BMDP the SMART RACE cDNA Amplification 
Kit (Clontech) was used. SMART technology maximises the probability of generating anchored, full-
length cDNAs in reverse transcription reactions, ensuring that complete 5’-end sequences will be 
amplified during PCR. As shown in Figure 7-2, first-strand cDNA synthesis is primed by a modified 
oligo (dT) primer. When MMLV reverse transcriptase reaches the 5’ end of the mRNA template, the 
enzyme’s terminal transferase activity adds a few (dC) residues. This overhang is recognised by 
SMART II Oligonucleotide, whose terminal stretch of guanine nucleotides anneals to the (dC)-rich 
cDNA tail and serves as an extended template. Reverse transcriptase then switches templates and 
replicates the oligonucleotide. The resulting single-stranded SMART cDNA contains the complete 
5’ end of the mRNA template, as well as the sequence complementary to the SMART II 
Oligonucleotide, called the SMART Anchor. This anchor serves as a universal priming site for 5’-
RACE-PCR. This method along with the techniques of suppression PCR and step-out PCR ensures 
high specificity for amplifying the target cDNA only. In suppression PCR, the incorporation of inverted 
repeats at the end of a DNA sequence prevents its amplification during PCR by forming panhandle-
like structures (illustrated in Figure 7-3). In step-out PCR, a mixture of two primers is used to 
incorporate additional sequence at one end of a DNA template. This Universal Primer Mix (UPM) is 
used in the SMART RACE protocol to add inverted repeat elements to the ends of cDNAs. One of the 
primers in the mix, the Long Universal Primer (Long UP), contains the SMART sequence at its 3’ end  
7  Experimental  87 
 
 
Figure 7-2 Detailed mechanism of the SMART 5’-RACE PCR. Adapted from Clontech. 
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and a 5’ heel of 20 bp which contains critical elements of the suppression PCR inverted repeat. As 
demonstrated in Figure 7-2, this primer incorporates the inverted repeat elements next to all SMART 
sequences present in the cDNA population during the early rounds of RACE-PCR. As a result, all 
cDNAs that were correctly primed by oligo (dT) and have only one SMART sequence at the 3’ end of 
the first-strand cDNA will contain one inverted repeat stretch at one end. In the second round of 
RACE-PCR the gene-specific primer (GSP) amplifies only the gene of interest from the cDNA-pool 
and in the remaining rounds of PCR the GSP together with the Short Universal Primer (Short UP), 
present at higher concentration than the Long UP, exclusively amplifies the gene specific sequence. 
Further background is reduced by a second PCR with nested gene-specific primers (NGSP) and 
nested universal primer (NUP). 
 
The techniques of suppression PCR and step-out PCR reduce background amplification by the 
following mechanisms (Figure 7-3): In some cases first-strand cDNA synthesis might be primed non-
specifically by SMART II Oligonucleotide and even in these cases the MMLV reverse transcriptase 
reaches the 5’ end of the mRNA template, its terminal transferase activity adds a few (dC) residues 
and this overhang is harnessed by SMART II Oligonucleotide. After template switching and 
replicating the oligonucleotide by RT these non-specifically primed transcripts are flanked by SMART 
sequences at both ends and thus, becoming flanked by the inverted repeats of Long UP in the first 
and remaining rounds of PCR (step-out PCR). As during PCR these inverted repeats anneal to each 
other intramolecularly according to a rapid first-order reaction kinetic, panhandle-like structures are 
formed which cannot be amplified as a result of missing priming sites for Short UP (suppression PCR).  
 
In this work cDNA synthesis was performed exactly according to the instructions given in the 
SMART RACE cDNA Amplification manual by using 1 µg of mRNA isolated as described in section 
7.2.6.3. In the first PCR the BMDP_5’RACE-R (f.c. 0.2 µM) and Universal Primer Mix (UPM, 
containing Long UP (f.c. 0.02 µM) and Short UP (f.c. 0.1 µM)) were used, followed by the second PCR 
with the primers BMDP_Nested5’RACE-R (f.c. 0.2 µM) and Nested Universal Primer (NUP, f.c. 0.2 
µM). The PCR product was subjected to gel electrophoresis as described in chapter 7.2.2, the DNA 
was excised (see section 7.2.3), quantified (see section 7.1.1.2), used for TA-cloning (see chapter 
7.2.11.3) and finally sequenced (see section 7.2.12). 
 
7.2.8.4 LD-PCR 
 
After RACE products had been characterised by sequencing, full-length cDNA was generated by long 
distance PCR (LD-PCR) using primers from the extreme 5’ and 3’ ends of BMDP cDNA and the 
SMART cDNA as template. In detail, 38.5 µl ddH2O, 5 µl 10 x Advantage PCR buffer, 1 µl 
BMDP_complete-F (10 µM), 1 µl BMDP_complete-R (10 µM), 1 µl dNTP mix (10 mM each 
nucleotide), 2.5 µl SMART cDNA and 0.5 µl 50 x Advantage cDNA Polymerase Mix were combined 
and incubated as follows: 3 min initial denaturation at 94°C, 30 cycles of 15 sec denaturation at 94°C, 
30 sec annealing of the primers at 60°C and 3 min elongation at 72°C. Afterwards the mixture was 
incubated for 5 min at 72°C to complete elongation and then stored at 4°C. The PCR product was  
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Figure 7-3 Mechanisms of suppression and step-out PCR. Adapted from Clontech. 
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subjected to gel electrophoresis as described in chapter 7.2.2, the DNA was excised (see section 
7.2.3), quantified (see section 7.1.1.2), used for restriction and cloning (see chapter 7.2.11.1 and 
7.2.11.2) and finally sequenced (see section 7.2.12). 
 
 
 
7.2.9 Site-directed mutagenesis 
 
After cloning of cDNA encoding 144 amino acids of BMDP in the expression system pMAL (New 
England Biolabs) in order to express BMDP as a fusion to the maltose binding protein, a stop codon 
had to be inserted by site-directed mutation. The amino acid tyrosine (Y) coded by the UAC triplet was 
changed into the termination codon UAG by using the QuickChange Site-Directed Mutagenesis Kit 
(Stratagene). The basic procedure utilises a supercoiled double-stranded DNA vector with an insert of 
interest and two synthetic oligonucleotide primers containing the desired mutation. The oligonucleotide 
primers, each complementary to opposite strands of the vector, are extended during temperature 
cycling by using PfuTurbo DNA polymerase, which replicates both plasmid strands with high accuracy. 
Incorporation of the oligonucleotide primers generates a mutated plasmid containing staggered nicks. 
Following temperature cycling, the product is treated with Dpn I. The Dpn I endonuclease is specific 
for methylated and hemimethylated DNA and is used to digest the parental DNA template and to 
select the mutation-containing synthesised DNA, since plasmid DNA isolated from E. coli is 
methylated and therefore, susceptible to Dpn I digestion. The nicked vector DNA holding the desired 
mutations is then transformed into E. coli competent cells. 
According to the detailed instructions given by Stratagene site-directed mutagenesis was performed 
with the primers 1040-Y546STOP-QC-sense and 1040-Y546STOP-QC-anti. Mutated DNA was 
transformed into E. coli TOP10F’ cells and amplified as described in section 7.3, isolated (see section 
7.2.4) and finally sequenced to confirm the correct mutation (see section 7.2.12). 
 
 
 
7.2.10 Nucleic acid blotting and hybridisation 
 
7.2.10.1 Northern blotting 
 
After separating RNA molecules in a denaturing gel (see section 7.2.2), RNA molecules in the gel 
were transferred to a positively charged nylon membrane (Hybond, Amersham Biotech) by capillary 
transfer. The RNA of interest was then identified by hybridisation with radioactive probes and 
visualised by autoradiography as described in the following sections 7.2.10.3 to 7.2.10.5. 
For the setup (Sambrook et al., 1989) nylon membrane and Whatman filter papers were equilibrated in 
transfer buffer (20 x SSC) and the gel was soaked in RNase-free water immediately after gel 
electrophoresis. Capillary transfer proceeded for 12-18 h. Afterwards, the membrane was neutralised 
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in 2 x SSC and RNA was fixed to the blot by UV-crosslinking (350 nm) for 100 sec and subsequent 
baking (2 h, 80°C). Membranes were stored between filter paper at room temperature until further use. 
 
20 x SSC   3 M  NaCl 
    0.3 M   sodium citrate 
 
7.2.10.2 Southern blotting 
 
For Southern blotting the genomic DNA prepared as described in section 7.2.5 was completely 
digested by three different hexanucleotide recognising restriction enzymes HindIII, EcoRI and BamHI 
and subsequently purified by phenol/chloroform/isoamyl alcohol extraction. In each case 50 µg of 
isolated genomic DNA were digested by 200 U restriction enzyme (New England Biolabs) in a volume 
of 100 µl at 37°C for four hours. 200 µl phenol/chloroform/isoamyl alcohol (25/24/1) were added and 
the solution was vigorously mixed. After centrifugation (12000 x g, 4°C, 20 min) the top aqueous layer 
was transferred to a new reaction tube and digested DNA was precipitated at –70°C for 30 min after 
adding 20 µl 5 M NaCl and 500 µl 100% ethanol. A pellet was obtained by centrifugation (12000 x g, 
4°C, 20 min), washed with 70% ethanol and air-dried before resuspension in 50 µl ddH2O. The 
amount of DNA was determined as described in section 7.2.1.1. 15 µg of each sample were separated 
on a 1% agarose gel (see section 7.2.2) and then blotted onto a positively charged nylon membrane 
according to the setup described by Sambrook et al. (1989). Prior to blotting the gel was agitated 
gently for 10 min in 0.25 M HCl to depurinate nucleic acids. Depurination reduces the size of 
fragments, which in turn fascilitates their transfer. The gel was then briefly rinsed in destilled water. In 
order to create suitable hybridisation targets the double-stranded DNA was denatured by soaking the 
gel in denaturing buffer for 30 min. Prior to blotting the gel was agitated in neutralisation buffer for 
30 min to remove the denaturation buffer. Capillary transfer was performed in the same way as 
described for northern blotting in the previous section. After blotting the membrane was treated with 
0.4 M NaOH for 1 min, neutralised with 0.1 M Tris/HCl (pH 7.5) for 1 min and finally with 2 x SSC for 
1 min. DNA was fixed by UV-crosslinking (350 nm) for 100 sec. 
 
20 x SSC   3 M  NaCl 
    0.3 M   sodium citrate 
 
denaturing buffer  0.4 M  NaOH 
    0.6 M  NaCl 
 
neutralisation buffer  1.5 M   NaCl 
    0.5 M   Tris/HCl (pH 7.5) 
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7.2.10.3 Preparation of α-32P-labelled DNA probes 
 
For probing both northern and Southern blots radioactive labelled DNA samples were generated by 
the Megaprime DNA labelling system (Amersham Biotech) exactly according to the supplied 
protocol. After denaturation of purified DNA samples (see section 7.2.3) the Klenow fragment of E. coli 
DNA polymerase synthesises a second DNA strand and incorporates 32P-labelled dCTP starting at the 
random primer present in the reaction mix. This primer mix contains nonanucleotides, which 
statistically bind every 80-100 nucleotides along the template. 
To 25 ng DNA and 5 µl random primer solution the appropriate volume of water were added to give a 
total volume of 50 µl in the final Megaprime reaction. After a 5 min denaturation time at 100°C 10 µl 
labelling buffer, 5 µl dCTP32 (10 µCi/µl) and 2 µl enzyme were added and incubated for 15 min at 
37°C. The reaction was stopped by applying 5 µl EDTA (0.2 M). 
The radioactive labelled probes were then purified from non-incorporated 32P-labelled dCTP by size-
exclusion using MicroSpin™ G-50 Columns (Amersham Biotech) before the activity was measured by 
a scintillation counter (Beckmann). 
 
7.2.10.4 Hybridisation 
 
To identify and visualise specific mRNA molecules or genomic DNA fragments the radiolabelled 
probes were hybridised to the nucleic acid bound onto the nylon membrane. Before hybridisation the 
membranes were equilibrated with 10 mg/ml denatured herring sperm DNA containing hybridisation 
solution at 42°C overnight to minimise unspecific binding of the probe to the membrane afterwards. 
For hybridisation the radiolabelled probe was denatured at 100°C for 10 min, chilled on ice and finally 
added to the hybridisation solution. Hybridisation was performed overnight at 42°C. 
 
hybridisation solution  5 x   SSPE 
    50% (v/v) formamide 
    5 x  Denhardt solution 
    1% (w/v) SDS 
    10% (w/v) dextran sulfate sodium salt 
 
20 x SSPE   3 M  NaCl 
    0.2 M  NaH2PO4.H2O 
    0.02 M  EDTA 
      pH 7.4 
 
100 x Denhardt solution 2% (w/v) Ficoll 400 
    2% (w/v) polyvinylpyrolidone 
    2% (w/v) bovine serum albumine 
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7.2.10.5 Washing 
 
Unspecifically bound radiolabelled probe was removed by repeated washing. Membranes were 
washed twice with low stringent buffer (2 x SSPE) for 15 min at room temperature, then twice with 
medium stringent buffer (2 x SSPE, 2% (w/v) SDS) for 15 min at 65°C. After monitoring the 
radioactivity high stringent buffer (0.1 x SSPE) was applied at room temperature as long as no further 
background activity could be monitored. For visualisation by autoradiography the membranes were 
exposed to Hyperfilms (Amersham Biotech) at –70°C for some hours up to some days depending on 
signal intensity. 
 
20 x SSPE   3 M  NaCl 
    0.2 M  NaH2PO4.H2O 
    0.02 M  EDTA 
      pH 7.4 
 
7.2.10.6 Stripping 
 
In case of northern blots the same blot needed to be hybridised with a α-32P-labelled GAPDH probe to 
normalise for RNA loading. Therefore, initially applied probes were removed by heating the membrane 
in stripping solution for 10 min at 100°C. 
 
stripping solution  0.015 M  NaCl 
    0.1 x  SSC 
    1% (w/v) SDS 
 
20 x SSC   3 M  NaCl 
    0.3 M  Na3citrate.H2O 
      pH 7 
 
 
 
7.2.11 Cloning and ligation 
 
The construction of vectors was performed by two different ways. Either DNA was generated by PCR 
(see section 7.2.8), purified from agarose gels (see section 7.2.2 and 7.2.3), digested in the primer 
sites (see section 7.2.11.1) and cloned into a vector of choice which was linearised using the same 
restriction endonucleases (see section 7.2.11.2). In case of a single cut reaction the vector was 
dephosphorylated with shrimp alkaline phosphatase (0.1 U/µl) (Roche) prior to ligation (30 min, 37°C). 
Or alternatively DNA was generated by PCR and directly cloned into pT-Adv Vector (Clontech) by TA-
cloning (see section 7.2.11.3). In both cases ligation mixes were transformed into E. coli competent 
cells to amplify plasmids (see section 7.3.2). Subsequently plasmids were isolated (see section 7.2.4) 
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and sequenced (see section 7.2.12). All vectors and a brief description of their construction are listed 
in Appendix F. 
 
7.2.11.1 Restriction 
 
1 to 5 µg of DNA (either plasmids or PCR-fragments) were cut by 1 µl restriction endonucleases 
(10 U/µl, New England Biolabs) in the presence of 2 µl of the appropriate 10 x restriction buffer (New 
England Biolabs) in a final volume of 20 µl. Depending on the endonucleases used the restriction mix 
was incubated for 90 min at 37°C or 55°C. In case of plasmids the restriction reaction was controlled 
by gel electrophoresis (see section 7.2.2) and the linearised DNA or the insert were isolated from the 
agarose gel (see section 7.2.3). Restricted PCR-fragments were directly purified by the QIAquick Gel 
Extraction Kit (Qiagen) similar to the protocol given in section 7.2.3 and according to the instructions of 
the manual. 
 
7.2.11.2 Ligation 
 
Prior to ligation the concentration of purified and restricted DNAs was estimated from an agarose gel 
as described in section 7.2.1.2. In order to calculate the proper vector/insert ratio of 1:3 for best 
ligation efficiencies the following formula was used: 
 
         a ng Insert = 3 x [(b bp Insert x c ng vector)/(d bp vector)] 
 
The ligation was carried out at 16°C overnight using 1 µl T4-DNA ligase (6 U/µl) (New England 
Biolabs), 2 µl 10 x ligation buffer (New England Biolabs), vector and insert DNA in the calculated ratio 
and ddH2O to a final volume of 20 µl. The ligation mix was stored at 4°C until transformation into E. 
coli cells (see section 7.3.2). 
 
7.2.11.3 TA-cloning 
 
TA-cloning was exactly performed as described by Clontech’s user manual. During PCR the 
thermostable Taq polymerase adds a single deoxyadenosine (A) to the 3’ ends and the pT-Adv 
Vector, with its 3’ T-overhangs, enables to directly clone these PCR products. 
According to the equation above fresh PCR product and 50 ng pT-Adv Vector were added to 1 µl 
ligation buffer and 1 µl T4 DNA ligase (4 U/µl)  in a final volume of 10 µl. The ligation reaction was 
incubated at 14°C either for 4 hours or preferably overnight and finally transformed into E. coli cells 
was performed (see section 7.3.2). 
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7.2.12 DNA sequencing 
 
DNA sequencing relies on the synthesis of a new strand of DNA starting at a specific priming site and 
ending with the incorporation of a chain terminating nucleotide such as a dideoxynucleoside 
triphosphate (ddNTP) (Sanger et al., 1977). In fluorescent dye-primer sequencing, the label is 
attached to the 5’ end of the primer. The relative concentrations of dNTPs and ddNTPs are balanced 
so that, on average, at each position within the desired length of sequence, there is an equal chance 
of a ddNTP being incorporated. When these fragments are separated on a suitable gel matrix, 
sequence information can be obtained. Cycle sequencing uses repeated cycles of thermal 
denaturation, annealing and extension/termination to increase signal levels and therefore decrease 
the amount of template required.  
 
In this work the apparatus Gene Read IR4200 (LI-COR) was used to detect the fluorescence labelled 
products separated on a denaturing polyacrylamide gel (sequencing gel). During gel electrophoresis 
an IR-laser (800 nm) screened the lower part of the sequencing gel and stimulated the fluorescence 
dye (IRD800) incorporated on the 5’ end of cycling products. The products were detected by the 
emitted light.  
For the sequencing reaction the SequiTherm EXCEL II DNA Sequencing Kit (Biozym) was used as 
described in Table 7-2. All sequencing primers are listed in Appendix E. The sequencing reactions 
were performed in the Mastercycler gradient (Eppendorf) with following sequence: 5 min of initial 
denaturation at 95°C, 40 cycles of 30 sec denaturation at 95°C, 30 sec annealing of the primers at a 
primer specific temperature (50-65°C, listed in Appendix E) and 1 min elongation at 70°C. Afterwards 
the mixture was incubated for 5 min at 70°C to complete elongation and then stored at 4°C. 3 µl 
Stop/Loading Buffer were then added to each reaction mix to denature the DNA and enhance the 
fluorescence light. Finally 2 µl sample were loaded onto the sequencing gel which was prepared with 
30.3 ml sequencing gel buffer, 4.7 ml acrylamid/bisacrylamid (50%/0.8% ) (USB), 47 µl TEMED and 
220 µl 10% APS. Gel electrophoresis was performed overnight with 1 x TBE long run buffer and the 
following operational parameters: max. 1500 V, max. 35 mA, max. 40 W, 45°C. 
 
 
Table 7-2 Scheme for sequencing reaction. 
 
master mix (16 µl) ddH2O 3.2 µl 
 3.5 x SequiTherm EXCEL II Sequencing Buffer 6.8 µl 
 plasmid-DNA (Miniprep, Qiagen, see section 7.2.4) 3 µl 
 IRD800-labelled sequencing primer (see appendix E) 2 µl 
 SequiTherm EXCEL II DNA Polymerase (5 U/µl) 1 µl 
ddATP-reaction ddCTP-reaction ddGTP-reaction ddTTP-reaction 
4 µl master mix 4 µl master mix 4 µl master mix 4 µl master mix 
2 µl termination mix A 2 µl termination mix C 2 µl termination mix G 2 µl termination mix T 
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sequencing gel buffer  3 M  urea 
    15% (v/v) 10 x TBE lung run buffer 
 
10 x TBE long run buffer 1.34 M  Tris base 
    450 mM boric acid 
    25 mM  EDTA 
 
 
 
7.2.13 Differential screening of a subtracted cDNA library 
 
7.2.13.1 Establishment of a subtracted cDNA library using SSH 
 
Establishment of the subtracted cDNA library was performed by the Subtractive Suppression 
Hybridisation (SSH) technique using Clontech PCR-SelectTM cDNA Subtraction Kit exactly according 
to the instructions given in the manual. Therefore, only the principle of the method is described here 
(Figure 7-4). 
 
First, cDNA is synthesised from hydrocortisone treated (tester) and untreated (driver) PBCEC. Tester 
and driver cDNAs are digested with RsaI, a four-base-cutting restriction enzyme that yields blunt ends. 
The tester cDNA is then subdivided into two portions, and each of which is ligated to a different ds 
cDNA adaptor (Adaptor 1 and Adaptor 2R). The ends of the adaptor do not have a phosphate group, 
so only one strand of each adaptor attaches to the 5’ ends of the cDNA. The two adaptors have 
stretches of identical sequence to allow annealing of the PCR primer once the recessed ends have 
been filled in. Two hybridisations are then performed. In the first, an excess of driver cDNA is added to 
each sample of tester cDNA. The samples are then heat denatured and allowed to anneal afterwards. 
Figure 7-4 shows the type a, b, c, and d molecules generated in each sample. The concentration of 
high- and low-abundance sequences is equalised among type a molecules because reannealing is 
faster for the more abundant molecules due to second-order kinetics of hybridisation. At the same 
time, the ss type a molecules are significantly enriched for differentially expressed sequences, as 
common non-target cDNAs form type c molecules with the driver. During the second hybridisation, the 
two primary hybridisation samples are mixed together without denaturing. Now, only the remaining 
equalised and subtracted ss type a cDNAs from each tester sample are able to associate and form 
new type e hybrids, ds tester molecules with different ss adaptor sequences on each end. Fresh 
denatured driver cDNA is added to further enrich fraction e for differentially expressed sequences. 
Next, the desired differentially expressed sequences are amplified by PCR. During the first cycle of 
primary PCR, the adaptor ends are filled in, creating the complementary primer binding sites needed 
for amplification. Thus, type a and d molecules are missing primer annealing sites and cannot be 
amplified. Due to the suppression PCR effect (explained in detail in section 7.2.8.3), type b molecules 
form a panhandle-like structure that prevents their exponential amplification. Type c molecules have 
one primer annealing site and can only be amplified linearly. Only type e molecules, which have two 
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Figure 7-4 Detailed mechanism of the PCR-Select cDNA Subtraction. Adapted from Clontech. 
mRNA
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different primer annealing sites, can be amplified exponentially. These are the equalised, differentially 
expressed sequences. Next, a secondary PCR amplification is performed using nested primers to 
further reduce any background PCR products and enrich the differentially expressed sequences. The 
cDNAs are directly cloned to create a subtracted library and are used as a hybridisation probe to 
screen a library. 
 
7.2.13.2 Differential screening 
 
The PCR-Select Differential Screening Kit (Clontech) was used to pre-screen clones before confirming 
differential expression by northern blot analysis. As shown clearly in Figure 7-5, clones from the 
subtracted library are arrayed on nylon membranes and hybridised with four different probes (Figure 
7-5): a probe made from the subtracted cDNA, another probe made from reverse-subtracted cDNA, 
and nonsubtracted probes synthesized directly from tester and driver cDNAs. To make the reverse-
subtracted probe, subtractive hybridisation was performed with the original tester cDNA as a driver 
and the driver cDNA as a tester. Clones hybridising to tester but not to driver are differentially 
expressed. However, nonsubtracted probes are not sensitive enough to detect rare messages, while 
subtracted probes are greatly enriched for rare differentially expressed sequences and can detect rare 
transcripts. Therefore, clones representing mRNAs that are truly differentially expressed will hybridise 
only with the forward-subtracted probe; clones that hybridise with the reverse-subtracted probe may 
be considered background. 
 
 
Figure 7-5 Overview of the PCR-Select Differential Screening. Adapted from Clontech. 
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7.3 Microbiology 
 
All microbiological procedures were done in a laminar-flow hood (Flow BSB 4a) with sterile devices 
and solutions and according to security level 1 conditions. Liquid cultures were weakly shaken and LB-
plates were kept in an incubator. Each E. coli strain used in this work is listed in Appendix D. 
 
 
7.3.1 Preparation of competent E. coli cells 
 
To produce competent E. coli cells the bacterial strain of choice was streaked out for a single colony 
on LB-plates. One colony was inoculated into 10 ml LB-medium and incubated overnight at 37°C. The 
next day 100 ml LB-medium were inoculated with approx. 5 ml of the overnight culture to give a final 
optical density of OD600 = 0.1 and the bacterial suspension was grown to OD600 = 0.7-1.0 at 37°C. 
50 ml of the culture were centrifuged (5 min, 4500 x g, 4°C), resuspended in 20 ml ice-cold 0.1 M 
MgCl2-solution and incubated for 10 min on ice. After a second centrifugation (5 min, 4500 x g, 4°C) 
the cell pellet was resuspended in 20 ml ice-cold 0.1 M CaCl2-solution and kept on ice for further 
25 min. Finally, the suspension was again centrifuged (5 min, 4500 x g, 4°C), the pellet resuspended 
in 2 ml ice-cold 0.1 M CaCl2-solution and 500 µl glycerol (100%) were added to immediately freeze 
cells in liquid nitrogen in 100 µl aliquots. Competent cells were stored at –70°C. 
 
LB-medium   1% (w/v) peptone 
    0.5% (w/v) yeast extract 
    1% (w/v) NaCl 
 
LB-plates     LB-medium 
    1.5% (w/v)  agar 
 
 
 
7.3.2 Transformation of E. coli cells 
 
For transformation one aliquot (100 µl) of competent E. coli cells was thawed on ice, either 10 µl of 
ligation mix or 1 µl isolated plasmid-DNA were added and the mixture was incubated on ice for 40 min. 
To allow the DNA to permeate the cell membrane, cells were heat shocked at 37°C for 5 min. After 
5 min incubation on ice, 300 µl LB-medium were added and the mixture was incubated at 37°C for 1 h. 
Cells were then plated onto LB-plates containing the antibiotic (50 µg/ml) against which resistance 
was introduced by the plasmid DNA and incubated at 37°C until single colonies were grown. In case of 
blue/white screenings additionally 0.01% (w/v) X-Gal and 0.1 mM IPTG had been spread on the LB-
plates before.  
7  Experimental  100 
7.3.3 Cultures of E. coli cells 
 
In order to isolate plasmid-DNA or to make glycerol stocks one single colony of choice was picked and 
inoculated into 5 ml LB-medium containing the appropriate antibiotic (50 µg/ml). Cells were grown 
overnight at 37°C until the culture was saturated. Instead of one colony 5 µl of bacterial suspension 
were used for inoculation. 
 
 
 
7.3.4 Storage of E. coli cells 
 
For long-time conservation 700 µl of a saturated bacterial suspension were mixed with 300 µl of 
glycerol (100%) and stored at –70°C. 
 
 
 
7.4 Protein biochemistry 
 
7.4.1 SDS-polyacrylamide gel electrophoresis 
 
Discontinuous SDS polyacrylamide gel electrophoresis (SDS-PAGE) (Laemmli, 1970) was performed 
to separate complex mixtures of proteins according to their size. Both the sample buffer containing the 
anionic detergent SDS and heating to 100°C denatures the proteins to give a so called random-coil 
conformation. SDS also masks the intrinsic protein charge and gives all proteins a net negative charge 
that is proportional to the molecular weight. When loaded onto a gel matrix and placed in an electric 
field, the negatively charged proteins migrate towards the anode and are separated by a molecular 
sieving effect. Discontinuous gels contain a short stacking gel of low percentage of polyacrylamide to 
concentrate samples prior to entering the resolving gel of higher percentage. As the degree of protein 
separation depends on the concentration of polyacrylamide, the polyacrylamid concentration of the 
resolving gel must be chosen according to the expected molecular weight of the sample proteins 
(Table 7-3). Experimental conditions for SDS-PAGE are listed in Table 7-4. Before gel electrophoresis 
protein samples were denatured for 10 min at 100°C in Laemmli sample buffer. For 10 cm x 10 cm 
gels electrophoresis was performed with 1 x electrophoresis buffer at 20 mA per gel. 
 
Table 7-3 Protein molecular weight resolved in gels of different polyacrylamid concentrations. 
 
resolving gel (%) 6 8 10 12 15 
molecular weight range (kDa) 30 - 200 20 - 175 15 - 150 10 - 100 6 - 50 
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Table 7-4 Components of SDS gels. 
 
 Stacking gel Resolving gel 
 4.3% 8% 10% 
dd H2O 3.25 ml 7.25 ml 6.25 ml 
0.4% (w/v) SDS, 1.5 M Tris/HCl, pH 8.8 - 3.75 ml 3.75 ml 
0.4% (w/v) SDS, 0.5 M Tris/HCl, pH 6.8 1.25 ml - - 
acrylamid / bisacrylamid (37.5 / 1)  0.75 ml 4 ml 5 ml 
TEMED 5 µl 6 µl 6 µl 
10% (w/v) APS 50 µl 150 µl 150 µl 
 
 
 
Laemmli sample buffer (3 x) 30% (v/v) glycerol 
    15% (v/v) β-mercaptoethanol 
    6% (w/v) SDS 
    37.5% (v/v) 0.4% (w/v) SDS, 0.5 M Tris/HCl, pH 6.8 
    small amounts of bromphenol blue 
 
electrophoresis buffer (10 x) 0.25 M  Tris/HCl 
    2 M  glycerol 
    10% (w/v) SDS 
 
 
 
7.4.2 Coomassie Blue staining 
 
The location of proteins in a gel was determined by Coomassie Blue staining. This detection method 
depends on non-specific binding of the dye Coomassie Brilliant Blue R to proteins. The detection limit 
is 0.3 to 1 µg per protein band. Proteins separated in a polyacrylamide gel were precipitated using a 
fixing solution containing 25% (v/v) isopropanol, 10% (v/v) acetic acid and 0.05% (w/v) Coomassie 
Brilliant Blue for 30 min. For destaining the gel was agitated in 10% (v/v) acetic acid until the blue 
protein bands appear against a clear background. 
 
 
 
7.4.3 Purification of BMDP-MBP-fusion protein 
 
For heterologous expression of 144 amino acids of BMDP fused to the maltose binding protein (MBP) 
a 40 ml culture of E. coli BL21(DE3)pLysS carrying the corresponding BMDP-MBP expression plasmid 
was grown in LB-medium supplemented with 50 µg/ml ampicillin at 37°C to an OD600 of 0.6 to 0.8. 
7  Experimental  102 
Protein expression was induced by addition of 0.1 mM IPTG to the medium. After 2 h cultivation the 
cells were harvested (4500 x g, 10 min, 4°C) and resuspended in 5 ml lysis buffer on ice. The bacterial 
extract was prepared by 3 freeze/thaw cycles using liquid nitrogen and a 37°C tempered water bath, 
followed by sonication (level 4, 4°C, up to 5 times 15 s each) and subsequent centrifugation at 
9000 x g for 20 min. 500 µl glycerol were added to the crude extract to allow rapid freezing in liquid 
nitrogen and storage at –70°C. 
 
Separated from insoluble material the BMDP-MBP-fusion protein was purified from the crude extract 
on amylose resin (New England BioLabs) according to the manufacturers instructions. Firstly, 100 µl 
amylose resin were equilibrated in lysis buffer. Then 100 µl bacterial extract were added and 
incubated on ice for 30 min to enable the maltose binding protein tag to bind to the amylose covalently 
attached to particles. After centrifugation (1 min, 2655 x g) the BMDP-MBP amylose pellet was 
washed with 1 ml lysis buffer. Stepwise elution with 50 µl fractions of 10 mM maltose containing lysis 
buffer followed at 4°C for 30 min. Protein expression and purification was checked by SDS-PAGE (see 
sections 7.4.1 and 7.4.2).  
 
To remove the maltose binding protein 50 µl of the eluded fractions were treated with 10 µl thrombin 
(1 U/µl) for 20 h at room temperature. The amount and qualitiy of purified BMDP was estimated on a 
Coomassie Blue stained SDS-gel (see sections 7.4.1 and 7.4.2). 
 
lysis buffer   0.05 M  Tris, pH 8 
    0.15 M  NaCl 
    1% (v/v) TritonX-100 
    1 mM  DTT 
    0.1 M  PMSF 
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8 Materials and devices 
 
8.1 Materials 
 
acetic acid      Merck (Darmstadt, Germany) 
acetone      Merck (Darmstadt, Germany) 
acrylamid/bisacrylamid (37.5/1)    AppliChem (Darmstadt, Germany) 
acrylamid/bisacrylamid (50/0.8)    USB (Cleveland, Ohio/USA) 
Advantage cDNA Polymerase Mix   Clontech (Palo Alto, California/USA) 
AdvanTAge PCR Cloning Kit    Clontech (Palo Alto, California/USA) 
agar       Sigma-Aldrich (Deisenhofen, Germany) 
agarose NEEO      ROTH (Karlsruhe, Germany) 
ammonium acetate     Riedel-de Haën (Seelze, Germany) 
ammonium sulfate     Merck (Darmstadt, Germany) 
ampicillin      Sigma-Aldrich (Deisenhofen, Germany) 
Amylose resin      New England Biolabs (Beverly, MA/USA) 
APS       Sigma-Aldrich (Deisenhofen, Germany) 
 
7B-marker      Sigma-Aldrich (Deisenhofen, Germany) 
bromophenol blue     ICN Biochemicals (Eschwege, Germany) 
BSA       Sigma-Aldrich (Deisenhofen, Germany) 
BXP-21 antibody     Alexis (Grünberg, Germany) 
 
CaCl2        Merck (Darmstadt, Germany) 
CAT-lysis buffer     Roche (Basel, Swiss) 
CellTiter 96 AQueous Cell Proliferation Assay   Promega (Madison, Wisconsin/USA) 
chloramphenicol     ROTH (Karlsruhe, Germany) 
chloroform      Merck (Darmstadt, Germany) 
cis-platin      Sigma-Aldrich (Deisenhofen, Germany) 
collagen G      Seromed (Berlin, Germany) 
collagenase/dispase     Roche (Basel, Swiss) 
Coomassie Brilliant Blue G250    Sigma-Aldrich (Deisenhofen, Germany) 
 
daunomycin      Sigma-Aldrich (Deisenhofen, Germany) 
3H-daunomycin      NEN Life Science Products (Boston, MA/USA) 
32P-dCTP      Amersham Biotech (Uppsala, Sweden) 
dextran (~ 1632 kDa/mol)    Sigma-Aldrich (Deisenhofen, Germany) 
dextran sulfate sodium salt    Sigma-Aldrich (Deisenhofen, Germany) 
DMEM       Biochrom KG (Berlin, Germany) 
DMEM/Ham’s F12     Sigma-Aldrich (Deisenhofen, Germany) 
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DMF       Sigma-Aldrich (Deisenhofen, Germany) 
DMPC       Sigma-Aldrich (Deisenhofen, Germany) 
DNA ladders (100 bp and 1 kb)    Life Technologies (Eggenstein, Germany) 
dNTPs, 10mM      Sigma-Aldrich (Deisenhofen, Germany) 
doxorubicin      Sigma-Aldrich (Deisenhofen, Germany) 
DTT       Sigma-Aldrich (Deisenhofen, Germany) 
 
EDTA       Merck (Darmstadt, Germany) 
Emerald Enhancer     Perkin Elmer (Weiterstadt, Germany) 
ethanol       Merck (Darmstadt, Germany) 
ethidiumbromide     ROTH (Karlsruhe, Germany) 
 
FCS       Life Technologies (Eggenstein, Germany) 
Ficoll 400      Sigma-Aldrich (Deisenhofen, Germany) 
formaldehyde (37%)     Merck (Darmstadt, Germany) 
formamide      Janssen (Neuss, Germany) 
 
Galacton      Perkin Elmer (Weiterstadt, Germany) 
geneticin (G418)     Life Technologies (Eggenstein, Germany) 
gentamicin      Biochrom KG (Berlin, Germany) 
glucose       Sigma-Aldrich (Deisenhofen, Germany) 
L-glutamine      Seromed (Berlin, Germany) 
glutaraldehyde      Sigma-Aldrich (Deisenhofen, Germany) 
glycerol       Merck (Darmstadt, Germany) 
glycine       Sigma-Aldrich (Deisenhofen, Germany) 
goat anti-mouse IgG-Cy3    Molecular Probes (Leiden, The Netherlands) 
 
HCl       Sigma-Aldrich (Deisenhofen, Germany) 
HEPES       Merck (Darmstadt, Germany) 
hering sperm DNA     Sigma-Aldrich (Deisenhofen, Germany) 
High Pure RNA Isolation Kit    Roche (Basel, Swiss) 
hydrocortisone      Sigma-Aldrich (Deisenhofen, Germany) 
Hyperfilm MP      Amersham Biotech (Uppsala, Sweden) 
 
IPTG       Biomol (Hamburg, Germany) 
isopropyl alcohol     Merck (Darmstadt, Germany) 
 
K3Fe(CN)6    Chemical stockroom of the institute for organic 
K4Fe(CN)6    chemistry WWU Münster (Münster, Germany) 
kanamycin      Sigma-Aldrich (Deisenhofen, Germany) 
KCl       Merck (Darmstadt, Germany) 
KH2PO4      Merck (Darmstadt, Germany) 
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lysozyme      Sigma-Aldrich (Deisenhofen, Germany) 
 
M 199 Earle      Seromed (Berlin, Germany) 
MegaPrime DNA Labelling System   Sigma-Aldrich (Deisenhofen, Germany) 
methanol      Merck (Darmstadt, Germany) 
MgCl2        Merck (Darmstadt, Germany) 
MicroSpin G-50 Columns    Amersham Biotech (Uppsala, Sweden) 
mitoxantrone      Sigma-Aldrich (Deisenhofen, Germany) 
molecular weight marker (HMW and LMW)  Amersham Biotech (Uppsala, Sweden) 
MOPS       Sigma-Aldrich (Deisenhofen, Germany) 
 
Na2HPO4       Merck (Darmstadt, Germany) 
NaCl       Merck (Darmstadt, Germany) 
NaHCO3      Sigma-Aldrich (Deisenhofen, Germany) 
NaOH       Sigma-Aldrich (Deisenhofen, Germany) 
NCS       Seromed (Berlin, Germany) 
NGS       Sigma-Aldrich (Deisenhofen, Germany) 
Nonidet P-40      Sigma-Aldrich (Deisenhofen, Germany) 
nylon membrane (GeneScreen Plus)   NEN Life Science Products (Boston, MA/USA) 
 
Oligo(dT)12-18 Primer     Life Technologies (Eggenstein, Germany) 
oligonucleotides     MWG Biotech (Ebersberg, Germany) 
Oligotex mRNA Mini Kit    Qiagen (Hilden, Germany) 
ox serum       PAA (Linz, Austria) 
 
paclitaxel      Sigma-Aldrich (Deisenhofen, Germany) 
paraformaldehyde     Merck (Darmstadt, Germany) 
Paramount      Polysciences Inc. (Warrington, PA/USA) 
pBluescript II KS (+/-)     Stratagene (Amsterdam, The Netherlands) 
pBluescript II SK (+/-)     Stratagene (Amsterdam, The Netherlands) 
pcDNA3      Invitrogen (Karlsruhe, Germany) 
pCMVβ       Clontech (Palo Alto, California/USA) 
PCR-Select cDNA Subtraction Kit   Clontech (Palo Alto, California/USA) 
PCR-Select Differential Screening Kit   Clontech (Palo Alto, California/USA) 
pEGFP-N1      Clontech (Palo Alto, California/USA) 
penicillin/streptomycin     Seromed (Berlin, Germany) 
peptone      Life Technologies (Eggenstein, Germany) 
percoll       Sigma-Aldrich (Deisenhofen, Germany) 
pET-28a(+)      Novagen ( Bad Soden, Germany) 
pGEX-4T-3      Amersham Biotech (Uppsala, Sweden) 
phenol/chloroform/isoamyl alcohol (25/24/1)  Sigma-Aldrich (Deisenhofen, Germany) 
pMal       New England Biolabs (Beverly, MA/USA) 
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polyvinylpyrrolidone     Sigma-Aldrich (Deisenhofen, Germany) 
protease inhibitor coctail    Roche (Basel, Swiss) 
protease/dispase     Sigma-Aldrich (Deisenhofen, Germany) 
proteinase K      Sigma-Aldrich (Deisenhofen, Germany) 
pRSET-A      Invitrogen (Karlsruhe, Germany) 
pT-Adv       Clontech (Palo Alto, California/USA) 
 
QIAprep Spin Mini and Maxi Kit    Qiagen (Hilden, Germany) 
QIAquick Gel Extraction Kit    Qiagen (Hilden, Germany) 
QuickChange Site-Directed Mutagenesis Kit  Stratagene (Amsterdam, The Netherlands) 
 
Rapid-Gel Acrylamid (40%)    USB (Cleveland, Ohio/USA) 
restriction endonucleases    New England Biolabs (Beverly, MA/USA) 
RNeasy Maxi-Kit     Qiagen (Hilden, Germany) 
 
SDS       Sigma-Aldrich (Deisenhofen, Germany) 
SequiTherm EXCELL II DNA Sequencing Kit  Biozym (Oldendorf, Germany) 
shrimp alkaline phosphatase    Roche (Basel, Swiss) 
SMART DNA ladders (100bp and 1 kb)   Eurogentec (Seraing, Belgium) 
SMART RACE cDNA Amplification Kit  Clontech (Palo Alto, California/USA) 
sodium acetate      Sigma-Aldrich (Deisenhofen, Germany) 
sodium citrate      Sigma-Aldrich (Deisenhofen, Germany) 
14C-sucrose      Amersham Biotech (Uppsala, Sweden) 
Superscript II Reverse Transcriptase   Life Technologies (Eggenstein, Germany) 
 
T4 DNA ligase      New England Biolabs (Beverly, MA/USA) 
Taq DNA polymerase     Life Technologies (Eggenstein, Germany) 
TEMED      AppliChem (Darmstadt, Germany) 
Tris       ICN Biochemicals (Eschwege, Germany) 
Triton X-100      Sigma-Aldrich (Deisenhofen, Germany) 
TRIzol Reagent      Life Technologies (Eggenstein, Germany) 
trypsine       Seromed (Berlin, Germany) 
trypsine/EDTA       Biochrom KG (Berlin, Germany) 
Tween-20      ICN Biochemicals (Eschwege, Germany) 
 
urea       Merck (Darmstadt, Germany) 
vincristine      Sigma-Aldrich (Deisenhofen, Germany) 
 
X-GAL       ROTH (Karlsruhe, Germany) 
xylene cyanole      ICN Biochemicals (Eschwege, Germany) 
 
yeast extract      Life Technologies (Eggenstein, Germany) 
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8.2 Devices 
 
Incubator 
Vortex       IKA Labortechnik (Staufen, Germany) 
Hybridisation incubator     Merck (Darmstadt, Germany) 
Thermomixer comfort     Eppendorf (Hamburg, Germany) 
 
PCR 
Mastercycler gradient     Eppendorf (Hamburg, Germany) 
Mastercycler personal     Eppendorf (Hamburg, Germany) 
Gen Read IR4200 (for sequencing)   LI-COR (Lincoln, Nebraska/USA) 
 
Centrifuge 
Avanti 300      Beckman (München, Germany) 
Centrifuge 5415 C     Eppendorf (Hamburg, Germany) 
Centrifuge 5804 R     Eppendorf (Hamburg, Germany) 
Centrifuge J2-21 with rotors JA-14 and JA-10  Beckman (München, Germany) 
Type universal 16 R     Hettich (Tuttlingen, Germany) 
Ultra centrifuge Optima-L70    Beckman (München, Germany) 
Sepatech Megafuge 1.0    Heraeus (Hanau, Germany) 
Mikro Rapid/K 1306     Hettich (Tuttlingen, Germany) 
 
pH-meter 
pH 213       Merck (Darmstadt, Germany) 
 
Photometer 
Perkin-Elmer 320     Perkin-Elmer (Überlingen, Germany) 
Shimadzu UV-2100     Shimadzu (Düsseldorf, Germany) 
Shimadzu UV-1601 PC     Shimadzu (Düsseldorf, Germany) 
Microplate reader MR700    Dynatech (Denkendorf, Germany) 
UV spectrometer GeneQuant II    Pharmacia (Freiburg, Germany) 
 
Electrophoresis 
Muppid 2      Eurogentec (Seraing, Belgium) 
Electrophoresis Power Supply EPS 1000  Amersham Biotech (Uppsala, Sweden) 
Power Pac 200      BioRAD (Hercules, Californien/USA) 
MultiSmall      Amersham Biotech (Uppsala, Sweden) 
 
Sonification 
Branson Sonifier 250     Heinemann (Schwäbisch Gmünd, Germany) 
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Cell culture      
Laminar flow hood Flow BSB 6A and BSB 4A  Gelaire (Meckenheim, Germany) 
Water bath GFL 1004     GFL (Burgwedel, Germany) 
Incubator BB 6220 CU     Heraeus (Hanau, Germany) 
Incubator IG 150     Astel (Chateau Gontier, France) 
Autoclave –steam sterilizer 3870EL   Jürgens (Münster, Germany) 
Sterilisator UT 6120     Heraeus (Hanau, Germany) 
Hemocytometer (Bürker)    Fischer (Frankfurt, Germany) 
 
Microscope 
Inverse phase-contrast microscope   Leika (Wetzlar, Germany)   
Fluorescence microscope Diaphot TMD   Nikon (Düsseldorf, Germany) 
Confocal laser-scanning microscope TCS  Leika (Wetzlar, Germany) 
 
Radioactive work 
Scintillation counter     Beckman (München, Germany) 
Autoradiography cassettes    Oncor Appligene (Geithersburg, MD/USA) 
Agfa Curix60      Agfa AG (Leverkusen, Germany) 
XOMAT AR Scientific Imaging Films   Eastman Kodal Comp. (Rochester, NY/USA) 
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Appendix A:  Abbreviations 
 
aa   amino acids 
ABC   ATP-binding cassette 
ABCP   placenta specific ATP-binding cassette transport protein 
APS   ammonium peroxodisulfate 
ATP   adenosine triphosphate 
 
BBB   blood-brain barrier 
BCEC   brain capillary endothelial cells 
BCRP   breast cancer resistance protein 
BMDP   brain multidrug resistance protein 
bp   base pair(s) 
BSA   bovine serum albumin 
 
cDNA   complementary deoxyribonucleic acid 
CNS   central nervous system 
CSF   cerebrospinal fluid 
 
Da   Dalton 
dATP   deoxyadenosine triphosphate 
dCTP   deoxycytosine triphosphate 
dd   double distilled 
ddNTP   dideoxynucleoside triphosphate 
dGTP   deoxyguanosine triphosphate 
DIV   days in vitro 
DMEM   Dulbecco’s Modified Eagle Medium 
DMF   dimethylformamide 
DMPC   dimethylpyrocarbonate 
DMSO   dimethylsulfoxide 
DNA   deoxyribonucleic acid 
dNTP   deoxynucleoside triphosphate 
ds   double-stranded 
DSMZ   Deutsche Sammlung von Mikroorganismen und Zellkulturen 
DTT   dithiothreitol 
dTTP   desoxytyrosinetriphosphate 
 
E. coli   Escherichia coli 
EDTA   ethylendiamine tetraacetic acid 
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F   forward 
f.c.   final concentration 
FCS   fetal calf serum 
FTC   fumitremorgin C 
 
g   acceleration due to gravity (9.81 m/s2) 
GAPDH  glyceraldehyde-3-phosphate dehydrogenase 
GFP   green fluorescent protein 
GSH   glutathione 
GST   glutathione-S-transferase 
 
h   hour(s) 
HBS   Hepes buffered saline 
HC   hydrocortisone 
HEK   human embryonic kidney cells 
Hepes   2-[4-(2-hydroxyethyl)-1-piperazinyl]-ethanesulfonic acid 
HMW   high molecular weight marker 
HUVEC  human umbilical vein endothelial cells 
 
IPTG   isopropyl-β-D-thiogalactopyranosid 
 
kb   kilo base 
kDa   kilo Dalton 
 
L   liter 
LB   Luria and Bertami 
LD-PCR  long-distance polymerase chain reaction 
LMW   low molecular weight marker 
 
M   molar (mol/l) 
MBP   maltose binding protein 
MDP   multidrug resistance protein 
MDR   multidrug resistance 
min   minute(s) 
MM   master mix 
MOPS   3-[N-morpholino]-propylsulfonic acid 
mRNA   messenger ribonucleic acid 
MRP1   multidrug resistance associated protein 1 
MW   molecular weight 
MXR   mitoxantrone resistance protein 
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NBD   nucleotide binding domain 
NCBI   National Centre for Biotechnology Information 
NCS   newborn calf serum 
NGS   newborn goat serum 
NT   nucleotide transport  
 
OAT   organic anion transport 
OCT   organic cation transport 
OD   optical density 
ORF   open reading frame 
OS   ox serum 
 
p.a.   pro analysis 
PAEC   porcine aortic endothelial cells 
PAGE   polyacrylamide gel electrophoresis 
PBCEC   porcine brain capillary endothelial cells 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
Pgp   P-glycoprotein 
PMSF   phenylmethylsulfonylfluorid 
 
R   reverse 
ρ   density 
RACE-PCR  rapid amplification of cDNA ends 
RNA   ribonucleic acid 
rpm   rounds per minute 
rRNA   ribosomal ribonucleic acid 
RT   reverse transcription 
 
S   Svedberg unit 
SDS   sodium dodecyl sulfate 
Sec   seconds 
ss   single-stranded 
SSC   standard saline citrate 
SSH   subtractive suppression hybridisation 
 
TEMED  N,N,N’,N’-tetramethylethyldiamine 
TER   transendothelial electrical resistance 
TMD   transmembrane domain 
Tris   tris-(hydroxymethyl)-aminomethane 
tRNA   transfer ribonucleic acid 
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U   unit 
UV   ultra violet 
 
V   voltage 
VIS   visible 
v/v   volume per volume 
vol   volume 
 
W   watt 
w/v   weight per volume 
WWW   Westfälische Wilhelms-Universität 
 
X-Gal   5-bromo-4-chloro-indoyl-β-D-galactopyranoside 
 
ZO   zonula occludens 
 
 
 
 
Abbreviations for amino acids 
 
A Ala  Alanin 
C Cys  Cysteine 
D Asp  Aspartic acid 
E Glu  Glutamic acid 
F Phe  Phenylalanine 
G Gly  Glycine 
H His  Histidine 
I Ile  Isoleucine 
K Lys  Lysine 
L Leu  Leucine 
M Met  Methionine 
N Asn  Asparagine 
P Pro  Proline 
Q Gln  Glutamine 
R Arg  Arginine 
S Ser  Serine 
T Thr  Threonine 
V Val  Valine 
W Trp  Tryptophan 
Y Tyr  Tyrosine 
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Appendix B:  Published sequences 
 
Following porcine sequences were submitted to the National Center for Biotechnology Information 
(NCBI) and published: 
 
 
Porcine brain multidrug resistance protein (BMDP) mRNA, complete cds  
GenBank accesion number AJ420927 
 
Porcine zonula occludens 1 protein (ZO-1) mRNA, partial cds   
 GenBank accesion number AJ318101 
 
Porcine claudin-1 protein mRNA, partial cds   
 GenBank accesion number AJ318101 
 
Porcine claudin-5 protein mRNA, partial cds   
 GenBank accesion number AJ318101 
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Appendix C:  WWW sites 
 
www.ub.uni-bielefeld.de/netahtml/jaso1.html Jason: ordering of literature 
www.uni-muenster.de/ULB/Welcome.html Uni-Muenster: download of papers 
 Medline: literature search 
www.embl-heidelberg.de/srs5/ Genbank, EMBL: sequence data bases 
www.ncbi.nlm.nih.gov/ NCBI: sequence alignment, basic blast search, PubMed 
www.ebi.ac.uk/embl/index.html EMBL: submission of new sequences 
www.pubmed.de/index.plip3 Literature data bases 
www.expasy.ch/ Expert Protein Analysis System Molecular Biology Server 
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Appendix D:  Genotypes of Escherichia coli K12 strains 
 
TOP10F This strain can be used for general cloning and blue/white screening without 
IPTG.  
F- mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆lacX74recA1 deoR araD139 
∆(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG 
 
TOP10F’ This strain exresses the Lac repressor (lacIq gene). For blue/white screening 
IPTG has to be added to obtain expressing from the lac promoter. This strain 
contains the F episome and can be used for single-strand rescue of plasmid 
DNA containing an f1 origin. 
F’ {lacIq Tn10(TetR)} mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 
∆lacX74recA1 deoR araD139 ∆(ara-leu)7697 galU galK rpsL (StrR) endA1 
nupG 
 
BL21(DE3)pLysS F- ompT hsdSB (rB-mB-) gal dcm (DE3) pLysS 
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Appendix E:  Primer sequences 
 
All primers were purchased from MWG Biotech and are listed in 5’-3’-orientation using following 
abbreviations: 
 
Tm   melting temperature given by MWG Biotech    h human 
TA   annealing temperature used     m mouse 
CTCGAG XhoI restriction site      p porcine 
AAGCTT HindIII restriction site      F forward 
GGTACC KpnI restriction site      R reverse 
GGATCC BamHI restriction site 
 
 
 
Porcine BMDP-specific primers 
 
BMDP_C8-F (Tm 62.4°C) 
GCA TTC CTC GAT ACG GCT TTT CG 
 
BMDP_5’RACE-R (Tm 73.6°C) 
GTG ATT CTG CCA CAG GCC CCA AGC GGA GAG 
 
BMDP_Nested5’RACE-R (Tm 68.0°C) 
GAT GCC CTG GTT TTC CAA ATA CTC GGC G 
 
BMDP_complete-F (Tm > 75°C) 
GCGAATTCTCGAGGATCCACGCGGGGGAGCATAAGAGTTCCTGAGATTG 
 
BMDP_complete-R (Tm > 75°C) 
GCGAATTCTCGAGGATCCGAAACCAGAATGCTTTCTCTTTAATGGGGGGTAAG 
 
BMDP-763-F (Tm > 75°C) 
GCGAATTCTCGAGGATCCGCTCCTGAAGAGGATGTCTAAACAAGG 
 
BMDP-1018-R (Tm > 75°C) 
GGGATCCAAGCTTGTCCGCTCTGCTTAACACCACAGCG 
 
BMDP-356-F (Tm > 75°C) 
CGTCGCGGATCCGCGTTAGATGTCTTAGCTGCAAGGAAAGATCCGC 
 
underlined if integrated 
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BMDP-789-R (Tm > 75°C) 
CCGCTCGAGCGGGGTACCCCCCTTGTTTAGACATCCTCTTCAGGAGC 
 
1040-Y546STOP-QC-sense (Tm 69.5°C) 
CTAAACAAGGGGGGTAGCATGGAATTCGAAGC 
 
1040-Y546STOP-QC-anti (Tm 69.5°C) 
GCTTCGAATTCCATGCTACCCCCCTTGTTTAG 
 
 
 
Other PCR primers 
 
Pgp-R (Tm 67.8°C) 
GCC GCT TGG TGA GGA TCT CTC CAG 
 
Pgp-F (Tm 64.6°C) 
GGA CCA CCA TTG TGA TAG CTC ATC G 
 
MRP1-Regina-F (Tm 57.3°C) 
CTG GCT TGG TGT GAA CTG AT 
 
MRP1-Regina-R (Tm 59.4°C) 
AGG CTC TGG CTT GGC TCT AT 
 
GAPDH-3’ (Tm 57.3°C) 
TGA GCT TGA CAA AGT GGT CG 
 
GAPDH-5’ (Tm 59.4°C) 
ACC ACA GTC CAT GCC ATC AC 
 
3’RACE-R (Tm 68.5°C) 
AAC TGG AAG AAT TCG CGC CCG CAG GAA TTT TTT TTT TTT TTT TTT T 
 
hBCRP-763-F (Tm > 75°C) 
GCGAATTCTCGAGGATCCGCTCCTGAAAAGGATGTCTAAGCAGGG 
 
hBCRP-1018-R (Tm 71.6°C) 
GGGATCCAAGCTTTTCTTCTCTGTTTAATGCCACAGCAG 
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mBCRP-356-F (Tm > 75°C) 
CGTCGCGGATCCGCGCTAGATGTCTTAGCAGCAAGGAAAGATCC 
 
mBCRP-789-R (Tm > 75°C) 
CCGCTCGAGCGGGGTACCCCCCCTGTTTAGACATCCTTTTCAGGAGC 
 
 
 
Primers for sequencing labelled with the dye IRD800 at their 5’ ends 
 
M13-F (TA 48°C, Tm 52.8°C) 
GTA AAA CGA CGG CCA GT 
 
M13-R (TA 50°C, Tm 46.6°C) 
AAC AGC TAT GAC CAT G 
 
T7 (TA 48°C, Tm 58.4°C) 
GTA ATA CGA CTC ACT ATA GGG C 
 
CMV-F (TA 48°C, Tm 65.7°C) 
CGC AAA TGG GCG GTA GGC GTG 
 
Sp6 (TA 45°C, Tm 53.2°C) 
CGA TTT AGG TGA CAC TAT AG 
 
pEGFP-N1-529-Sequ-F (TA 48°C, Tm 60.5°C) 
GGT AGG CGT GTA CGG TGG 
 
pEGFP-N1-771-Sequ-R (TA 48°C, Tm 58.8°C) 
GGA CAC GCT GAA CTT GTG G 
 
pRSET-Sequ-F (TA 45°C, Tm 47.9°C) 
GGA GAT ATA CAT ATG CG 
 
pGEX-5’ (TA 48°C, Tm 67.8°C) 
GGG CTG GCA AGC CAC GTT TGG TG 
 
pGEX-3’ (TA 48°C, Tm 67.8°C) 
CCG GGA GCT GCA TGT GTC AGA GG 
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pMAL-Sequ-F1 (TA 48°C, Tm 69.5°C) 
CAG CGG TCG TCA GAC TGT CGA TGA AGC 
 
pMAL-Sequ-R1 (TA 48°C, Tm 66.5°C) 
CTG CAA GGC GAT TAA GTT GGG TAA CGC 
 
BMDP-457-Sequo-F (TA 48°C, Tm 58.8°C) 
GGTACAGGATGACGTCGTG 
 
BMDP-1173-Sequo-F (TA 45°C, Tm 55.2°C) 
CGGTGTACAAGGAGGTC 
 
BMDP-1470-Sequo-F (TA 45°C, Tm 50.4°C) 
GTGGATACTACAGAGTG 
 
BMDP-Sequ-F (TA 50°C, Tm 58.2°C) 
GTGGTGTGTCTGGAGGAG 
 
BMDP-Sequ-R (TA 45°C, Tm 53.7°C) 
GGCTTCAGTCCTAACAAG 
 
BMDP-340-Sequ-R (TA 48°C, Tm 60.0°C) 
CCTCCACCTGTGGGTCC 
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Appendix F:  Clone charts  
 
Vectors designed for generating full-length cDNA of BMDP 
 
pBMDP_C8 in pT-Adv (1012) 
cDNA clone C8 of a subtracted cDNA library established from mRNA of PBCEC using the PCR-
SelectTM cDNA Subtraction Kit and PCR-Select Differential Screening Kit (Clontech). 
 
pBMDP_3’RACE in pT-Adv (1007) 
3’-RACE-PCR (total RNA from PBCEC, BMDP_C8-F and 3’RACE-R, 55°C); TA-cloning. 
 
pBMDP_5’RACE in pT-Adv (1009) 
5’-RACE-PCR using SMART RACE cDNA Amplification Kit (Clontech) (mRNA from PBCEC, 
BMDP_5’RACE-R and Universal Primer Mix (Clontech), BMDP_Nested5’RACE-R and Nested 
Universal Primer (Clontech), 68°C); TA-cloning. 
 
pBMDP-complete in pBluescript II KS (+/-) (1025) 
LD-PCR (mRNA from PBCEC, BMDP_complete-F and BMDP_ccomplete-R, 60°C); XhoI digested 
PCR product ligated into XhoI linearised pBluescript II KS (+/-). 
 
 
 
Vectors designed for probing and sequencing 
 
pGAPDH in pT-Adv  
RT-PCR (total RNA from PBCEC, GAPDH-F and GAPDH-R, TA 55°C); TA-cloning. 
 
hGAPDH in pT-Adv  
RT-PCR (total RNA from human brain (Clontech), GAPDH-F and GAPDH-R, TA 50°C); TA-cloning. 
 
mGAPDH in pT-Adv  
RT-PCR (total RNA from mouse brain (Bastian Budde), GAPDH-F and GAPDH-R, TA 50°C); TA-
cloning. 
 
pBMDP763-1018 in pBluescript II KS (+/-) (1031) 
RT-PCR (total RNA from PBCEC, BMDP-763-F and BMDP-1018-R, TA 60°C); XhoI and HindIII 
digested PCR product ligated into XhoI and HindII linearised pBluescript II KS (+/-). 
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hBMDP763-1018 in pBluescript II SK (+/-) (1042) 
RT-PCR (total RNA from human brain (Clontech), hBCRP-763-F and hBCRP-1018-R, TA 55°C); XhoI 
and HindIII digested PCR product ligated into XhoI and HindII linearised pBluescript II SK (+/-). 
 
mBMDP763-1018 in pBluescript II KS (+/-) (1032) 
RT-PCR (total RNA from mouse brain (provided by Bastian Budde), BMDP-763-F and BMDP-1018-R, 
TA 45°C); XhoI and HindIII digested PCR product ligated into XhoI and HindII linearised pBluescript II 
KS (+/-). 
 
pBMDP356-789 in pRSET-A (1036) 
PCR (template: pBMDP_ORF in pcDNA3 (1004), BMDP-356-F and BMDP-789-R, TA 60°C); BamHI 
and KpnI digested PCR product ligated into BamHI and KpnI linearised pRSET-A. 
 
hBMDP356-789 in pBluescript II SK (+/-) (1039) 
RT-PCR (total RNA from human brain (Clontech), BMDP-356-F and BMDP-789-R, TA 50°C); BamHI 
and KpnI digested PCR product ligated into BamHI and KpnI linearised pBluescript II SK (+/-). 
 
mBMDP356-789 in pBluescript II SK (+/-) (1043) 
RT-PCR (total RNA from mouse brain (Bastian Budde), mBCRP-356-F and mBCRP-789-R, TA 55°C); 
BamHI and XhoI digested PCR product ligated into BamHI and XhoI linearised pBluescript II SK (+/-). 
 
pPgp in pT-Adv (2002) 
RT-PCR (total RNA from PBCEC, Pgp-F and Pgp-R, TA 60°C); TA-cloning. 
 
hPgp in pT-Adv (2007) 
RT-PCR (total RNA from human brain (Clontech), Pgp-F and Pgp-R, TA 55°C); TA-cloning. 
 
mPgp in pT-Adv (2006) 
RT-PCR (total RNA from mouse brain (Bastian Budde), Pgp-F and Pgp-R, TA 55°C); TA-cloning. 
 
rMRP1 in pT-Adv (2005) 
RT-PCR (total RNA from RBE4-cells, MRP1-Regina-F and MRP1-Regina-R, TA 55°C); TA-cloning. 
 
 
 
Vectors designed for recombinant protein expression in E. coli 
 
pBMDP356-789 in pRSET-A (1036) 
PCR (template: pBMDP_ORF in pcDNA3 (1004), BMDP-356-F and BMDP-789-R, TA 60°C); BamHI 
and KpnI digested PCR product ligated into BamHI and KpnI linearised pRSET-A. 
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pBMDP356-789 in pGEX-4T-3 (1037) 
PCR (template: pBMDP_ORF in pcDNA3 (1004), BMDP-356-F and BMDP-789-R, TA 60°C); BamHI 
and XhoI digested PCR product ligated into BamHI and XhoI linearised pGEX-4T-3. 
 
pBMDP356-789 in pET28a(+) (1038) 
PCR (template: pBMDP_ORF in pcDNA3 (1004), BMDP-356-F and BMDP-789-R, TA 60°C); BamHI 
and XhoI digested PCR product ligated into BamHI and XhoI pET28a(+) (+/-). 
 
pBMDP356-789 in pMAL (1041) 
BamHI and HindIII digested insert of pBMDP356-789 in pRSET-A (1036) ligated into BamHI and HindIII 
linearised pMAL; QuickChange Site-Directed Mutagenesis (Stratagene) of Y (UAC) into termination 
codon UAG at the end of BMDP insert (1040-Y546STOP-QC-sense and 1040-Y546STOP-QC-anti, 
55°C). 
 
 
 
Vectors designed for transfection into HEK 293 cells 
 
pBMDP_ORF in pcDNA3 (1004) 
RT-PCR (mRNA from PBCEC, BMDP-cDNA-F and BMDP-cDNA-R, TA 60°C); XhoI digested PCR 
product ligated into XhoI linearised pcDNA3. 
 
pBMDP_ORF in pEGFP-N1 (1035) 
XhoI and HindIII digested insert of pBMDP_ORF in pcDNA3 (1004) ligated into XhoI and HindIII 
linearised pEGFP-N1. 
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Cloning vectors 
 
pT-Adv-Vector (Clontech) 
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pBluescript II KS (+/-) (Stratagene) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pBluescript II SK (+/-) (Stratagene) 
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Prokaryotic expression vectors  
 
pET-28a(+) (Novagen) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pGEX-4T-3 (Amersham Biotech) 
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pRSET-A (Invitrogen) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pMAL (New England Biolabs) 
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Eukaryotic transfection vectors 
 
pcDNA3 (Invitrogen) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pEGFP-N1 (Clontech) 
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pCMVβ (Clontech) 
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Appendix G:  List of table and figure captions 
 
Table captions 
 
Table 2-1 Organic cation transport systems and their tissue specificity.  
Table 2-2 Organic anion transport systems and their tissue expression and substrate specificity.  
Table 2-3 Nucleoside transport systems, their tissue distribution and substrate specificity.  
Table 2-4 The P-glycoprotein family.  
Table 2-5 The human MRP family, some of the alternative names used in the literature and their 
tissue distribution. 
 
Table 3-1 Nucleotide identities of the porcine BMDP cDNA sequence. 
Table 3-2 Identities and homologies of the amino acid sequence of porcine BMDP. 
 
Table 4-1 mRNA tissue expression profile of the human, murine and porcine half-transporters. 
 
Table 5-1 Summarised cytotoxicity analysis of transfected HEK 293 cells. 
Table 5-2 Comparison of measured EC50 values to published data. 
Table 5-3 EC50 values of chemotherapeutic drugs in different clones of BMDP transfected cells. 
Table 5-4 Effect of several inhibitors on BCRP and P-glycoprotein activity. 
 
Table 7-1 Concentration of standard agarose used for separating DNA of different sizes. 
Table 7-2 Scheme for sequencing reaction. 
Table 7-3 Protein molecular weight resolved in gels of different polyacrylamid concentrations. 
Table 7-4 Components of SDS gels. 
 
 
 
Figure captions 
 
Figure 2-1 The mammalian brain (Spector and Johanson, 1989). 
Figure 2-2 Cross-section of a brain capillary (Krstic, 1988). 
Figure 2-3 Putative membrane topology of MDR1 P-glycoprotein (Borst et al., 2000b). 
Figure 2-4 Possible mechanisms of action for drug efflux by P-glycoprotein (Johnstone et al., 
2000). 
Figure 2-5 Two-dimensional membrane topology models (Borst et al., 2000a) for 190 kDa MRP1 
(MRP2, MRP3, MRP6, MRP7) and 160 kDa MRP5 (MRP4, MRP8).  
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Figure 2-6 Schematic representation of the localisation of MDR1 (Pgp), MRP1, MRP2, MRP3 and 
MRP5 in transfected polarised epithelial cells (Borst et al., 1999). 
Figure 2-7 Pgp and MRP1 efflux systems in the blood-brain barrier (BBB) and choroid plexus (CP) 
(Lee et al., 2001).  
 
Figure 3-1 Differential screening of a subtracted cDNA library. 
Figure 3-2 Nucleotide sequence of cDNA clone C8. 
Figure 3-3 Northern blot analysis for the expression of cDNA clone C8 (BMDP). 
Figure 3-4 Southern blot analysis of cDNA clone C8 (BMDP). 
Figure 3-5 Isolation of the full-length cDNA sequence of BMDP by RACE-PCR tenchnology. 
Figure 3-6 Schematic description of PCR reactions to obtain the full-length cDNA of BMDP. 
Figure 3-7 Nucleotide sequence and the deduced amino acid sequence of BMDP. 
Figure 3-8 Sequence alignment of pBMDP, hBCRP and mBCRP. 
Figure 3-9 Putative membrane topology model of BMDP. 
Figure 3-10 Hydrophobicity plots of pBMDP, hBCRP and mBCRP. 
Figure 3-11 Phylogenetic tree showing the relationship of BMDP to representative ABC transporters. 
 
Figure 4-1 Time course of BMDP expression in vitro. 
Figure 4-2 BMDP expression in vivo, primary cultured cells and immortalised cells. 
Figure 4-3 BMDP expression at the blood-brain and blood-cerebrospinal fluid barrier. 
Figure 4-4 BMDP expression in different types of brain specific cells. 
Figure 4-5 BMDP expression in different types of endothelial cells. 
Figure 4-6 BMDP expression in selected porcine tissues. 
Figure 4-7 BMDP expression in human, mouse and porcine tissue. 
Figure 4-8 BMDP expression compared to Pgp and MRP1. 
Figure 4-9 Positions of antigenic sites for antibodies. 
Figure 4-10 MBP-BMDP-fusion protein expression in E.coli. 
Figure 4-11 Fluorescence micrographs of immunocytochemical stainings of BMDP in PBCEC. 
 
Figure 5-1 BMDP expression in subclones of HEK 293 cells. 
Figure 5-2 Representative formazan cytoxoxicity studies for mitoxantrone. 
Figure 5-3 Formazan cytoxoxicity studies for four different HEK 293 clones. 
Figure 5-4 Transendothelial transport of 3H-daunorubicin in PBCECs. 
Figure 5-5 Inhibition studies of 3H-daunorubicin transport in PBCECs. 
 
Figure 7-1 Cross-section of a brain capillary and filter set-up.  
Figure 7-2 Detailed mechanism of the SMART 5’-RACE PCR.  
Figure 7-3 Mechanisms of suppression and step-out PCR.  
Figure 7-4 Detailed mechanism of the PCR-Select cDNA Subtraction.  
Figure 7-5 Overview of the PCR-Select Differential Screening.  
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